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ABSTRACT
Hepatitis B virus (HBV) infection is endemic to several populous regions and is 
often complicated by cirrhosis and hepatocellular carcinoma (HCC). Present 
treatment of chronic HBV infection is usually ineffective and novel therapeutic 
approaches are an important medical objective. The X open reading frame (ORF) 
of HBV, HBx, is a conserved sequence that overlaps with the polymerase ORF 
and viral c/'s-elements, and is present within all viral transcripts. In addition, the 
HBx ORF encodes a 17 kDa transactivator protein, HBx, which is required for the 
establishment of viral infection and has been implicated in HBV-associated 
hepatocarcinogenesis. The HBx sequence thus represents a compelling target for 
applying nucleic acid hybridisation-based therapeutic agents for the inhibition of 
HBV gene expression and replication.
Hammerhead ribozymes are RNA enzymes that can be designed to 
hybridise to short complementary RNA sequences and catalyse the specific 
endonucleolytic cleavage of the phosphodiester backbone in trans at conserved 5' 
NUH 3' triplet sequences. Trans-cleaving hammerhead ribozymes have been 
applied as therapeutic agents to a number of different diseases for the targeted 
‘knockdown’ of both viral and cellular gene expression. Although previous studies 
have shown that HBV RNA is susceptible to hammerhead ribozyme cleavage in 
vitro, the intracellular inhibitory effects of hammerhead ribozymes targeted to HBV 
remained unresolved.
Liver-derived cells were co-transfected with anti-HBx ribozyme 
expression vectors (along with catalytically inactive and antisense RNA control 
vectors) together with plasmids that constitutively express HBx or reconstitute 
intracellular HBV infection. Hammerhead ribozymes that were catalytically active 
in vitro were able to inactivate HBx mRNA, and inhibit HBx trans-activation 
function in cultured cells. Using a replication-competent HBV vector, ribozymes 
inhibited markers of HBV replication by inhibiting viral gene expression and 
decreasing the secretion of HBsAg and HBeAg into the culture medium. To 
confirm ribozyme antireplicative effects, a sensitive in situ measurement of 
ribozyme action in co-transfected Huh7 cells was assessed using an HBV vector, 
where the preS2/S region was replaced by DNA encoding enhanced green
fluorescent protein (EGFP). Ribozymes inhibited EGFP marker gene expression in 
situ and provided an accurate measurement of ribozyme antireplicative efficacy in 
cell culture. Flowever, the data do not exclude a dominant antisense effect.
Vectors were developed that include head-to-tail concatamers of 
different ribozyme-encoding units, each with a respective 3'-flanked cis 
complementary target cleavage sequence. The aim was to generate expression 
cassettes encoding single transcripts with many c/s-cleaving hammerhead 
ribozymes that retain the ability to cleave simultaneously in trans. All multimeric 
hammerhead ribozyme transcripts generated in vitro, self-cleaved to release 5' 
and 3' trimmed trans-acting hammerhead ribozymes. Expression vectors that 
encode multimeric cis- and trans-cleaving hammerhead ribozymes decreased 
HBsAg and FIBeAg secretion when co-transfected along with HBV vectors in Fluh7 
cells. These ribozymes demonstrated an improved antireplicative effect when 
compared to previous single-unit, or catalytically defective ribozyme controls. The 
most elaborate multimeric hammerhead ribozyme expression vector, a 24-mer 
construct, that generates eight units of each of the three ribozymes, inhibited 
EGFP marker gene expression 10-15% more efficiently than single-unit ribozyme 
counterparts when measured in situ using a modified HBV EGFP vector.
In conclusion, the hammerhead ribozyme-encoding vectors generated 
represent a significant improvement on previously described anti-HBV ribozyme 
constructs. Moreover, the HBx ORF proved to be a suitable target site for 
hammerhead ribozyme-mediated inhibition of HBV gene expression and markers 
of replication in cell culture. For future use in vivo, expression cassettes encoding 
multimeric hammerhead ribozymes may be incorporated into liposomes or viral 
delivery vectors. Should the endogenously expressed hammerhead ribozymes 
presented in this thesis prove to be safe and efficacious in animal models of viral 
infection they may be further applied as therapeutic agents for the treatment of 
chronic HBV infection.
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1.0 INTRODUCTION
The hepatitis B virus (HBV) is an aetiological agent of both acute and chronic 
viral hepatitis. Chronic HBV infection represents a worldwide health problem. It is 
estimated that 375 million people are infected, that is, over 5% of the world’s 
population (World Health Organisation, 1998). Endemic areas include sub- 
Saharan Africa, east and South-East Asia, and the western Pacific islands. In 
these regions between 8-15% of the population are chronic carriers (Beasley et 
ai, 1981). Although clinical manifestations of infection vary considerably, there is 
a strong correlation between chronic HBV infection and the risk of developing 
cirrhosis and hepatocellular carcinoma (HCC) (Robinson, 1994). In fact, nearly 
25% of deaths in chronic carriers can be attributed to HCC (Beasley, 1988) 
which, along with cirrhosis, is the primary cause of morbidity and mortality in 
chronic HBV infected individuals.
Antiviral chemotherapy, using immune modulators and nucleoside 
analogues, remains presently the only treatment option for chronic HBV infection 
(Ganem, 1998; Lok, 2000). None of the many different chemotherapeutic 
strategies used at present and in the past has proven consistently successful. 
Moreover, chronic HBV infection continues to persist despite the availably of a 
suitable prophylactic vaccine for over 20 years. The global implementation of 
HBV vaccines, within the Expanded Programme on Immunisation (EPI), has not 
achieved the desired penetration, especially in sub-Saharan Africa.
An effective treatment of HBV remains elusive and represents an 
important medical objective. New knowledge will come from a better 
understanding of HBV replication and pathogenesis as well as from the 
propagation of new molecular tools for the treatment of viral diseases. One such 
approach is in the application of ribonucleic acid (RNA) catalysts, or ribozymes, 
which hold much promise as novel molecular therapeutic agents. The enzymatic 
effects of ribozymes have recently been examined for their therapeutic potential 
in a number of different acquired and inherited diseases (James and Gibson,
1998). Ribozymes can in principle be designed to inhibit HBV gene expression 
and viral replication and prevent the onset of disease-causing sequelae of 
chronic HBV infection. Of particular interest is the therapeutic potential of the
hammerhead ribozymes, which are the most versatile of the naturally occurring 
ribozymes (Birikh et al., 1997b; Bramlage et al., 1998). Although presynthesized 
hammerhead ribozymes can be constructed as therapeutic agents (Usman and 
Blatt, 2000), hammerhead ribozymes can be exploited to induce their potential 
antiviral effects as RNA generated endogenously from a ribozyme-encoding 
expression cassette.
In this thesis the antiviral potential of hammerhead ribozymes targeted 
to unique sequences within HBV was determined using cell culture models of 
HBV infection. Hammerhead ribozymes targeted to HBV have, to date, only been 
tested in vitro. Plasmid vectors were generated such that they expressed single­
unit and/or multiple-unit hammerhead ribozymes. These ribozymes and their 
catalytically inactive ribozyme controls were tested along with antisense RNAs 
using assays that were specifically designed to test the efficacy of nucleic acid- 
mediated inhibition of HBV in cell culture. By characterising the effects of 
hammerhead ribozymes as intracellular inhibitors, the feasibility of these 
endogenously expressed nucleic acids was established for the future treatment of 
chronic HBV and the prevention of hepatocarcinogenesis.
1.1 Hepatitis B virus biology
1.1.1 Hepadnaviruses
HBV was first identified in 1965 by Blumberg as a new antigen in leukaemic sera 
of native Australians and was originally referred to as the “Australia antigen” 
(Blumberg et al., 1965). Only later was this antigen shown to be the viral surface 
antigen or HBsAg. In 1970, Dane managed to isolate an infectious complete 
particle and identify it by electron microscopy (Dane et al., 1970). Since then, 
significant strides have been made in characterising HBV biology, epidemiology 
and pathogenesis.
Human HBV represents the prototype of the Hepadnaviridae, a family 
of small DNA viruses that persistently infect liver cells and whose genome is the 
smallest known for mammalian viruses. The hepatocyte is the only confirmed site 
of replication for all members of this virus family. Nevertheless, HBV has been 
shown to infect bile ductule epithelial cells and a number of extrahepatic sites.
These include, but are not necessarily limited to, cells of the pancreas, kidney 
and lymphoid systems (Blum et al., 1984; Nicoll et al., 1997). HBV shares 70% 
sequence homology with mammalian hepadnaviruses discovered in woodchucks 
(Summers et al., 1978) and in various ground squirrel species (Marion et al., 
1980). Old and New World primates possess wild-type infection of HBV 
subvariants that may prove to be species specific (Takahashi et al., 2001). 
Human HBV is, however, capable of infecting chimpanzees, baboons and other 
great apes as well as various marsupials (Seeger and Mason, 2000). More 
distantly related viruses have been found in ducks (DHBV) (Mason et al., 1980), 
wild herons (Sprengel et al., 1988) and recently in white storks (Pult et al., 2001). 
Domestic geese and other hosts are susceptible to infection from other avian 
hepadnaviral species (Marion et al., 1987). Avian hepadnaviruses are grouped in 
the genus avihepadnavirus and share a similar genome structure, albeit with little 
sequence homology, to the mammalian hepadnaviruses, which belong to the 
genus orthohepadnavirus.
There are other significant differences between avian and mammalian 
hepadnaviruses. The genome of the avihepadnaviruses, which is slightly smaller 
than the orthohepadnaviruses, codes for two surface envelope proteins (as 
opposed to three in the mammalian viruses), and lacks the open reading frame 
(ORF) for a multifunctional protein termed HBx (Sprengel et al., 1988). There 
does, however, appear to be a sequence vestige of the HBx ORF in the 
avihepadnaviruses, suggesting that HBx was present at some point in the 
evolution of the avian viruses (Lin and Anderson, 2000; Netter et al., 1997). Both 
avian and mammalian viruses are often used as models to study the molecular 
biology of HBV, particularly with respect to the infection cycle, host immune 
response and disease-causing sequelae of chronic infection such as cirrhosis 
and liver cancer. More specifically, the woodchuck hepatitis virus (WHV) is used 
predominantly as a model of viral-induced hepatocarcinogenesis as DHBV- 
infected ducks or geese do not develop viral-associated HCC (Seifer et al., 
1991).
1.1.2 HBV structure, genome and transcripts
The genome of HBV, within virus particles or spherical virions (Dane particle), is 
composed of relaxed-circular, partially double-stranded DNA (pdsDNA) (Figures
1.1 and 1.2) (Robinson et al., 1974). The long, full-length minus-strand is 
approximately 3200 nucleotides (nt) in length and has a protein (the viral 
polymerase) covalently bound to its 5' terminus. The plus-strand, which varies 
between 1700 and 2800 nt in length, depending on species and subtype, has a 
capped oligoribonucleotide at its 5' end. The plus-strand maintains genome 
circularity by a cohesive overlap across the 5' and 3' termini of the minus-strand.
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Figure 1.1 A diagrammatic illustration of an infectious HBV virion or ‘Dane’ particle. The 
envelope bilayer contains the large (L), middle (M) and small (S) surface 
glycoproteins. The preS1 domain of L is displayed on both internal and 
external virion compartments (Prange and Streeck, 1995). The partially double 
stranded DNA (pdsDNA) genome is present within the icosahedral 
nucleocapsid. The 5’ end of the complete minus-strand DNA is covalently 
linked to the terminal protein (TP) domain of Polymerase (P). Hsc70 
represents a cellular chaperone, which co-purifies with virions and S particles 
(Nassal, 1999).
The HBV genome includes four ORFs that encode at least seven translation 
products through the use of varying in-frame initiation codons. These translation 
products include three surface antigens (HBsAg), the envelope glycoproteins 
preS1, preS2, and S; core (C or HBcAg) and e antigens (HBeAg); viral 
polymerase (P); and the X protein (HBx) (Figure 1.2). The genome is also replete 
with c/s-elements required for the regulation of HBV gene expression and
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Figure 1.2 Transcriptional and translational organisation of the hepatitis B virus genome 
(strain ayw). Co-ordinates of the genome are given relative to the single 
EcoRI restriction site. Partially double stranded (pds) HBV DNA comprises + 
and - strands with cohesive complementary 5' ends. Attached to the 5' end 
of the - DNA strand is a terminal protein (TP), whilst the 5' end of the + 
strand includes a short RNA oligomer cap. The c/s-elements that regulate 
HBV transcription are represented by the circular and rectangular symbols. 
The positions of direct repeats DR1 and DR2 are indicated as black 
rectangles. Thick circular arrows immediately surrounding the genome 
indicate the viral open reading frames (with initiation codons) that 
encompass the entire genome. Four outer arrows, that give the 5' to 3' 
polarity, indicate the HBV transcripts. Multiple arrowheads at the 5' ends of 
the PreC/Pregenome and PreS2/S transcripts indicate heterogeneous 
transcription start sites. The common 3' end of all the HBV transcripts is 
depicted by the identical termination site and sequences that overlap with 
the HBx transcript.
replication. These include viral promoters, enhancers and signal regions. The 5' 
terminus of both strands contains regions of short (11 nucleotide) direct repeats, 
DR1 and DR2, which are essential for priming the synthesis of their respective 
DNA strands during replication. HBV’s compact coding organisation ensures that 
every nucleotide falls within a transcribed region and that 50% of translated 
sequences are present in more than one ORF.
Covalently closed circular HBV DNA (cccDNA) is the template for both 
genomic and subgenomic viral transcript mRNAs, which are produced using cellular 
RNA polymerase II. The 5' terminus of the preC/pregenome and preS2/S 
transcripts both have heterogeneous transcription start sites. The HBx transcript, 
however, has only one unique start site. The preC and pregenomic RNA 
(preC/pgRNA) transcripts, which are approximately 3500 nt in size, are more than a 
full genome in length and contain terminal repeats at each end (Figure 1.2). The 
pgRNA transcript is unique in that, apart from being the genomic template for 
reverse transcription, it represents the mRNA for production of the core protein as 
well as the viral polymerase protein (Summers and Mason, 1982). Unlike the 
pgRNA, the genomic preC mRNA is not encapsidated (Jeong et al., 2000; Nassal et 
al., 1990). The S transcript is 2400 nt in length whilst the preS2 family of transcripts 
are roughly 2100 nt in size. The HBx mRNA is a single 900 nt transcript. The 
presence of a common 3' polyadenylation termination signal on the FIBV genome 
results in all transcripts sharing the same 3' terminal sequences (see section 
1 .1 .4.2).
1.1.3 Viral gene products
1.1.3.1 Core and preC/eAg
The core ORF contains two in-frame initiation codons that divide it into the pre 
core (preC) and core (C) domains. Translation from the C initiation codon results 
in the formation of the viral core or capsid protein, C (or HBcAg). Core proteins 
dimerise and assemble independently to form an icosahedral nucleocapsid, 
which is 22 to 25 nm in diameter (Chang et al., 1994). Short carboxy-terminal 
truncated core proteins can induce the formation of smaller nucleocapsid shells 
(Conway et al., 1998). Translation from the preC initiation codon results in the 
synthesis of a fusion protein containing a signal peptide (Ou et al., 1986). The
signal peptide targets the fusion protein for translocation through the lumen of the 
endoplasmic reticulum and onto a pathway where proteolytic cleavage of the 
carboxy- and amino-termini generates a soluble secreted product, the HBeAg 
(Bruss and Gerlich, 1988). Although the exact function of the eAg is unknown, its 
detection in serum is an important clinical marker as its presence indicates active 
viral replication.
1.1.3.2 Surface proteins
Surrounding the viral core is a lipid envelope which is derived from the host cell 
membrane and endoplasmic reticulum (Kamimura etal., 1981). The infectious 42 
nm virion or Dane particle contains an envelope with three classes of surface 
proteins embedded in the lipid membrane: small (S), middle (M) and large (L). All 
three surface proteins are glycosylated and form stable, transmembrane 
structures. The S protein (226 amino acids long) defines the S domain. The two 
larger proteins, M and L, contain S plus two additional amino terminal extensions 
(Seeger and Mason, 2000). The preS2 extension defines the extra domain of M, 
whilst L consists of both preS1 and preS2 domain extensions. Infectious particles 
are composed of up to 70% S, with the remainder of the particle constituted by 
approximately equal amounts of M and L (Heermann et a!., 1987). These 
envelope glycoproteins are also secreted in the form of small, non-infectious, 
non-DNA-containing, lipoprotein particles. These subviral particles are 
abundantly secreted and greatly outnumber the infectious HBV virions. Subviral 
particles are found in two forms: spheres, which consist of mainly S and M 
proteins; and filaments, which have slightly more L protein than spheres 
(Heermann et at., 1984). Owing to the abundance of subviral particles in infected 
sera, they are thought to be largely responsible for the immune complex 
syndromes that occur in transient infections and may possibly act as decoys for 
anti-S neutralising antibodies (Seeger and Mason, 2000).
Although much remains to be ascertained, the specific function of the 
surface proteins appears to be in selectively transporting the nucleocapsid into 
and out of the host hepatocyte without causing cellular lysis. The preS1 domain 
appears to have a dual role in HBV biology. PreS1 is both a ligand to core
Figure 1.3 Schematic illustration of the HBV infection and replicative cycle within the hepatocyte. Infectious virions attach to a cellular receptor(s) 
and uncoat, releasing nucleocapsids that migrate to the cell nucleus. The pdsDNA genome is converted to cccDNA, which is the 
template for the transcription of four viral transcripts. Translation occurs following transcript export to the cytoplasm. The pgRNA 
interacts with two gene products, Polymerase (P) and Core (C), to form immature, RNA packaged, nucleocapsids. The preC/pgRNA is 
reverse transcribed into DNA by P. The DNA genome can be either redelivered to the nucleus, or nucleocapsids can be coated by 
surface glycoproteins (in the Golgi and endoplasmic reticulum) before being exported as enveloped virions.
particles during viral envelope assembly (which is why a fraction of L particles 
display the preS1 domain towards the cytosolic interior), and a substrate to an 
unidentified host cell receptor during viral infection (Nassal, 1999) (Figure 1.3). 
Although antibodies to S alone provide sufficient protection against all strains of 
HBV, the preS1 epitope is also suited for the generation of virus-neutralising 
antibodies (Lambert, 1991). The precise function of preS2, however, is not as 
well understood but appears not to be required for viral infection (Fernholz et at.,
1993).
1.1.3.3 Polymerase
The P ORF encodes the viral polymerase, which is translated from an internal 
initiation codon on the viral preC/pgRNA. The P ORF is not in frame with the C 
ORF (Chang et at., 1989) and the P gene is transcribed as part of a second 
cistron of the preC or pgRNA transcript and thus lacks its own direct upstream 
promoter element. Regulation of P appears, therefore, to be at the level of 
translation. Translation of P requires ribosomal ‘scanning’ of the preC/pgRNA and 
thus P is produced less efficiently than either eAg or C proteins (Seeger and 
Mason, 2000).
HBV polymerase is responsible for both DNA- and RNA-dependent 
DNA polymerase activity during viral DNA replication (Toh et al., 1983). P is 
further endowed with two functional domains: the terminal protein (TP) at its 
amino terminal, and RNase H-like activity at its carboxy-terminal (Radziwill et al.,
1990). The TP is found covalently linked to the 5' end of HBV minus-strand DNA 
and is important for the packaging of the RNA pregenome as well as acting as a 
primer for reverse transcription (Wang and Seeger, 1993).
The viral polymerase is principally responsible for reverse transcription 
of pgRNA to produce minus-strand DNA, concomitant degradation of the RNA 
template, and synthesis of plus-strand DNA. P is also required as a structural 
component for the packaging of pgRNA into immature core particles 
(Bartenschlager et al., 1990) and may play a role in orchestrating entry into the 
host cell nucleus for early replication (Wang and Seeger, 1993).
1.1.3.4 X Protein, HBx
Considering the efficient utilisation of sequence space by HBV, with significant 
portions of the viral genome coding for more than one protein, it is expected that 
a coding region unique to hepadnaviruses would reveal a protein whose function 
is obvious in the biology of the virus. However, understanding the biological role 
of the X protein, HBx, has been far from simple. The name, ‘X’ gene, was 
assigned when no amino acid sequence homology was observed with the 
existing database of viral or cellular proteins (Miller and Robinson, 1986).
HBx is a small, 17 kDa protein and although poorly immunogenic, 
produces antibodies in sera of infected humans and naturally infected animals 
(Feitelson and Clayton, 1990). Although the specific function of HBx in natural 
infection remains elusive, its presence is necessary for the establishment of viral 
infection in vivo in animals (Chen et al., 1993; Zoulim et al., 1994). HBx appears 
to possess a multitude of activities in vitro, although few of these define a specific 
role for this protein during viral replication.
HBx has been shown to activate the transcription of a variety of viral 
and host cellular genes (Caselmann, 1996; Rossner, 1992). This indiscriminate 
or ‘promiscuous’ trans-activation activity appears to be via an indirect process. 
HBx, without DNA-binding domains, cannot act alone. Although it appears that 
trans-activation is supplementary to HBx’s intended primary function, recent 
studies suggest a more prominent role for this function in the HBV life cycle as 
HBx was shown to activate transcription of the core gene in vivo in HBx 
transgenic mice (Reifenberg et al., 1999). Apart from modulating transcription, 
HBx is a multifunctional viral regulator that adapts cell responses to genotoxic 
stress (by modulating or affecting DNA repair and apoptosis), protein 
degradation, signalling pathways, and cell cycle checkpoints (reviewed in 
Arbuthnot et al., 2000). These modulations affect viral replication, directly or 
indirectly, and in turn provide insight into the possible role of HBx in the aetiology 
of HBV-induced carcinogenesis (see section 1.1.7.3). The overwhelming array of 
host-cell factors that are associated with HBx (as well as other viral factors) 
underscores the exquisite sensitivity and specificity which HBV enjoys in its 
natural cellular environment.
1.1.4 Viral cis-elements
1.1.4.1 HBVpromoters and enhancers
Transcription of the four ORFs is controlled by four promoter elements: preS1, 
preS2, core and X promoter (Figure 1.2). Two viral enhancer elements, 
enhancers I (Enhl) and II (Enhll), located upstream of the core promoter (CP), as 
well as cis-acting negative regulatory elements, are necessary for regulation of all 
viral genes (Schaller and Fischer, 1991b). The basic (basal) core promoter (BCP) 
along with an uptream regulatory region (URR), constitute the major functional 
elements of the core promoter. Although the BCP lacks the canonical TATA box 
sequence, distinct TATA-box like sequences form part of two partially overlapping 
yet genetically distinct cis-acting elements that independently drive the 
transcription of both preC and pgRNA transcripts (Yu and Mertz, 1996). URR can 
be further divided into positive and negative regulatory regions (Guo et al., 1993). 
The core upstream regulatory sequence (CURS) region contains several 
domains (c/'s-elements) that stimulate BCP activity. Two domains in the CURS 
region (CURS-A and CURS-B) span most of the Enhll sequence. However, 
unlike CURS, which is position and orientation dependent in activating BCP, 
Enhll activates preS1, preS2 and X promoters alone and functions indifferently to 
its position and orientation (Kramvis and Kew, 1999). Further upstream of the 
BCP and CURS is a negative regulatory element (NRE), which acts to suppress 
BCP and Enhll activity (Lo and Ting, 1994). In addition, a number of liver-derived 
transcription factors bind to the BCP and its upstream regulatory sequence as 
well as other viral promoters in order to modulate viral transcription (reviewed by 
Kramvis and Kew, 1999, and Schaller and Fischer, 1991a).
The preS1 and preS2 promoters control the expression of the surface 
transcript mRNAs and accurately regulate the abundance of each of the three 
surface glycoproteins. The preS1 promoter regulates transcription of the entire S 
ORF, which is translated into the large surface protein (L). The preS2 promoter 
controls transcription of a family of transcripts resulting in middle (M) and small 
(S) surface proteins upon translation. Unlike the preS1 promoter, the preS2 
promoter lacks a TATA box and is contained within two ORFs (Schaller and 
Fischer, 1991a). Although present on all viral transcripts, the HBx ORF encodes 
a unique HBx transcript, which is under its own transcriptional control. Uniquely,
the X promoter overlaps with the 3'-end sequence of Enhl. However, the minimal 
X promoter can be separated from Enhl whilst retaining its function (Guo et al.,
1991). Since Enhl dramatically influences the transcription of preC/pgRNAs and 
HBx mRNA (Hu and Siddiqui, 1991), the virus must avoid the impact of promoter 
occlusion. Seeger and Mason speculate that different cccDNA templates, which 
behave like mini-chromosomes, may differentiate promoter-coupled transcription 
events (Seeger and Mason, 2000). Additionally, the X promoter contains cis- 
elements for binding of transcription factors, some of which are liver-specific. This 
includes the tumour suppressor protein, p53, which has been shown to 
downregulate the function of the X promoter.
1.1.4.2 Polyadenylation signal
All HBV transcripts share the same 3' termini due to the presence of a common 
polyadenylation signal on the cccDNA viral genome. PreC/pgRNA transcripts are 
larger-than-genome-length since RNA polymerase II skips the polyadenylation 
signal on the first pass. The polyadenylation signal is only recognised on the 
second encounter (Russnak, 1991). The resultant transcripts possess terminal 
sequence repeats at both their 5' and 3' termini. The greater-than-genome-length 
pgRNA sequence is necessary for viral replication and packaging into 
nucleocapsids (see sections 1.1.4.3 and 1.1.5). A number of factors possibly 
affect the termination of transcription. The HBV polyadenylation signal (5' 
UAUAAA 3') is known to be less effective than the canonical eukaryotic 
polyadenylation signal sequence 5' AAUAAA 3', suggesting a necessary 
adaptation for the differential use by HBV (Russnak, 1991). More specifically, 
DHBV cccDNA possesses a c/s-element or positive effector of transcription 
(PET), which is located within the 5' transcribed region of the pgRNA-encoding 
sequence. The presence of PET ensures that RNA polymerase II skips the 
transcription termination site during first passage of pregenome transcription 
(Huang and Summers, 1994). Termination of transcription during the second 
encounter appears to be regulated by a second c/s-element, termed negative 
effector of transcription (NET) (Beckel-Mitchener and Summers, 1997).
1.1.4.3 Epsilon (a)
The terminal repeats of the pgRNA contain a stem-loop sequence, or epsilon (s), 
which plays a key role in HBV DNA encapsidation and reverse transcription. The 
location of s was determined by fusing heterologous genes to various regions of 
the HBV genome and by observing subsequent encapsidation (Junker-Niepmann 
etal., 1990; Pollack and Ganem, 1993). Despite the presence of terminal repeats 
on the pgRNA, only the 5 's retains functionality resulting in encapsidation of the 
pgRNA transcript, notwithstanding the fact that all HBV transcripts have the s 
coding region at their 3' ends. Analysis of s shows a series of inverted repeats 
that fold into a three-dimensional stem-loop structure. This stem-loop is 
conserved among all hepadnaviruses irrespective of differences in the primary 
sequence (Junker-Niepmann et a i, 1990). Polymerase recognises and directly 
interacts with s, initiating both encapsidation as well as reverse transcription of 
the HBV pgRNA (Fallows and Goff, 1995).
1.1.5 HBV life cycle
Although knowledge of the HBV replicative cycle is comprehensive, a number of 
important questions remain unanswered. Surprisingly, little is known about the 
mode of receptor-mediated infection of host hepatocytes. Most pertinently, the 
absence of cell lines susceptible to hepadnavirus infection has prevented an 
accurate understanding of the initial stages of viral infection. A large membrane 
glycoprotein termed gp180 or p170 (a protein of the carboxypeptidase D [CPD] 
family) has been identified as a component of the cellular receptor for DHBV 
(Breiner et a i, 1998; Urban et a i, 1998). Although human homologues of CPD 
have been identified, it appears that further receptor components are necessary 
for HBV-mediated infections in hepatocytes (Seeger and Mason, 2000).
Once inside the nucleus, using host-dependent factors, the virus 
converts its partially double-stranded genome into covalently closed circular DNA 
(cccDNA) through an as yet unknown mechanism of DNA repair. The presence of 
cccDNA in hepatocytes indicates a successful initiation of infection (Ruiz-Opazo 
et ai, 1982). CccDNA is the template for transcription of genomic and 
subgenomic viral mRNAs. The greater-than-genome-length pgRNA, which is
transcribed by cellular RNA polymerase II, represents the mRNAs (along with 
preC mRNAs) for the translation of P and C proteins as well as being the 
template for reverse transcription of minus-strand DNA (Schaller and Fischer, 
1991a). The pgRNA interacts, possibly simultaneously, with both its gene 
products, C and P. Translation of P and pgRNA packaging are tightly coupled 
events. Polymerase binds to the 5' end s (Figure 1.4A), and triggers the addition 
of core complex dimers, which allows for packaging into capsids (Figure 1.3) 
(Bartenschlager et al., 1990; Junker-Niepmann et a i, 1990). Reverse 
transcription takes place during capsid formation (Figure 1.4) (Nassal and 
Schaller, 1993).
A unique polymerase-linked DNA primer consisting of three or four 
nucleotides is synthesized using the bulge region of the stem-loop c as template 
(Tavis et al., 1994; Wang and Seeger, 1993) (Figure 1.4B). Following priming, the 
first of three template switches occurs. The short primer translocates to a 
homologous three/four-nucleotide sequence, which is part of direct repeat DR1, 
at the 3' end of the pgRNA (Figure 1.4C). Subsequently, minus-strand DNA 
synthesis continues within the immature nucleocapsid (Havert and Loeb, 1997). 
RNase H activity of P then degrades the pgRNA which is hybridised to the minus- 
strand DNA (Summers and Mason, 1982) (Figure 1.4D). Degradation is complete 
except for a short stretch at the 5' terminus (16-18 nt) which acts as the primer for 
synthesis of the complementary plus-strand viral DNA (Loeb et al., 1991; Seeger 
et al., 1986). This primer RNA is translocated to the second direct repeat (DR2) 
where the synthesis of plus-strand DNA is initiated (Figure 1.4E). Plus-strand 
DNA is extended to the physical end of minus-strand DNA using a short terminal 
repeat r followed by a template switch from the 5'- to the 3'-end of the minus- 
strand DNA (Flavert and Loeb, 1997). Failure to translocate, referred to as in situ 
priming (Staprans et al., 1991), leads to the synthesis of a double-stranded linear 
form of the viral genome, which is often observed in tissue culture. A third 
template switch enables the synthesis of the partially double-stranded DNA 
genome found in mature, infectious virions (Seeger et al., 1986) (Figure 1.4F). 
The plus-strand DNA maintains genome circularity through a cohesive overlap 
across the 5' and 3' ends of the minus-strand DNA.
Within the viral replicative cycle there are a number of potential targets 
for drug development. However, many of these await the identification of both
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Figure 1.4 Essential steps involved in hepadnaviral DNA replication starting from a newly transcribed pgRNA template, with terminal repeats (R), 5' 
cap and a polyA tail. A) The reverse transcriptase (P) binds to the epsilon (e) stem-loop structure near the 5' terminus of the pgRNA 
(blue). B) Reverse transcription is by a protein priming mechanism, utilising a tyrosine located near the amino terminus of the reverse 
transcriptase itself (Zoulim and Seeger, 1994). C) Following the synthesis of three or four bases in the bulge region of e, P translocates 
to the 3' terminus of the RNA template, where the four bases can anneal with a complementary sequence. D) Elongation of the minus- 
strand DNA (red) to the 5' end is concomitant with RNase H degradation of the pregenome sparing the 5' cap and DR1, which remain 
hybridised to the minus-strand. Completion of minus strand produces a short (~9 nt) terminal repeat (r) in the -  strand DNA. E) The 
remaining oligoribonucleotide fragment serves as primer for plus-strand DNA synthesis (green), following its translocation to DR2. 
Failure to translocate leads to a double-stranded, linear form of the viral genome (a process referred to as in situ priming). F) A third 
translocation occurs when the plus-strand DNA reaches the 5' terminus of the minus-strand, circularising the molecule and allowing 
continued plus-strand elongation. This translocation is facilitated by the short terminal repeat on the minus strand DNA (r) (Nassal, 
1999).
viral and cellular determinants that are involved in each step of the viral life cycle 
Antiviral strategies to date have focused on inhibiting viral DNA polymerase or 
reverse transcriptase. Future antiviral targets under consideration include: viral 
attachment to the host cell, penetration and translocation to the nucleus, and 
uncoating of the viral nucleocapsid. More accessible targets include: viral 
transcription and translation, viral genome packaging, maturation of the viral 
nucleocapsid, and envelope formation. Of particular interest are the antiviral 
strategies that target HBV nucleic acid sequences. Since HBV sequences are 
distinct from that of the host hepatocyte, targeting the inhibition of viral gene 
expression and replication can be highly specific. The HBV genome life cycle 
uses both DNA and RNA as replicative intermediates. Consequently, therapeutic 
strategies that make use of nucleic-acid hybridisation may suppress viral 
replication and gene expression by degrading viral RNA intermediates or by 
blocking translation of important proteins necessary for viral propagation.
1.1.6 Serotypes and genotypes
1.1.6.1 Serotypes
Four serotypes, also known as subtypes of HBsAg, were initially defined by two 
mutually exclusive determinant pairs, d/y and w/r, and a common a determinant 
(Le Bouvier and McCollum, 1970). Nine different subtypes were identified 
following further subdivision of the w subdeterminant into w1 through to w4, and 
the acquisition of the q determinant. Thus in total, eleven subtypes have been 
identified: ayw, ayw2, ayw3, ayw4, adw2, adw4 (adw4q+ and adw4q~), adr, ayr, 
and adr (adrq+ and adrq'). Further modifications were later made by adding two 
compound subtypes: adyr and adwr (Courouce-Pauty et at., 1983).
1.1.6.2 Genotypes
To determine a molecular basis for the serological variations of HBsAg, variants 
of the HBV S gene were sequenced and compared. HBV sequence data 
established a phylogenetic relationship between HBV variants resulting in the 
definition of six HBV genotypes: A to F (Norder et at., 1993; Okamoto et at., 
1988). A possible seventh genotype, G, appears to correlate with the serotype
adw2 (Stuyver et ai, 2000). However, in general, the interrelation between the 
nine subtypes and the seven genotypes remains unclear. Genotypes A and D are 
prevalent in sub-Saharan Africa (Bollyky and Holmes, 1999; Bowyer et ai, 1997; 
Norder et al., 1994). The most divergent genotype is F, which is geographically 
distributed in South America. The F genotype differs by up to 14% from other 
HBV genomes (Norder et ai, 1993).
1.1.7 Pathogenesis
1.1.7.1 A cute and chronic HB V infection
Primary infection of HBV can result in both acute and chronic hepatitis. Acute 
hepatitis represents a transient infection which generally runs a course of one to 
six months, and which includes an asymptomatic period characterised by high- 
titre viraemia (1010 per ml). Both cellular and humoral immune responses to HBV- 
encoded antigens are responsible for viral clearance, and have been extensively 
reviewed elsewhere (Chisari and Ferrari, 1995).
The risk of developing a persistent or chronic infection following a 
usually mild acute infection is inversely correlated with age and 
immunocompetence (Hyams, 1995). Infections occur in less than 5% of adult 
individuals and in approximately 90% of neonates. The latter is usually through 
perinatal infection. Chronic infection is defined as the persistence of HBsAg in the 
serum of an individual for six months or longer (Evans and London, 1998). As 
HBV is not cytopathic, liver damage from chronic HBV infection is thought to be 
largely immune-mediated, in which various mechanisms are involved. These may 
include recognition of viral antigens (both expressed on hepatocytes and 
secreted) by B cell immunoglobulin receptors, and recognition of short, 
processed viral antigen peptides associated with human leucocyte antigen (HLA) 
molecules of the a-p heterodimer receptors on T cells (Chisari and Ferrari, 1995). 
Viral peptide fragments, processed within the infected hepatocyte, are presented 
along with HLA class I to CD8+ cytotoxic T cells, leading to both cytolytic and 
noncytolytic inhibition of viral replication (Guidotti et a i, 1996).
In chronically infected patients with little to no serum HBeAg levels, 
viral persistence appears to be through a ‘non-replicative’ mechanism as the rate 
of viral replication is low. HBV mutations in the preC gene can, however, result in
viral infection occurring in the absence of detectable serum HBeAg (Carman et 
al., 1989) and may be responsible for 95% HBeAg-negativity rate in sub-Saharan 
asymptomatic carriers of infection (Kramvis et al., 1997).
1.1.7.2 HBV and hepatocellular carcinoma (HCC)
The correlation between chronic HBV infection and the development of HCC is 
well established globally with several lines of evidence implicating the virus and 
its persistent infection in the aetiology of hepatocyte tumorigenesis (reviewed by 
Arbuthnot and Kew, 2001; Sherlock et al., 1970). In a cohort study in Taiwan, 
HBV chronic carriers showed a greater than 100-fold increased relative risk of 
developing HBV-associated HCC (Beasley et al., 1981), thus ranking chronic 
HBV infection as one of the worst environmental carcinogenic risk-factors known 
to humans. The relative risk of HBV-associated HCC varies depending on a 
number of factors, some of which include geographical environment, age and 
method of infection, the presence or absence of HBeAg, and the presence of 
cirrhosis (Figure 1.5 correlates the geographical distribution of HBV with HCC; 
reviewed by Arbuthnot and Kew, 2001).
Both direct and indirect processes are involved in establishing HBV- 
associated HCC. Integration of HBV into the chromosomes of infected 
hepatocytes, although not required for HBV replication, represents a direct 
mechanism of establishing HCC. Evidence of viral integration is observed in 
infected hepatocytes during the course of chronic infection with a higher 
proportion of viral integrants detected in HBV-associated HCC tumours (Brechot 
et al., 1981; Takada et al., 1990). Infected hepatocytes are susceptible to 
chromosomal integration of HBV DNA via an illegitimate recombination 
mechanism. The linear, double-stranded HBV DNA produced by in situ priming is 
the predominant precursor for integration (Gong etal., 1995; Yang and Summers,
1995). Integration often results in several heterogeneous rearrangements of the 
viral genome causing significant disruption of the expression of viral genes. Core 
and polymerase coding regions are usually interrupted while envelope protein 
reading frames and their promoters, as well as the HBx ORF, often remain intact 
(although fewer than 50% of integrants have a complete HBx sequence) (Miyaki 
et al., 1986; Paterlini etal., 1995; Robinson, 1994).
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Figure 1.5 Global maps showing the similarity between the geographical distributions of 
chronic hepatitis B virus infection (A) and hepatocellular carcinoma (B).
Integration may stimulate tumorigenesis through the cis-activation of 
cellular genes. This is certainly true for woodchuck infections where WHV 
integration appears to be near or in c-myc and N-myc proto-oncogenes in 50% of 
WHV-associated HCC (Hsu et al., 1988). There is a direct correlation between 
viral integration and activation of the myc family of genes in woodchucks (Fourel 
et al., 1990). No such correlation exists in HBV-associated HCC. Viral surface 
proteins M and L possess trans-activation properties if truncated at the carboxy- 
terminal and have been shown to trans-activate several cellular oncogenes. For 
the most part, c/s-activation of oncogenes appears to be rare in human HBV 
infections. An alternative model for HBV-associated tumorigenesis implies that 
HBV, like tumour viruses, contains an oncogene. One of the principle candidates 
for a viral oncogene is the HBx protein.
1.1.7.3 The role of HBx in HBV-associated HCC
The HBx protein has been widely studied in the development of HBV-associated 
HCC and has been the subject of recent reviews (Arbuthnot et al., 2000; 
Caselmann, 1996). This is mainly due to the plethora of activities displayed by 
HBx both in vitro and in cell culture. HBx is a non-specific transcriptional trans- 
activator and is believed to trans-activate a large variety of viral and host cell cis- 
elements (Caselmann, 1996; Rossner, 1992). Trans-activation by HBx involves
1) interaction with transcriptional factors and 2) activation of cell signalling 
pathway activity.
Several viral transcription regulatory elements, such as Enhl, are 
responsive to HBx-induced trans-activation (Spandau and Lee, 1988). Host 
genes that are activated by HBx include, inter alia, those of the major 
histocompatability complex (Zhou et al., 1990), c-myc (Balsano et al., 1991), c- 
fos (Avantaggiati et al., 1993), c-jun (Twu et al., 1993), p-interferon (Aufiero and 
Schneider, 1990; Twu and Schloemer, 1987) and tRNAAla (Aufiero and 
Schneider, 1990; Twu and Schloemer, 1987). HBx mediates transcription 
responses to cAMP by binding to cAMP-responsive element binding protein 
(CREB) thus affecting DNA binding through the interaction with transcription 
factors such as ATF-2 and NF-kB (Maguire et al., 1991; Twu and Robinson, 
1989). Other HBx trans-activation activities include stimulation of the mitogen-
activated protein kinase (MAP) and Janus family tyrosine kinase (JAK)/ signal 
transducer and activator of transcription (STAT) signal transduction pathways 
(Benn and Schneider, 1994; Kekule et al., 1993), and interactions with the tumour 
suppressor protein p53 (Feitelson et al., 1993). These latter interactions implicate 
HBx in the regulation of cell cycle control (Benn and Schneider, 1995) and 
programmed cell death (reviewed in Arbuthnot et al., 2000).
Lastly, HBx may be directly responsible for hepatocarcinogenesis by 
modulating DNA repair in the host cell (for a recent review, refer to Arbuthnot et 
al., 2000). HBx has been shown to compromise the repair of UV-damaged DNA 
and is known to interact with factors that participate in cellular DNA repair 
pathways (Becker et al., 1998; Capovilla et al., 1997; Lee et al., 1995). 
Intracellular factors, which are known to interact with HBx, include the tumour- 
suppressor protein p53 (thus affecting the p53-mediated repair pathway), and 
damaged DNA binding protein, DDB (Becker et al., 1998).
1.2 Treatment of chronic HBV infection
As stated previously, treatment of HBV infection remains largely ineffective. 
Although HBV immunisation usually prevents HBV infection, those who are 
already chronically infected with the virus continue to be at risk for developing 
cirrhosis and liver cancer. Most therapeutic agents under clinical evaluation 
belong to a new generation of immune system modulators and nucleoside or 
nucleotide analogues. These agents may deliver therapeutic benefits in the short­
term. However, it remains to be seen whether these will overcome the serious 
concerns regarding long-term efficacy and tolerability.
Most anti-HBV agents developed to date target the inhibition of viral 
DNA synthesis. Since the HBV polymerase possesses multiple functions, some 
of which are unique to hepadnaviruses, it represents an ideal target for antiviral 
agents. Deoxy- and dideoxynucleoside analogues specifically inhibit the RNA- 
dependent DNA polymerase action of HBV polymerase by competing with natural 
substrates and leading to truncated DNA synthesis. Other strategies rely on 
boosting the immune system response to viral infection. Patients who develop 
HBV chronic infection appear to have a deficient immune response to HBV 
antigens (Chisari and Ferrari, 1995). The immune system modulators developed
to date possess both a direct antiviral and an immune modulatory action (Vilcek 
and Sen, 1996).
1.2.1 Nucleoside analogues and immune system modulators
The second generation nucleoside analogue lamivudine or 3TC (p-L-2',3'- 
dideoxy-3'-thiacytidine) is a deoxycytidine analogue with an unnatural 
levorotatory ‘L’ configuration and is currently the only approved alternative to 
interferon-alpha (IFN-a) treatment. Lamivudine is part of a new generation of 
biochemically novel nucleoside analogues that was originally developed to 
combat human immunodeficiency virus (HIV) and members of the herpes simplex 
virus family. Although lamivudine appears to be a well-tolerated inhibitor of HBV 
replication, it has been established that short-term lamivudine monotherapy is 
ineffective in clearing residual viral infection. A twelve-month course of 
lamivudine monotherapy was found to achieve clearance of HBeAg in 20-30% of 
eAg-positive chronic patients and virological remission in more than 65-70% of 
HBeAg-negative chronic carriers (Papatheodoridis et al. 2002). However, for the 
latter, relapses were observed in the majority of responders following the 
cessation of therapy. Although long-term lamivudine therapy appears to be 
relatively safe, prolonged therapy (for longer than twelve months) is associated 
with a progressive increase in the rate of viral resistance to lamivudine (Ling et 
al., 1996). Virological breakthrough usually develops after six months of 
lamivudine monotherapy and that rate varies between 15-30% after twelve 
months, and exceeds 50% after three years of therapy in both HBeAg positive 
and negative chronic carriers (Delaney et al., 2001). The propensity to develop 
resistant HBV strains is likely the result of a combination of high viral turnover 
and HBV polymerase function. HBV polymerase, like most retroviral 
polymerases, lacks proof-reading ability and as a result is prone to a high error 
rate. It has not been firmly established whether resistant HBV mutant strains exist 
prior to therapy or whether these occur during the course of therapy. However, 
there does appear to be some evidence supporting the hypothesis that 
lamivudine-resistant strains are present ab initio and are then selected 
immediately following treatment.
The first lamivudine-resistant HBV strains presented mutations within 
the YMDD motif (tyrosine-methionine-aspartate-aspartate) of the HBV 
polymerase. This motif is in catalytic region C of the HBV polymerase and is 
conserved in all viral reverse transcriptases. The most common nucleotide 
substitutions result in a change from leucine (L) at position 526 to methionine (M), 
and M to valine (V) at position 550 (L526M and M550V, respectively) (Ling et ai, 
1996; Tipples et a i, 1996). Many mutations have been identified in different 
regions of HBV polymerase yet the next most common resistance mutation is the 
substitution of M with isoleucine (I) at position 550 (M550I) (Tipples et ai, 1996). 
Other mutations of HBV polymerase have been described predominantly within 
catalytic regions B and C, but their significance towards resistance remains 
undetermined (Delaney et ai, 2001). The replication rate of lamivudine-resistant 
mutant strains in cell culture is a lot lower than that of wild-type HBV. A single 
mutation at position 550 (M550V or M550I) was found to decrease significantly 
the rate of viral replication (Dienstag et a i, 1999; Lai et a i, 1998), whereas this 
does not seem to be affected by additional mutations at position 526 (L526M). 
Lamivudine-resistant mutant strains suffer from a selective disadvantage in the 
absence of antiviral pressure, which may explain why wild-type HBV reappears a 
few months after the discontinuation of lamivudine therapy (Chayama et ai,
1998).
The clinical impact of lamivudine resistant mutations has not been 
clarified. Biochemical evidence for viral breakthrough, which is usually expressed 
as an increase in serum transaminase levels, appears several months after the 
first detection of lamivudine resistant strains (Liaw et a i, 1999). This may be 
either after or before the peak detection of HBV viraemia levels. Nevertheless, 
several studies recommend that patients who develop resistant strains should 
continue to be treated with lamivudine since resistant strains are less aggressive 
than wild-type HBV (Honkoop et ai, 2000).
Among newer HBV antivirals in clinical studies, the purine derivatives 
such as adefovir dipivoxil and entecavir, and the pyrimidine derivative 
emtricitabine, appear to be at least as potent as lamivudine in suppressing HBV 
replication. The carbocyclic deoxyguanosine analogue famciclovir has recently 
undergone Stage III clinical trials. However, famciclovir appears to have a 
relatively limited efficacy for general use in patients with chronic HBV. Extensive
clinical trials are necessary for the development of any new nucleoside/tide 
analogues since some have been shown to be severely toxic in vivo and have 
even resulted in death (McKenzie et a/., 1995).
Of serious concern to the future of nucleoside/tide analogues are the 
results obtained from in vitro studies which indicate that mutations found in 
lamivudine- and famciclovir-resistant HBV strains (in particular, the YMDD 
mutations of viral polymerase) can confer cross-resistance to emtricitabine, and 
the pyrimidine derivative p-L-Fd4C (2',3'-dideoxy-2',3'-didehydro-[3-L-5- 
fluorocytidine). Notwithstanding the above concerns, preliminary studies using 
adefovir dipivoxil show that clinical efficacy is possible following the development 
of lamivudine resistance (Xiong et al., 2000). A number of nucleoside analogues, 
which include adefovir dipivoxil and entecavir, suppress replication of YMDD 
mutant HBV (Delaney et al., 2001; Perrillo et al., 2000). However, since only 
short-term studies have been completed to date, it remains to be seen whether 
these nucleoside/nucleotide analogues will develop their own mutant-resistant 
HBV quasi-species in vivo. The most likely future outcome will include 
combination-based therapies for treatment of chronic HBV infection using various 
nucleoside/nucleotide analogues in combination with the immune modulator 
interferon-alpha (IFN-a). These combinations may be augmented at a later stage 
by novel molecular approaches to therapy. However, the ease with which drug- 
resistant strains develop and the added toxicity of combination therapy must be 
worrying factors for the future development of these antiviral chemotherapeutic 
agents (Delaney et al., 2001).
Present therapy for chronic HBV infection includes the immune 
modulator IFN-a. Positive results have been reported in only a limited number of 
cases. A subgroup of patients with active viral replication (HBeAg positive), with 
elevated serum transaminases, and low viraemia, appear to respond well to IFN- 
a treatment. But, for the vast majority of chronic carriers IFN-a therapy remains 
ineffective. Interferon therapy is also associated with unfavourable dose-limiting 
side effects (Niederau et al., 1996). Although a number of other immune 
modulators have been tested for their effects against chronic HBV infection, such 
as interferon-gamma (Guidotti et al., 2002), thymosin alphal (Lau, 2000), and 
interleukin-12 (Zeuzem and Carreno, 2001), it is obvious that a better
understanding of the antiviral effects of the immune modulators is needed in 
order to improve their therapeutic efficacy and tolerability.
1.2.2 Novel molecular approaches to therapy
Significant progress is being made in establishing entirely novel treatment 
strategies for chronic HBV infection. Owing to the emergence of various cellular 
and animal models of viral infection, as well as to advances in the field of 
molecular biology, a number of different and innovative molecular approaches 
have been tested for their therapeutic potential against chronic HBV infection. 
Many review articles deal with the emegence of these novel molecular or gene- 
based approaches to therapy (Nassal, 1997; von Weizsacker e ta i, 1997; Wands 
et al., 1997; Zoulim and Trepo, 1999). Most putative molecular therapeutic 
strategies are presently in an early stage of development, and many remain 
untested hypotheses. However, some of these novel molecular therapies appear 
to represent an improvement on existing pharmacological treatment regimes and 
have imminent clinical application, particularly with regard to specificity and 
toxicity. Promising candidates include antisense oligonucleotides, naked DNA 
vaccines, hairpin and hammerhead ribozymes, and decoy attenuated viruses 
(dominant negative mutants). Of these candidates, the therapeutic effects of 
hybridising nucleic acids will be explored, namely antisense oligoribonucleotides 
and ribozymes.
As potentially novel therapeutic agents, antisense RNA molecules can 
inactivate viral nucleic acid by Watson-Crick hybridisation to complementary viral 
RNAs, thereby inducing viral RNA degradation or preventing the translation of 
viral proteins. Catalytic RNAs, or ribozymes, differ from antisense molecules in 
that they function as endonucleolytic enzymes, targeting and degrading viral RNA 
in a sequence-specific manner. Both nucleic acid approaches to therapy of 
chronic HBV infection are explored. However, this thesis specifically focuses on 
the antiviral effects of hammerhead ribozymes, which are the most 
therapeutically versatile of the ribozyme species.
1.3 Ribozymes
This section briefly reviews the discovery of catalytic RNAs and their significance 
with regard to the origins of biomolecular replicators and the early evolution of 
life. The vast array of research conducted on hammerhead ribozymes is 
explored, emphasising the efforts made to engineer this RNA species into 
potentially viable antiviral therapeutic agents.
1.3.1 Catalytic RNAs
Since their discovery over 100 years ago, proteins were regarded as the only 
macromolecule capable of fulfilling the role of biological catalysts. For all life, 
proteins represent a ubiquitous and versatile catalyst. Enzymes are so intimately 
coupled to their protein nature that they have always been unambiguously 
defined as proteins. Yet, until relatively recently, there has been little appreciation 
of the scope and biological contribution of other macromolecular biocatalysts, in 
other words, of non-protein enzymes.
Although early studies on the nature and function of the ribosome 
suggested a role for RNA in the catalytic functions of this organelle, it was not 
until the early 1980’s that Thomas Cech, Sydney Altman and colleagues 
discovered independent RNA catalysts. These were reported in 1982 for group I 
intervening sequences (introns) of Tetrahymena (Kruger et al., 1982) and in 1983 
for the RNA subunit component of ribonuclease P (RNase P), which is necessary 
for tRNA maturation (Guerrier-Takada et al., 1983). The name ‘ribozyme’ was 
thus coined to denote all ribonucleic acid sequences with enzyme-like functions. 
There are seven different types of naturally existing ribozymes (Table 1.1). These 
are conveniently divided into two groups, namely the large and small ribozymes. 
Large ribozymes include group I and II introns and the catalytic RNA subunit of 
RNase P (Guerrier-Takada et al., 1983; Kruger et al., 1982; Peebles et al., 1986). 
Small ribozymes include hammerhead (Forster and Symons, 1987; Uhlenbeck, 
1987), hairpin (Wu et al., 1989), hepatitis delta virus (HDV) (Buzayan et al., 1986; 
Dange et al., 1990) and the Neurospora mitochondrial Varkud Satellite (VS) 
ribozymes (Saville and Collins, 1990).
Table 1.1 Naturally occurring ribozyme species (Cech and Golden, 1999; Doudna and
Cech, 2002).
Category Number
Sequenced Biological Source
Reaction
performed3
Self splicing RNAs:
Group I >1500 Eukaryotes (nuclear and 
organellar), prokaryotes 
and bacteriophages
Trans-esterification 
(3' - OH)
Group II >700 Eukaryotes (organellar) and 
prokaryotes
Trans-esterification 
(3 '-OH)
Self-cleaving:
Group l-like 6 Didymium, Naeglaria Hydrolysis (3'-OH)
Small self-cleavers:
Hammerhead 11 Plant viroids, virusoids and 
Satellite RNAs (newts & 
cave crickets)
Trans-esterification 
(2', 3' >p)
Hairpin 1 Satellite RNAs of tobacco 
ringspot virus
Trans-esterification 
(2', 3' >p)
Hepatitis 5 
Virus (HDV)
2 Human hepatitis virus Trans-esterification 
(2', 3' >p)
Varkud Satellite 1 Neurospora mitochondria Trans-esterification 
(2', 3' >p)
RNase P RNAs
Various >500 Eukaryotes (nuclear and 
organellar), prokaryotes
Hydrolysis
(3'-OH)
aAs seen from the reaction products.
Recent studies suggest that the ribosomal RNA as well as the RNA 
component of the spliceosome is a ribozyme (Cech, 2000; Collins and Guthrie, 
2000; Nissen et ai, 2000). In nature, however, the catalytic repertoire of 
ribozymes is limited to RNA processing reactions. Ribozymes generally catalyse 
the endonucleolytic trans-esterification of the phosphodiester bond backbone of 
RNA, requiring structural and/or catalytic divalent metal ions under physiological 
conditions. The group I and II introns are found in bacteria and in organelles of 
higher plants, fungi and algae (Cech and Herschlag, 1996; Michel et a i , 1989). 
These large ribozymes cleave RNA phosphodiester linkages, using an external 
nucleophile in a two-step reaction to splice-out their primary transcripts. The 5' 
splice site is attacked by the 3'-OH of the external guanosine in group I introns, or 
by the 2'-OH of internal adenosine for group II introns. RNase P is an 
endonuclease that, in a simpler reaction, generates the mature 5' end of tRNAs 
(Takagi et ai, 2001). The bacterial RNase P RNA subunit has catalytic activity 
independent of its protein subunit component. However, both components are 
necessary for catalysis in vivo. By contrast, the small ribozymes use an internal 
nucleophile (usually the 2' oxygen of the ribose moiety at the cleavage site) for a 
non-hydrolytic cleavage reaction, which results in the formation of 2',3'-cyclic 
phosphate and 5'-hydroxyl termini (Takagi et ai, 2001).
1.3.2 Ribozymes and the origins of life debate
The central dogma of molecular biology, that biological information flows from 
DNA to RNA (transcription) and from RNA to proteins (translation), defines the 
role of nucleic acids as molecules of information storage and retrieval. An 
evolutionary paradox is established, since each component of the biological 
information pathway requires catalysis, a role previously the sole preserve of 
protein enzymes. Molecules capable of sustaining early life require, theoretically, 
two fundamental criteria: catalytic function as well as information storage and 
retrieval. It is not surprising then that catalytic RNAs, or ribozymes, which 
possess both these requirements, fulfil the role of candidate progenitor molecule 
for all life. The storage, transfer and replication of information allow any system to 
undergo natural selection and improve biological viability. Equally important is
catalytic function. At the very least the information-carrying molecules require 
enzymatic properties in order to copy their information from generation to 
generation. The enzymatic process must be specific and proceed with high 
fidelity, but a frequency of errors is necessary for the diversity to drive adaptation 
and evolution. It is now thought that the evolution of life did include a phase 
where RNA was the predominant biological macromolecule, predating both 
proteins and DNA. Today, a multitude of evidence supports RNA as a precursor 
hereditary biological molecule in what has been termed “The RNA World” 
hypothesis (Figure 1.6) (Di Giulio, 1997; Gilbert, 1986).
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Figure 1.6 The ‘R N A W orld  hypo thes is ’ as envis ioned by Cech and G olden (Cech and 
G olden, 1999). The RNA W orld  predates both D N A and prote ins and 
suggests  tha t all life, both extan t and extinct, derives from  R N A-based se lf­
rep licators. In the RNA W orld , the tw o im portant p re requ is ites fo r life, 
in form ation  storage and ca ta ly tic  power, is in the  dom ain  o f RNA. Later, the 
deve lopm en t o f specia lised ro les m ay have resulted in the transfe rence  o f 
ca ta ly tic  activ ity  to RN A-pro te in  com plexes and u ltim ate ly  to prote ins alone. 
S im ilarly, in form ation  storage m ay have been transfe rred  from  RNA to the 
dom ain  o f DNA. Today, all o f life lies w ith in  the ‘DNA W o rld ’. Y e t a preb io tic  
world  o r p re -R N A  environm ent, w hich is specu la ted  to involve m ore sim ple 
cata lysts, m ust have preceded the R N A W orld . Th is is like ly due to the 
d ifficu lties  in deve lop ing com plex RN A-based reactions in  v itro . These 
reactions are im plic it in the chem istry  o f the RNA W orld . There  is, however, 
no d irec t evidence from  extant life o f a p re -R N A  W orld .
Two major hurdles persist in the analysis of the RNA World. Firstly, few 
ribozymes from extant species possess the catalytic repertoire necessary for 
even the most basic of replication reactions. Secondly, RNA is a complex 
macromolecule and is unlikely to self-assemble by random molecular evolution 
even under a highly reducing environment (lack of free oxygen) (Mojzsis et al.,
1999). For this reason, there is general consensus that a pre-biotic condition 
must have preceded the RNA World (Mojzsis et al., 1999). However, the exact 
nature of such a pre-RNA World environment remains speculative. Although the 
second hurdle still remains unsolved, the first hurdle has been tackled by in vitro 
experiments, which aim to increase the catalytic variability of ribozymes. 
Techniques have been developed which improve the repertoire of ribozyme- 
catalysed reactions, thus exploring the chemical boundaries of the RNA World. 
Since any sequence change to the ribozyme backbone directly results in a 
different phenotype (as the catalytic action is altered), specific ribozyme 
phenotypes can be selected from a pool of random RNA sequences. Successive 
rounds of in vitro selection and evolution mould and refine the creation of 
artificially desired phenotypic traits (Green et al., 1990; Joyce, 1989). Briefly, a 
large combinatorial library of different RNA sequences is chemically challenged 
to express a particular phenotypic trait. The molecules that succeed are amplified 
and reselected. Through successive iterations of challenging, selecting and re­
amplifying generations of RNA molecules, new enzymatic traits are created 
(Green et al., 1990; Joyce, 1989). This represents a useful way of mining 
sequence space (up to 1015 different oligoribonucleotides can be screened). 
Newly identified nucleic acid catalysts may shed light on previously extinct 
enzymatic functions or offer completely new traits altogether. In vitro 
selection/evolution has greatly improved the catalytic repertoire of RNA (and 
DNAs). Some of the catalytic activities that have been selected in vitro include 
RNAs that utilise nucleoside triphosphate substrates (Ekland and Bartel, 1996; 
Lorsch and Szostak, 1994), make and break amide bonds (Dai et al., 1995; 
Wiegand et al., 1997), alkylate a nucleoside or a thiophosphate (Wilson and 
Szostak, 1995), and add an amino acid to a nucleoside via an ester linkage 
(lllangasekare et al., 1995). Although these reactions all utilise RNA as a 
substrate, other substrates have been tested. Notably, RNAs have been selected 
to catalyse a classical chemistry reaction, Diels-Alder cycloaddition, in the
presence of Cu2+ ions (Tarasow et at., 1997), and have been selected to insert 
metal ions into porphyrin rings (Conn etal., 1996).
Perhaps the most intriguing developments to date are in the efforts to 
develop an in vitro RNA replicator. An RNA-dependent RNA polymerase was 
generated and selected in vitro that repeatedly extends an RNA chain up to 14 
nucleotides from a specified template (Johnston et ai, 2001). Apart from their 
value to studies aimed at understanding the role of RNA in the early history of 
life, experiments of this nature may lead to the development of in vitro self- 
replicating systems. These sytems are likely to facilitate the discovery of new 
RNA enzymes by automating Joyce and Green’s in vitro evolution technique 
(Green etai ,  1990; Joyce, 1989).
1.3.3 Hammerhead ribozymes
Hammerhead ribozymes are the smallest known RNA catalysts capable of 
directing the site-specific trans-esterification of a phosphodiester bond in the 
presence of divalent metal ion cofactors. These ribozymes were discovered in the 
RNA genomes of several different small plant pathogens possessing site-specific 
self-cleavage activity. The hammerhead ribozyme catalytic motif was first 
identified in viroid RNA (Hutchins et a i, 1986) and later in virusoids (Forster and 
Symons, 1987) and in small satellite RNAs (Miller et al., 1991). Hammerhead 
ribozymes have also been found in RNA transcripts of satellite DNA tandem 
repeat sequences in several newt (Koizumi et ai, 1988), schistosome (Ferbeyre 
et ai, 1998) and cave cricket species (Rojas et ai, 2000). In contrast to the 
catalytic activity of hammerhead ribozymes in the newt, schistosome, and cave 
cricket (which are all associated with transcribed repetitive DNA sequences in 
animals), hammerhead ribozyme activity in the small plant pathogens is well 
defined and appears to be an integral component for genomic replication. The 
observed RNA processing involves the site-specific, self-cleavage of linear RNA 
intermediates (multimeric RNA precursors). These pregenomic viral concatamers 
represent the precursor RNA multiples of monomeric plus and minus RNA 
template strands that undergo site-specific internal RNA editing (Bratty et ai, 
1993; Symons, 1992). Spliced monomers then join head-to-tail to form a 
circularised single-stranded RNA genome. This form of the rolling-circle
replication mechanism is a feature shared by all ribozyme-containing RNA 
pathogens.
Recent evidence from experiments using in vitro selection techniques 
suggests that the hammerhead ribozyme catalytic motif is ubiquitously conserved 
for the catalysis of phosphodiester bond hydrolysis. The divergent organisms 
may thus have derived their hammerhead ribozyme function independently 
(Salehi-Ashtiani and Szostak, 2001). The biological role of hammerhead 
ribozymes in newt, schistosomes and cave crickets remains speculative. These 
ribozymes were found to be active in vivo and appear to impact RNA processing 
events at the riboprotein complex (Denti et al., 2000; Luzi et at., 1997). More 
specifically, with respect to the newt hammerhead ribozyme, dimeric and 
multimeric RNA transcripts, which are generated by all somatic tissues as well as 
in the testes, self-cleave into monomers at the hammerhead domain. Monomeric 
units contain intact hammerhead ribozyme sequences. These sequences 
associate with the newt ovary riboprotein complex with the help of a protein that 
specifically binds to the ovarian form of the newt ribozyme (Cremisi et ai., 1992; 
Denti et al., 2000).
1.3.4 Hammerhead ribozyme structure and function
The hammerhead ribozyme, in its wild-type conformation, consists of roughly 
forty nucleotide sequences and folds into a secondary structure containing three 
distinct domains that form stem-loop helical motifs. These domains are 
designated helix I, II and III. The consensus sequence requisite for the catalytic 
core consists of at least thirteen conserved nucleotides at the junction of three 
duplex stems (Figure 1.7) (Forster et al., 1990; Forster and Symons, 1987; 
Haseloff and Gerlach, 1988). Endonucleolytic cleavage of a phosphodiester bond 
then takes place 3' of the 5' NUH 3' catalytic core, where N represents any base, 
U represents a conserved uridine and H represents any base except G, to 
generate sequences terminating in 2',3'-cyclic phosphate and 5'-hydroxyl termini 
(Shimayama et al., 1995; Zoumadakis and Tabler, 1995). Recent experiments 
determining hammerhead ribozyme sequence specificity at the cleavage site 
have resulted in the reformulation of the 5' NUH 3' rule to 5' NHH 3' (Kore et al., 
1998). The hammerhead ribozyme is a metalloenzyme and requires the presence
of divalent metal ion cofactors for catalysis to occur. Although in nature, Mg2+ is 
the most commonly found metal ion cofactor, Co2+, Mn2+ and Ca2+ have proven to 
be effective substitutes (Dahm and Uhlenbeck, 1991). Studies have also shown 
that ribozymes are catalytically active using high concentrations of monovalent 
cations (Murray et al., 1998).
The distinctive shape of the hammerhead ribozyme was first observed 
in the stable conformation computations of two-dimensional RNA folding patterns 
(Forster and Symons, 1987; Symons, 1992). Evidence for this particular 
conformation was also later observed in thermodynamic studies and NMR 
measurements (Heus et al., 1990; Odai et al., 1990; Pease and Wemmer, 1990). 
More recent configurations derived from X-ray diffraction data 
(Pley et al., 1994; Scott et al., 1995) and fluorescent resonance energy transfer 
(FRET) studies (Tuschl et al., 1994), indicate a three-dimensional y or ‘wishbone’ 
shape, where helices II and III are part of the same axis and where helix I lies 
adjacent to helix II (see Figure 1.7B). X-ray crystal analyses have provided a 
wealth of information regarding the overall function and structure of the 
hammerhead ribozyme. Structurally, the hammerhead ribozyme’s catalytic core, 
which resides predominantly in helix II, is well defined and is divided into two 
domains (Hertel et al., 1992). The hammerhead ribozyme numbering system is 
defined according to Hertel et al. (1992) and refers to the nucleotides in the 
catalytic core essential for hammerhead ribozyme function. These include 
domain I comprising nucleotides 5' C3U4G5A6 3' and domain II comprising 
nucleotides 5' G12A13A14 3' and 5' UzGsAg 3' (shaded in blue in Figure 1.7A & B). 
Nucleotides 5' Ui6Hi7 3', however, form part of the catalytic core on the 
complementary RNA strand (red italicised letters in Figure 1.7A & B). The three- 
dimensional configuration of the hammerhead ribozyme described by Pley et al 
(1994) and Scott et al (1995) elucidates its putative catalytic action (Birikh et al., 
1997b) and proposes domain II as the location for Mg2+ ion binding sites. The 
exact sites, however, remain to be determined.
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Figure 1.7 A two-dimensional representation of the hammerhead ribozyme with all three helical arms terminated by nucleotide loops.
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diagram is an adaptation from Birikh et at. (1997b).
1.3.5 Hammerhead ribozymes that cleave in-trans
The wild-type hammerhead ribozyme has two of its three helical arms terminated 
by nucleotide loops allowing for intramolecular (c/'s) cleavage only. Intermolecular 
(trans) cleaving ribozymes, however, can be created synthetically by removing a 
loop terminating one of the helical arms. The trans-acting ribozyme thus requires 
the hybridisation of two independent RNA strands. Trans-cleaving hammerhead 
ribozymes have been constructed from two RNA strands in a number of ways: 
with helix III closed and helices I and II open-ended (Clouet-D'Orval and 
Uhlenbeck, 1996), with helix I closed and helices II and III open-ended (Jeffries 
and Symons, 1989; Uhlenbeck, 1987), and similarly with helix II closed and 
helices I and III open-ended (Haseloff and Gerlach, 1988).
The hammerhead ribozyme described by Haseloff and Gerlach (1988), 
where a nucleotide loop terminates helix II, is the most versatile of the trans- 
cleaving hammerhead ribozymes and has been shown to cleave substrates more 
efficiently than other constructs (Ruffner et a/., 1989). In this example, most of the 
conserved sequences necessary for the hammerhead ribozyme catalytic core 
(the RNA sequence containing a closed helix II) are present on one strand. The 
target complementary RNA strand, which forms helices I and III upon 
hybridisation, requires only the cleavage triplet (as described above) to generate 
an active site for effective catalysis. The Haseloff-Gerlach ribozyme has the least 
sequence constraints when defining its ‘substrate’ RNA strand, making it the best 
model for applications that require the targeting of ribozymes to foreign RNA 
substrates. Strictly speaking, the hammerhead ribozyme requires both RNA 
strands to contribute elements of the hammerhead ribozyme catalytic core for 
cleavage activity to occur. This is to say, the presence of all three helices is 
necessary for the hammerhead ribozyme to act catalytically. The Haseloff- 
Gerlach hammerhead ribozyme, however, distinguishes the RNA strand 
harbouring most of the catalytic core as the ‘enzyme’ or ‘ribozyme’ component 
from the cleaved target complementary RNA strand which is defined as the 
‘substrate’ component. By definition, a true enzyme requires sequential catalysis 
for substrate to product turnover. Identifying two RNA molecules as distinct 
moieties, one of which is regarded as the enzyme and the other the substrate, 
allows for the study of hammerhead ribozyme enzyme kinetics (Haseloff and
Gerlach, 1988; Koizumi et at., 1989; Koizumi et al., 1988). The separation of 
substrate from enzyme in the Haseloff-Gerlach model has allowed the use of 
hammerhead ribozymes for the site-specific intermolecular cleavage of an array 
of RNA targets. The targeted ‘knockdown’ of specific RNA molecules represents 
the single most important innovation for the potential use of ribozymes as novel 
therapeutic agents.
1.3.5.1 Defining the trans-c/eaving activity of hammerhead ribozymes
The consensus sequence requisite for the target RNA is a 5' NUH 3' triplet. The 
sequences either side of the helix II active site on the hammerhead ribozyme 
strand are complementary to the target substrate sequence adjacent to the 
cleavage triplet (Figure 1.8). These sequences form hammerhead ribozyme 
helices I and III respectively and bind the ribozyme to its substrate. The only 
requirement for helices I and III are that they bind through Watson-Crick base 
complementation with their respective substrate. By altering the sequence of the 
ribozyme arms that form helices I and III, it is theoretically possible to design 
synthetic hammerhead ribozymes that cleave substrate RNAs of any sequence. 
Random RNA sequences are replete with 5' NUH 3' cleavage triplet sites, hence 
any RNA species is theoretically accessible for hammerhead ribozyme cleavage. 
The most common naturally occurring cleavage triplet is 5' GUC 3', which 
statistically appears once every 64 nucleotides. Other naturally occurring 
hammerhead ribozyme cleavage triplets include 5' GUA 3' and 5' AUA 3' (Miller 
et al., 1991). There are only slight differences in catalytic efficiency with regard to 
the nucleotide composition of the cleavage triplet. However, for conditions that 
include saturated levels of ribozyme and substrate, the most catalytically efficient 
hammerhead ribozyme cleavage site remains 5' GUC 3' (Shimayama et al., 
1995).
1.3.5.2 In vitro kinetics of trans-c/ea ving hammerhead ribozymes
Hammerhead ribozyme steady state kinetics lends itself to Michaelis-Menten 
analysis in vitro in the same way as do kinetics studies of protein-based enzymes
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Figure 1.8 Cis- and trans-cleaving hammerhead ribozymes derived from the Haseloff- 
Gerlach model (Haseloff and Gerlach, 1988). A) C/s-cleaving ribozyme with 
helix III closed. Cleavage of the same strand yields two cleavage products. 
B) Trans-cleavage ribozyme where helical arms I and III hybridise prior to 
cleavage. The consensus sequence of helix II, which is not part of the active 
site, is shown in its native form. Mg2+ is required for catalysis. Watson-Crick 
hybridisation is shown as points between nucleotides. The cleavage triplet 
is highlighted in black. Cleavage is shown 3' of the 5' GUC 3' triplet (shaded 
in blue) by a black arrow.
(Perreault et a!., 1990; Uhlenbeck, 1987). The enzymatic parameters /ccat 
(chemical turnover) and Km (ribozyme-substrate affinity) allow for mechanistic 
studies of the ribozyme enzymatic reaction. The minimal kinetic mechanism for 
hammerhead ribozyme catalytic action can be summarised in three reversible 
reaction steps. Ribozyme (Rz) and substrate (S) assemble into an enzyme- 
substrate complex (Rz.S) followed by cleavage of the phosphodiester bond 
generating 5' and 3' end products with a 2',3'-cyclic phosphate terminus (P1) and 
a 5'-hydroxyl terminus (P2) respectively, and followed lastly by the release of 
both products (Figure 1.9). Defining each step, where each represents the
Figure 1.9 An illustration of the minimal kinetic description and reaction scheme for a 
trans-cleaving hammerhead ribozyme. The ribozyme catalysed reaction 
consists of at least three reversible steps: A) and B) Together with Mg2+ 
ions, the substrate RNA (S) first binds to the ribozyme (Rz) (kassoc) followed 
by C) Mg2+-induced cleavage of the phosphodiester bond of the bound 
substrate (kcieav). D) The cleaved products (P1 and P2) fragments then 
dissociate from the ribozyme allowing the liberated ribozyme to engage in 
new catalytic events (kdiss) (Hertel eta!., 1994; Hertel and Uhlenbeck, 1995).
elemental rate constants in both the forward and reverse reaction, facilitates the 
analysis of individual catalytic parameters for every stage of the reaction. 
Although such an analysis yields important information, it still represents a 
simplified model as both the parameters of turnover and affinity, respectively kcat 
and Km, may unwittingly be affected by indistinguishable contributions from 
several of the reversible reaction steps. These include the folding of ribozyme
and substrates into alternative inactive conformations (Clouet-D'Orval and 
Uhlenbeck, 1996; Fedor and Uhlenbeck, 1992; Hertel et al., 1994) or unusually 
slow release (dissociation) of reaction products (Fedor and Uhlenbeck, 1990). 
Flence determining an accurate kinetic scheme for hammerhead ribozyme 
catalysis necessitates the delineation of rate constants for each individual 
reaction step. Most importantly, it is necessary to separate the rate of chemical 
cleavage activity from the rates of substrate binding and substrate-product 
dissociation (Hertel etal., 1994).
Under multiple turnover conditions where ribozyme concentrations are 
small relative to that of substrate, in vitro kinetic studies have shown that the rate 
limiting step, kcaU occurs during bond cleavage, where the cleavage rate (/cCieav) is 
less than the rate of product dissociation (kdiss) (Sawata et al., 1993; Takagi and 
Taira, 1995). Substrate binding and product dissociation is relatively fast as long 
as ribozyme helices I and III contain fewer than six nucleotides each. However, 
substrate binding and product release can become rate limiting even with the 
modest elongation of both helices I and III to 8 nuceotides each. The lengthening 
of the helical arms appears to result in protracted binding and increased ribozyme 
stability, which concomitantly increases ribozyme-substrate specificity. The 
association/dissociation rate for both substrates and products decreases 
drastically, resulting in a decrease in the overall catalytic rate (kcat < 0.008 min'1). 
The dissociation rate, kdlss, becomes rate limiting and the reaction kinetics change 
to that described under single-turnover conditions, where the ribozyme is present 
in excess over substrate (Hertel et al., 1994; Hertel and Uhlenbeck, 1995). It can 
be seen that, along with changes in pH or divalent metal ion concentration (Dahm 
et al., 1993; Dahm and Uhlenbeck, 1991), the binding nature of helices I and III 
plays the largest role in affecting the reaction rate constants. Varying the 
sequence length and nucleotide composition of the substrate-binding arms is an 
important tool for modulating the rate of substrate and product dissociation 
(Fedor and Uhlenbeck, 1992) (see section 5.2.1). The general nucleotide 
composition and the sequence encoding the hammerhead ribozyme catalytic 
core, by contrast, have a very limited effect on the rates of substrate and product 
binding. Although the cleavage reaction is reversible under standard conditions 
(10 mM MgCI2, 40-50 mM Tris-CI pH 7.5 at 25°C), the formation of products from 
substrates is 130-fold more favourable at reaction equilibrium for ribozymes
containing a total of 16 complementary annealing nucleotides. In this case the 
rate of ligation, k\\gat, is approxmately 0.008 min'1. This is due to an increase in 
entropy subsequent to bond cleavage of the bound ribozyme-substrate complex 
(Hertel and Uhlenbeck, 1995). The binding and release of substrate and 
products, on the other hand, follow the kinetics expected from a Watson-Crick 
dissociation curve.
Wild-type cleavage rates for most of the described hammerhead 
ribozymes as well as other small ribozyme species (for example, hairpin and VS 
ribozyme) are remarkably similar, with typical catalytic turnover approximating 
one molecule per minute (kcat« 1 min'1) (McKay and Wedekind, 1999). Evident is 
the fact that ribozyme catalytic rates in general are paltry when compared to 
protein-based enzymes, suggesting that ribozymes are intrinsically adapted to 
perform a single catalytic reaction in their wild-type conformation. This, perhaps, 
underscores their function and biological origin as intramolecular (in-c/s) cleaving 
enzymes, which have a higher emphasis on specificity rather than turnover.
1.3.6 Other small ribozymes designed to cleave in-trans
Of the naturally occurring small ribozymes, the hairpin (Hampel et al., 1990), 
HDV (Been, 1994) and Neurospora VS (Guo and Collins, 1995) ribozymes have 
all been converted to cleave in trans. The construction of these trans-acting 
ribozymes was achieved by adopting a similar approach to that used for 
hammerhead ribozymes. Sequences were selected that allow the ribozyme to be 
distinguished into substrate and enzyme components. The substrate sequence 
selected contains the minimal number of nucleotides necessary to complement 
the nucleotides provided by the ribozyme sequence for proper catalytic core 
function.
A number of different hairpin (Kruger et al., 1982; Ojwang et al., 1992) 
and HDV ribozymes (Ananvoranich and Perreault, 1998; Kato et al., 2001) have 
been adapted and used extensively to cleave RNA molecules in trans. Their 
enzymatic properties are discussed in detail elsewhere (Takagi et al., 2001). Of 
the naturally occurring small ribozymes, the Neurospora VS trans-cleaving 
ribozyme is the least understood and is unlikely to be immediately applied as a 
therapeutic agent (James and Gibson, 1998).
Hairpin ribozymes are unique among the small ribozymes in that they 
do not require Mg2+ ions for catalysis (Chowrira et al., 1993; Hampel and Cowan, 
1997). This ribozyme species is composed of four helical regions interspersed by 
two nonduplexed regions. The trans-cleaving hairpin ribozyme hybridises with its 
substrate forming helices I and II. A nonduplexed region lies between the two 
helices (Berzal-Herranz et al., 1993). The substrate RNA requires a minimal 
sequence necessary to complement the hairpin ribozyme catalytic core for 
cleavage, namely, 5' RYNGHYB 3' (where N = any base; R = A,G; Y = C,U; B = 
C,G,U; H = A,C,U; V = A,C,G) (Figure 1.10A). Cleavage occurs immediately 5' of 
the guanosine in the nonduplexed region of the substrate sequence. Like the 
hammerhead ribozyme, the hairpin ribozyme has been widely applied for its 
potential as a therapeutic agent (James and Gibson, 1998). Although the 
hammerhead ribozyme is reversibile with cleavage being favoured over ligation, 
hairpin ribozymes favour ligation ten-fold over cleavage in the presence of excess 
products (Hegg and Fedor, 1995; Nesbitt et al., 1997). This is assumed to be the 
result of a more rigid cleavage reaction, which constrains the products within the 
cleavage site (McKay and Wedekind, 1999).
Both genomic and antigenomic HDV ribozymes possess a pseudoknot 
secondary structure consisting of four helices and three single-stranded regions 
(Ferre-D'Amare et al., 1998; Takagi et al., 2001). The fra/is-cleaving ribozyme 
(Figure 1.1 OB) is divided at the junction of helices I and II (referred to as P1 and 
P2). P1, consisting of 7 bp in the wild-type HDV ribozymes, has a cleavage site at 
the 5'-end of the cleavage recognition sequence 5' GN6 3' (G followed by six 
nucleotides) (Roy et al., 1999). Like hammerhead ribozymes, the HDV ribozyme 
requires divalent metal ions for catalysis. Their catalytic properties are different to 
hammerhead ribozymes in that a cytosine (or pyrimidine) base distal to the 
cleavage site is thought to act as a general acid during catalysis (Takagi et al., 
2001). Helices II and III (P2 and P3) retain the catalytic core structure while helix 
IV (P4) acts to stabilise the active site conformation. However, studies have 
shown that P4 is dispensable in the function of the trans-cleaving HDV ribozyme 
(Bartolome et al., 1995).
Since the natural host of HDV is the human hepatocyte, HDV 
ribozymes have the unique advantage of acting naturally within an intracellular
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Figure 1.10 The general secondary structure depicting the minimal core sequences of 
both a trans-cleaving A) hairpin (Berzal-Herranz et at., 1993) and B) 
antigenomic HDV ribozyme (Ananvoranich and Perreault, 1998) and their 
complementary substrates. The hairpin catalytic region is defined by helices 
III and IV, whilst recognition of the susbtrate is by Watson-Crick base 
pairing within helices I and II. The pseudoknot HDV structure is numbered 
according to Perrotta and Been (Perrotta and Been, 1991). The minimal 
substrate strand for both hairpin and HDV ribozymes is labelled in blue with 
the essential cleavage recognition region shaded (light blue). Single dots 
represent Watson-Crick base pairing. A red dash represents the G-U 
wobble basepair in the P1 helix, while a blue dash denotes a homopurine 
basepair at the top of the P4 helix. The black arrows indicate the cleavage 
sites. IUB codes are used: N = any base; R = A,G; Y = C,U; B = C,G,U; H = 
A,C,U; V = A,C,G.
environment. These ribozymes are especially attractive in targeting HBV given 
that the HDV infection life cycle is dependent on the presence of HBV, as HDV 
makes use of HBV-generated envelope proteins. Interestingly, HDV has been 
proposed as a vector for the delivery of ribozymes specific for chronic HBV 
infection (Hsieh and Taylor, 1992). Yet, little is known about the aetiology of 
HDV-associated liver disease and the possibility of cytopathic effects induced by 
HDV ribozyme sequences in the course of infection. There exists a 75% 
homology between the antigenomic HDV self-cleavage region and the first 55 
nucleotides of human 7SL RNA (Negro et at., 1991; Negro et at., 1989), which is 
an essential component of the signal recognition particle (SRP), a small 
cytoplasmic ribonucleoprotein that targets nascent secretory and membrane 
proteins, to the rough endoplasmic reticulum (Walter and Blobel, 1982). HDV 
ribozymes may induce cytopathic effects on the host cell through an antisense 
mechanism by hybridising to 7SL RNA (Bartolome et at., 1995).
Clearly other small ribozymes can be designed to act as therapeutic 
agents. Nevertheless, their unique features do not, at this moment, appear to add 
value to the trans-cleaving effects of hammerhead ribozymes, which have a more 
simple structure and can be designed to cleave almost any RNA backbone with 
exquisite specificity (Kato et at., 2001).
In summary, the hammerhead ribozyme is the most amenable 
ribozyme species for experimental study owing to its size and versatility (Kato et 
at., 2001; Sczakiel and Nedbal, 1995). It has been extensively applied as a tool to 
understand the molecular evolution of biological life. Furthermore, X-ray crystal 
analyses of the hammerhead ribozyme have revealed the intricacies of RNA 
catalysis, facilitating the study of ribozyme mechanics and enzyme kinetics. It is, 
however, as a potential therapeutic agent that the hammerhead ribozyme offers 
interesting prospects in the treatment of HBV infection.
1.4 Nucleic acid-based therapy of HBV
Ribozymes and antisense molecules are examples of hybridising nucleic acid 
sequences that can be designed to inhibit the expression of specific genes. 
Targeted inhibition or ‘knockdown’ of gene expression represents the most potent 
therapeutic application of both antisense and ribozyme approaches. Like
ribozymes, antisense DNA or RNA oligonucleotides are designed specifically to 
hybridise to the target ‘sense’ mRNA by virtue of Watson-Crick hybridisation. 
Unlike ribozymes, which inactivate target substrate RNA through both antisense 
binding and endonucleolytic cleavage, antisense oligonucleotides form double- 
stranded DNA-RNA (antisense DNA) or RNA-RNA (antisense RNA) duplexed 
hybrids that prevent RNA replication, reverse transcription or block translation of 
mRNA. Additionally, double-stranded RNA-RNA or RNA-DNA duplexed hybrids 
elicit the action of RNase H, which degrades these duplexed hybrids, thereby 
inactivating target RNA (Agrawal and Zhao, 1998).
Ribozymes possess a significant pharmacological advantage over 
antisense molecules because of their enzymatic properties. Unlike antisense 
molecules, which behave like conventional competitive inhibitors, ribozyme 
molecules can cleave multiple RNA substrates, and are thus theoretically more 
efficient. Considering the parallels between ribozymes and antisense 
mechanisms, studies using antisense oligonucleotides for the inactivation of gene 
expression hold valuable information for the construction of ribozymes. Of 
particular importance are results obtained from antisense research regarding 
optimal target site selection. Even though antisense oligonucleotide therapeutic 
strategies preceded the use of ribozymes, antisense RNAs are still integrated into 
ribozyme studies as additional experimental controls. Antisense approaches that 
target HBV will be discussed first as a prelude to a review of anti-HBV ribozymes.
1.4.1 Presynthesized antisense oligodeoxynucleotides
Antisense approaches include both presynthesized oligodeoxynucleotides 
(ODNs) and endogenously expressed RNAs. Goodarzi and colleagues were the 
first to apply presynthesized antisense molecules to inhibit HBV gene expression 
(Goodarzi et al., 1990). In their study, a range of presynthesized antisense ODNs 
of 15 nt in length were directed to the preS2/S ORF of HBV. These antisense 
ODNs inhibited HBsAg production by up to 96% in the HOC cell line, PLC/PRF/5, 
which contains several copies of integrated HBV DNA. The results obtained by 
Goodarzi et al. (1990) were later confirmed using HBV-transfected Huh7 human 
hepatoma cells (Blum et al., 1991a). In the latter experiments, both the
production of HBsAg and HBeAg were significantly inhibited by antisense ODNs 
(Blum et al., 1991a).
Later studies, testing 56 different antisense target sites, showed that 
antisense ODNs targeting the HBV encapsidation signal (s) were the most 
effective inhibitors of the generation of nascent viral particles (Korba and Gerin, 
1995). None of the antisense ODNs examined had any effect on HBV transcript 
RNA levels, indicating that its therapeutic action was through the blocking of 
translation and not necessarily by degrading the target RNA (Korba and Gerin, 
1995). Antisense ODNs targeted to the core ORF, including the sequences 
complementary to the polyadenylation signal of HBV, were specifically directed to 
liver cells via their asialoglycoprotein receptors (Wu and Wu, 1992). This was 
achieved by complexing DNA to polycations, namely poly-L-lysine conjugated to 
asialo-orosomucoid. In this case, cellular uptake of complexed DNA was 
significantly faster than for uncomplexed antisense DNA. Furthermore, 
complexed antisense ODNs proved to be more effective in reducing HBsAg 
secretion and viral replication than the uncomplexed counterparts. All ODNs 
constructed were linked together by phosphorothioate bonds resulting in 
reduction of their susceptibility to nuclease degradation (Wu and Wu, 1992). In a 
later study it was also noted that pre-exposure of cells to targeted complexed 
antisense DNA blocked viral gene expression and replication following 
transfection of HBV DNA (Nakazono et al., 1996). A similar approach targeting 
ODNs to avian liver cells was attempted using complexes of unmodified human 
adenoviral particles and a protein conjugate consisting of modified bovine serum 
albumin, streptavidin and poly-L-lysine (Madon and Blum, 1996). With this 
delivery system, an antisense ODN targeted to the encapsidation site of the HBV 
pregenome caused a modest inhibition of HBV replication in transfected cells.
The first in vivo application of anti-hepadnaviral antisense ODNs was 
reported for the inhibition of Peking duck hepatitis B virus (DHBV) in Peking 
ducks. The most effective antisense ODN was directed against the 5' region of 
the preS gene and resulted in a significant inhibition of viral replication and gene 
expression in vivo (Offensperger et al., 1993). Following on from earlier in vitro 
work by Wu and colleagues (Wu and Wu, 1992), antisense ODNs complexed to 
asialo-orosomucoid poly-L-lysine conjugates were adapted to target the 
polyadenylation region and adjacent upstream sequences of the pregenome of
woodchuck hepatitis virus (WHV) in vivo (Bartholomew etai., 1995). Woodchucks 
presenting with hepatitis were injected with both complexed and uncomplexed 
antisense DNA, which resulted in a significant decrease in circulating viral DNA 
for up to 25 days post treatment. Uncomplexed antisense ODNs and random 
DNA sequences did not reduce circulating viral DNA levels (Bartholomew et al.,
1995) .
Using a mouse model for HCC, which is transgenic for the HBx gene of 
HBV, phosphorothioate antisense ODNs were targeted to two sites, including the 
initiation codon and 5' coding region of the HBx ORF. Significantly, antisense 
DNAs were able to inhibit the expression of HBx and prevented the development 
of preneoplastic lesions in the liver of treated mice (Moriya et al., 1996). In 
another study, an animal model expressing HBV markers was developed in order 
to test phosphorothioate antisense ODNs targeting HBV in vivo (Yao et al.,
1996) . Athymic BALB/c nude mice were transplanted subcutaneously with the 
hepatoma cell line, HepG2 2.2.15. This HBV transfected hepatoma cell line 
continuously replicates HBV and produces infectious particles which resulted in 
the formation of tumours after two weeks. Antisense DNA, which was injected 
directly into the tumour that developed post-transplantation, resulted in a 
decrease in the presence of viral antigens, HBsAg and HBeAg, ten days after 
treatment (Yao et al., 1996).
Most studies thus far have used phosphorothioate-modified ODNs in 
order to prevent the degradative effects of serum and cellular nucleases. 
However, their use in human therapy is hampered by questions regarding 
toxicity. Of particular concern is the risk that chemically modified nucleosides will 
be incorporated into cellular DNA (Agrawal and Zhao, 1998; Plenat, 1996). 
Robaczewska and colleagues used a polymeric DNA-binding cation, namely 
linear polyethylenimine (IPEI), as a synthetic carrier of natural unmodified 
antisense ODNs (Robaczewska et al., 2001). DHBV-infected Pekin ducklings 
were injected with natural antisense DNA complexed to IPEI targeting the 
initiation codon of the large surface protein. The unmodified antisense DNA/IPEI 
conjugates were better at targeting hepatocytes than antisense molecules alone 
and were able to inhibit viral replication and protein expression. However, the 
results were not as significant as those achieved using phosophorothioate 
modified antisense DNA (Robaczewska et al., 2001).
1.4.2 Endogenously expressed antisense RNA
Presynthesized oligonucleotides must be given continuously and in large 
quantities in order to suppress viral gene expression and replication. 
Furthermore, as has been indicated these molecules, especially 
phosphorothioates, often have undesired toxic and immunological effects 
(Branch, 1998; Stein, 1995). These effects have been reported in animal models 
and include: decreased blood clotting, white blood cell count, and heart rate 
(Guidotti and Chisari, 1996). The constitutive expression of antisense RNA from a 
DNA expression cassette may negate many of the toxicity and efficacy concerns 
of antisense ODNs and phosphorothioates. Antisense gene therapy may 
potentially provide long-term protection against the pathogenic effects of chronic 
HBV infection.
Wu and Gerber (1997) were the first to test the therapeutic effects of 
expressed antisense RNAs as antiviral agents against HBV. Initially prokaryote 
expression vectors were used to express three RNAs, which were targeted to 
inhibit the translation of HBsAg mRNA in vitro. In addition, the secretion of HBsAg 
was significantly inhibited in an HBsAg-secreting cell line transfected with 
antisense RNA-expressing vectors. The inhibitory effects lasted for many months 
post-transfection (Wu and Gerber, 1997). Using a retroviral vector delivery 
system, two antisense RNAs targeting the preC/C and preS2/S regions of HBV 
were expressed in the HepG2 2.2.15 cell line (Ji and Si, 1997). Antisense RNA 
targeted to preS2/S inhibited HBsAg and HBeAg secretion by 71% and 23% 
respectively in transduced cells, while the antisense RNA targeted to preC/C 
inhibited secretion of HBsAg and HBeAg by 23% and 59% respectively (Ji and Si,
1997).
A comprehensive study was conducted using five subgenomic 
fragments of the HBV genome to generate antisense and sense RNAs. These 
were tested for their ability to interfere with HBV replication in cultured cells (zu 
Putlitz et al., 1998). A replication-competent HBV vector was transfected into 
human HCC cells, in order to reconstitute viral replication. Antisense RNAs of 
approximately 300 nt in length targeting the preS2/S and the C/P regions 
inhibited viral antigen secretion and HBV replication by between 60% to 75%. 
Unlike the Wu and Gerber study, there was no significant reduction of HBV
transcript RNA, indicating that the antisense molecules were exerting their 
antiviral effects via the blocking of translation. However, an antisense RNA 
complementary to preS2/S was able to prevent the encapsidation of viral 
pregenomic RNA (zu Putlitz et al., 1998). Apart from the problems regarding the 
general safety and efficacy of presynthesized oligonucleotides (see section 
5.3.3), there are other concerns associated with the therapeutic application of 
both antisense DNA and RNA that warrant consideration. Although evidence in 
eukaryotic cells is slight, it is generally accepted that expressed RNAs deploy 
their antisense-mediated antiviral effects via Watson-Crick hybridisation with viral 
RNAs. Apart from impeding translation (refered to as ‘translational arrest’) and 
becoming substrates for rapid degradation by double-strand-specific RNases, 
duplexed RNA-DNA or RNA-RNA hybrids may also elicit unwanted non-specific 
or ‘non-antisense’ effects. The latter include the degradation of alternative, non- 
targeted RNAs by cellular RNase H. Since most expressed antisense RNAs are 
several hundred nucleotides in length and since only ten hybridised nucleotides 
are enough to elicit an RNase H response, the potential for antisense RNAs to 
inactivate cellular mRNAs is considerable (Branch, 1996; Branch, 1998).
Additional concerns include the fact that duplexed RNA-RNA species 
may also first serve as substrates for cellular deaminases, which modify RNA 
sequences within the duplex (Poison et al., 1996); and secondly, activate 
components of the interferon-associated antiviral pathway whose products in turn 
are known to activate the usually latent endonuclease, RNase L (Baglioni, 1979; 
Desai et al., 1995). While it is clear from most of the antisense studies that 
inhibition of HBV gene expression and replication is possible, few have 
adequately addressed these non-antisense effects. In order for antisense 
approaches to be given therapeutic credence, non-antisense effects need to be 
mitigated in any future applications.
1.4.3 Ribozymes targeting HBV
Ribozymes were first observed to cleave HBV RNA in vitro in 1992 (von 
Weizsacker et al., 1992). In contrast to research conducted using antisense 
oligonucleotides, there have only been a handful of studies exploring the potential 
of ribozymes as anti-HBV therapeutic agents.
The first anti-HBV ribozyme study made use of a triple hammerhead 
ribozyme construct. A single transcript RNA encompassing a total length of 44 
antisense nucleotides was produced from a single DNA template (von 
Weizsacker et al., 1992). These linked ribozymes were targeted to three adjacent 
cleavage triplet sites on the C ORF of HBV. All three ribozymes efficiently 
cleaved a transcribed HBV RNA substrate in a cell-free system in vitro. The study 
found that 80% cleavage of a short target RNA was possible using a 1:1 molar 
ratio of ribozyme to substrate under physiological conditions. Furthermore, the 
cleavage efficiency and kinetics of the triple ribozyme transcript was similar to 
that previously described for single ribozymes. The authors speculate that this is 
due to the fact that cleavage products were able independently to dissociate from 
the cleavage complex, thus reducing the dissociation rate of the remaining 
complementary antisense hybridising arms. However, the hammerhead 
ribozymes developed by von Weizsacker et al. (1992) showed cleavage in vitro 
using either artificial or truncated RNA substrates. These substrates prevent a 
native secondary structure conformation resulting in ribozyme cleavage 
conditions different to those found in vivo. In a later study, Beck and Nassal 
(1995) were able to express high levels of hammerhead ribozymes, which were 
driven by an RNA Polymerase III (RNA Pol III) U6 snRNA promoter in transfected 
cells. These ribozymes were directed to cleave the highly conserved 
encapsidation signal (s) of HBV. In intact cells, ribozymes were unable to reduce 
the steady-state levels of full-length HBV pgRNA, which was expressed from a 
co-transfected DNA construct. Nevertheless, ribozymes cleaved target expressed 
RNA in extracts of transfected cells in vitro since prior to cleavage, the cellular 
extracts were treated with proteinase K and phenol, and supplemented with 
additional MgCI2. These results indicate that some unknown factor(s), possibly 
proteins, prevented the intracellular hybridisation of hammerhead ribozymes to 
the s region of the pgRNA transcript. It also appears that low intracellular Mg2+ 
concentration limited the efficiency of intracellular ribozyme activity (Beck and 
Nassal, 1995). However, Mg2+ ions are critical for the establishment of the active 
form of the ribozyme-substrate complex. It was concluded that intracellular Mg2+ 
ion concentration is limiting in cases were ribozyme-substrate annealing is 
hampered by a highly structured target, such as the viral encapsidation signal. 
This result does not preclude the possibility that alternative sites on the HBV
genome are susceptible to ribozyme cleavage. The s region of HBV is known to 
be highly structured and to bind to viral polymerase, which may have 
compromised the activity of hammerhead ribozymes.
To date, the antiviral effects of hammerhead ribozymes have not been 
characterised in vivo. Other studies were able to assess the antiviral effects of 
hairpin ribozymes targeting HBV in an intracellular context. A retroviral-mediated 
delivery system was constructed in order to express three hairpin ribozyme- 
encoded sequences in hepatoma cells (Welch et a/., 1997). In this study, HOC 
cells were co-transfected with a plasmid vector containing a replication- 
competent dimer of HBV. This vector reconstitutes HBV infection in transfected 
hepatocyte cell cultures. Hairpin ribozymes, which were targeted to three regions 
on the viral pgRNA, reduced the level of viral particle production by 66% using an 
endogenous polymerase assay (Welch et al., 1997). To find accessible ribozyme 
cleavage sites on the HBV genome, a library of modified hairpin ribozymes with 
randomised substrate binding domains was constructed (zu Putlitz et al., 1999). 
This hairpin library was challenged to cleave target sites on a full-length in vitro 
transcribed HBV pgRNA substrate. Primer extension analysis revealed cleavage 
products which define potential candidate cleavage sites. Of the 40 sites 
identified, 17 conserved sites were selected for further study. Selected ribozyme 
constructs were transfected, expressed from both RNA Pol II and Pol III promoter 
elements, and tested for their antiviral effects in cultured cells. Accessible 
cleavage sites were clustered around three regions of the HBV genome: the 5' 
end of the C ORF, several sites in preS2/S, and between DR1 and DR2 on the 
HBx ORF. Four hairpin ribozymes targeting the preS2/S region were selected for 
their ability to inhibit viral replication and gene expression in transfected cells in 
culture and were shown to inhibit HBV replication and antigen synthesis by up to 
80%. Although three of the four ribozymes selected were driven by the U6 
snRNA Pol III promoter, there did not appear to be a significant difference in 
either the intracellular levels of ribozyme expression or in ribozyme-mediated 
antireplicative effects using different promoter systems.
Both studies using hairpin ribozymes offer valuable information 
regarding target-site accessibility. Further information was obtained from the 
observation of ribozyme-mediated antiviral effects in cell culture transfection and 
transduction experiments. However, hairpin ribozymes have a significantly
different catalytic mode of action compared to hammerhead ribozymes, and 
results obtained for the hairpin ribozymes cannot necessarily be interpreted for 
hammerhead ribozymes.
1.4.4 Thesis objectives
There are unique features of the hepatitis B virus that make it receptive to the 
targeting effects of therapeutic nucleic acids. The HBV genome consists of 
overlapping ORFs that cover the entire 3200 nt length of the viral genome. The 
sequence heterogeneity among hepadnaviral species is modest in comparison to 
other RNA viruses such as HIV. Conserved regions of the compact HBV genome 
may encode more than one protein as well as HBV c/'s-elements required for viral 
replication (Tiollais et al., 1981). Moreover, HBV replicates its genome from a 
pregenomic RNA template and produces numerous subgenomic transcripts. Both 
pregenomic and preC RNA species are greater-than-genome-length and 
encompass the entire 3200 nt genomic sequence of HBV. Other important RNA 
species include the 2100 and 2400 nt preS/S and the 900 nt HBx transcripts. 
Since all HBV transcripts are indispensable in the viral life cycle, any viral RNA 
entity is a potential target for attack using therapeutic nucleic acids.
Many of the viral transcripts share the same sequences, ensuring that 
ribozyme and antisense molecules can be exploited simultaneously to orchestrate 
the targeted inactivation of multiple viral RNAs. Even though there appears to be 
numerous antisense recognition sequences suitable for targeting, it is important 
to select sequences implicated in multiple functions in the life cycle of the virus, 
since the targeting of conserved sequences is less likely to result in the 
generation of ribozyme-resistant viral variants. Moreover, oncogenic viral proteins 
such as HBx and preS2/S are often expressed endogenously in non-replicative 
HBV chronic individuals. Viral integration into the chromosomes of the host 
hepatocyte usually renders the virus incapable of replicating. The onset of 
disease-causing complications of viral infection may be caused by persistent 
gene expression and is not necessarily dependent on viral replication. Therefore, 
it may also be necessary to target those viral transcripts in which translational 
products are potentially carcinogenic.
The inhibitory effects of therapeutic hammerhead ribozymes targeting 
HBV infection have not been characterised in a cellular environment. For the 
present thesis, the multifunctional HBx region was chosen as a target for 
antisense and hammerhead ribozyme-mediated attack. Previous studies using 
antisense DNA/RNA and hairpin ribozymes have indicated that the HBx region of 
HBV is accessible to nucleic acid hybridisation (Moriya et al., 1996; Welch et ai, 
1997; zu Putlitz etal., 1999). Thus, this thesis broadly encompassed the following 
objectives:
1) Mammalian expression vectors were generated to constitutively 
express RNA encoding: hammerhead ribozymes, catalytically inactive 
ribozyme controls, and antisense RNA targeted to two sites of the HBx 
ORF of HBV.
2) The functional endonucleolytic cleavage activities of various 
hammerhead ribozyme transcripts were determined in vitro. 
Hammerhead ribozyme-mediated cleavage of target HBx RNA 
substrate at specific sites was assayed in an in vitro cleavage reaction.
3) Endogenously expressed hammerhead ribozymes and antisense 
RNAs were tested to inhibit HBx mRNA expression and HBx trans- 
activation function in transfected liver-derived cells.
4) The efficacy of hammerhead ribozymes for the inhibition of viral gene 
expression and markers of viral replication was determined in 
transfected cells that reconstitute HBV infection following co­
transfection with a replication-competent vector of HBV.
5) The antireplicative effects of the anti-HBx ribozymes were assayed in 
situ in transfected cells by measuring the expression of a marker gene 
for Enhanced Green Fluorescent Protein (EGFP). The EGFP ORF was 
used to substitute the preS2/surface ORF in a vector that constitutively 
expressed all HBV pregenomic and subgenomic transcripts.
6) Multimeric cis- and trans-cleaving hammerhead ribozyme vectors were 
generated to increase the intracellular concentration anti-HBx 
hammerhead ribozymes and improve their efficacy in vivo. Cis- and 
trans-cleavage activities were determined using in vitro transcribed 
multimeric ribozyme transcripts and substrate HBx RNA.
7) The antireplicative effects of multimeric ribozymes targeted to the HBx 
ORF of HBV was assessed in transfected cells using the EGFP/HBV 
reporter assay and using vectors which reconstitute viral infection in 
transfected cells.
Some of the approaches used to modify hammerhead ribozymes for therapeutic 
use are discussed later in section 5.2. Of particular interest to this thesis are the 
methods used to deliver ribozyme therapeutic genes to their target tissue or cells 
and the methods employed to maintain their intracellular expression and 
concentration once acquired. These issues are discussed in the view of applying 
hammerhead ribozymes for the future treatment of chronic HBV infection.
2.0 HAMMERHEAD RIBOZYMES AND ANTISENSE 
RNAs TARGETED TO THE HBV H B x  OPEN 
READING FRAME
2.1 Summary
The multifunctional HBx ORF of HBV encodes a 17 kDa protein, HBx, which is 
necessary for viral infection and implicated in HBV-associated 
hepatocarcinogenesis. In this study, the HBx ORF of HBV was chosen as a 
target for hammerhead ribozyme hybridisation and cleavage. Oligonucleotides 
encoding two selected hammerhead ribozymes and sequences encoding 
respective antisense RNA as well as catalytically inactive ribozyme sequences, 
were cloned into the mammalian expression vector pCI neo to generate plasmids 
pHBx.Rzl U73 and pHBx:Rz2165i.
Hammerhead ribozymes HBx:Rz11473 and HBx:Rz2165i, cleaved their 
target HBx sequences in vitro within 60 minutes under standard physiological 
conditions. HBx:Rz1 1473 was slightly more efficient than HBx:Rz2165i and 
suggested that the site targeted by HBx:Rz1 i473 was more accessible for 
cleavage. The efficacy of the two endogenously expressed hammerhead 
ribozymes and their antisense RNA controls were tested in co-transfections of 
various liver-derived hepatoma cells. The target vectors included a plasmid that 
constitutively expresses HBx and a replication-competent dimer of HBV, which 
reconstitutes HBV infection in transfected Huh7 cells. Both ribozyme-encoding 
expression vectors, pHBx:Rz1 1473 and pHBx:Rz2165i, inactivated HBx mRNA, and 
concomitantly inhibited HBx trans-activation of the reporter plasmid pp-actin p- 
gal, which expresses p-galactosidase under control of the HBx-inducible p-actin 
promoter. HBx trans-activator function was inhibited in Chang and PLC/PRF/5 
cells and in primary hepatocellular carcinoma cultures that express endogenous 
HBx. However, since the antisense RNA control p/-/Bx;At2165i was equally as 
effective as p/-/Bx:Rz2165i, it is evident that, for this ribozyme species at least, 
antisense effects were likely to be largely responsible for ribozyme-mediated 
inhibition in cell culture.
2.2 Introduction
The HBx open reading frame (ORF) represents an ideal target for nucleic acid- 
based hybridisation. HBx is required for viral replication and the HBx sequence 
encodes multiple functions in the HBV genome (see sections 1.1.3.4 and 1.1.7.3) 
(Chen et al., 1993; Tiollais et al., 1985; Zoulim et al., 1994). The multifunctional 
HBx sequence overlaps with the 3'-terminal sequence of the polymerase ORF as 
well as HBV sequences encoding the essential basic core promoter (BCP), which 
is relatively conserved amongst the mammalian hepadnaviruses (Chen et al., 
1993; Tiollais et al., 1985; Zoulim et al., 1994). These factors restrict sequence 
plasticity of the HBx ORF and limit the ability of the virus to evade therapeutic 
nucleic acid hybridisation. All viral transcripts share a common 3' end owing to the 
presence of a single polyadenylation signal on the viral genome (Figure 1.2). As a 
result, the sequence of the smallest HBx transcript is fully included in the 3'-end 
sequences of all HBV transcripts including the pregenome (Tiollais et al., 1985). 
Targeting the HBx ORF allows for the simultaneous inactivation of the template 
RNA necessary for viral replication, along with all viral transcript mRNA species.
Although the function of HBx in the life cycle of the virus remains 
unclear, HBx is directly implicated in HBV-associated hepatocarcinogenesis 
(section 1.1.7.3) (Arbuthnot et al., 2000). As a preventative measure against the 
onset of HOC in chronic HBV individuals, inactivating the expression of viral 
proteins that are potentially carcinogenic, which include HBx, is an important 
medical objective. Since HBx can be expressed from replication-incompetent viral 
integrants, the presence of HBx-encoding sequences may be independently 
responsible for the onset of hepatocarcinogenesis, irrespective of whether 
successful suppression of viral replication is achieved. Reducing the intracellular 
presence of HBx may improve the long-term prognosis of chronically infected 
individuals.
In this chapter, two hammerhead ribozymes targeting different sites of 
the HBx ORF were investigated for the potential to cleave HBx mRNA transcribed 
in vitro. Moreover, these ribozymes were targeted to inhibit HBx trans-activator 
function in co-transfected liver-derived cell cultures. Two regions of the HBx ORF 
were chosen as targets for nucleic acid hybridisation and cleavage based on 
conserved sequences and computer predictions of accessible RNA secondary
structures- Two antisense RNA expression vectors, which anneal to the same 
sites as their hammerhead ribozyme counterparts, were used in addition to 
defective ribozyme variants as ribozyme-negative controls.
2.3 Materials and methods
2.3.1 Hammerhead ribozyme and antisense RNA expression vectors
Plasmids producing ribozyme sequences (p/-/Bx:Rz11473 and p/-/Bx:Rz2165i), their 
catalytically inactive counterparts (p/-/Bx:Rz1*u73 and pHBx:Rz2*i65i) and 
antisense oligonucleotides sequences (p/-/Bx:At1 1473 and pHBx:At21651) directed 
to the HBx ORF were generated in the pCI neo mammalian expression vector 
(Promega, Wl, USA). Oligonucleotides designed to encode the ribozyme and 
antisense sequences were synthesized using standard phosphoramadite 
chemistry (Ransom Hill, USA). Complementary sense and antisense 
oligonucleotide sequences for hammerhead ribozyme cassettes HBx:Rz1 1473 and 
HBx: Rz2i65i, and their respective catalytically-defective counterparts 
HBx:Rz1*1473 and HBx:Rz2*-|65i are presented in Table 2.1. Complementary 
sequences for antisense oligonucleotide cassettes /-/Bx:At1 1473 and HBx:At2165i 
are presented in Table 2.2. Altered bases in the sequences encoding catalytically 
inactive ribozymes are underlined. Oligonucleotides were annealed after heating 
to 95°C for 5 minutes followed by slow cooling to room temperature. Double 
stranded DNA, with 5' EcoRI and 3' Xba\ cohesive ends, was cloned into the 
equivalent restriction sites of the pCI neo vector.
Plasmid pCI neo was digested with EcoRI and Xbal. The vector 
backbone fragment was excised and eluted from a 1% agarose gel. Following 
extraction with chlorophorm/phenol (Appendix A4-1), the DNA was precipitated 
with ethanol (see Appendix A4-2). A ligation reaction containing a 50:1 molar 
ratio of annealed fragment to vector (0.6 pmol vector backbone to 30 pmol 
annealed fragment insert) was incubated at room temperature for 1 hour in a 20 
pi reaction volume containing 20 U T4 DNA Ligase (New England Biolabs, MA, 
USA). Aliquots (10 pi) of the ligation reaction were used to transform competent
Table 2.1 Complementary sense (S) and antisense (A) oligonucleotide sequences for single 
unit hammerhead ribozymes and their respective cleavage-defective counterparts.
HBx :Rz11473 S
5' AATTCTCCCAAGCCTGATGAGTCCGTGAGGACGAAACCCCG 
AGT 3'
HBx: Rz 1 1 4 7 3 A 5' CTAGACTCGGGGTTTCGTCCTCACGGACTCATCAGGCTTGG 
GAG 3'
HBx : Rz1*1473 S 5' AATTCTCCCAAGCCTAATGAGTCCGTGAGGACGACACCCCG 
AGT 3,a
HBx: Rz1*1473 A 5' CTAGACTCGGGGTGTCGTCCTCACGGACTCATIAGGCTTGG 
GAG 3'a
HBx: Rz2i65i S 5' AATTCTTATGTAACTGATGAGTCCGTGAGGACGAAACCTTGGGT 3'
HBx :Rz21651 A 5' CT AGACCCAAGGTTT CGT CCT CACGG ACT CAT CAGTTACAT AAG 3'
HBx : Rz2*165i S 5' AATTCTTATGTAACTAATGAGTCCGTGAGGACGACACCTTG GGT 
3,a
HBx: Rz2*1651 A 5' CTAGACCCAAGGTGT CGT CCT CACGG ACT CATTAGTT ACATAAG3 ,a
a Underlined nucleotides indicate the alterations made to the ribozyme catalytic site 
rendering hammerhead ribozymes H B x :Rz1* 1473 and H B x :Rz2 *165i catalytically 
defective (see Figure 2.1).
Table 2.2 Complementary sense (S) and antisense (A) oligonucleotide sequences for 
antisense RNA encoding vectors.
HBx: At11473 S 5' AATTCTCCCAAGCGAACCCCGAGT 3'
HBx: At11473 A 5' CTAGACTCGGGGTCGCTTGGGAG 3'
HBx:At2i65i S 5' AATTCTTATGTAAGACCTTGGGT 3'
H B x i At2! 65 i A 5' CTAGACCCAAGGTCTTACATAAG 3'
Escherischia coli XL1-Blue™ (Stratagene, CA, USA), which were plated on Luria 
Bertani ampicillin positive (100 pg/ml ampicillin; Gibco BRL, United Kingdom) 
agar plates (see Appendices B3-1, B3-2). To identify correctly cloned ribozyme- 
encoding plasmids, individual colonies (± 10) were cultured in 50 ml of ampicillin 
positive medium (Appendix B3-1). Plasmids were prepared by silica mini-prep 
plasmid purification (see Appendix A2-1) and digested with EcoRI and Xba\. 
Digested fragments were run on non-denaturing 8% polyacrylamide gels along 
with 30 pmol of annealed dsDNA oligonucleotides encoding HBx:Rz1 1473 as a 
molecular weight control. Gels were soaked for 5 minutes in 0.5 pg/ml ethidium 
bromide solution in 1xTAE buffer (Appendix B2-1) prior to viewing on a UV 
transilluminator. Successfully cloned plasmids were sequenced using the 
Sequenase™ Version 2.0 Kit (USB, OH, USA) to confirm the fidelity of sequence 
(Appendix A5-1). The resulting cassettes produce transcripts from the 
cytomegalovirus (CMV) immediate early promoter/enhancer. Transcripts derived 
from pHBx:Rz1 1473, pHBx:Rz1*u73 and p/-/Bx:At1 i473 contain complementary 
sequences to HBV ayw co-ordinates 1465-1481; similarly, the HBx:Rz2 16si and 
HBx: Rz2* 1651 and HBx.At21651 RNAs include sequences complementary to co­
ordinates 1643-1661 (GenBank® accession number J02203) (Figure 2.1).
2.3.2 Target and reporter plasmids
Plasmids pBS-X and pCI neo HBx have been previously described (Capovilla et 
al., 1997). In summary, DNA encoding HBx from HBV strain ayw was amplified 
using PCR. The sequence was cloned into the EcoRI and BamHI sites of the 
pBluescript II™ KS(+) (pBSII KS[+J; Stratagene, CA, USA) multiple cloning site to 
produce pBS-X. The HBx sequence was then excised from pBS-X and inserted 
into the mammalian expression vector pCI neo (Promega, Wl, USA) to produce 
pCI neo HBx. In this plasmid, HBx expression is under control of the constitutively 
active CMV promoter.
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Figure 2.1 The catalytic sequences for hammerhead ribozymes HBx:Rz11473 and 
/-/Bx:Rz2i65i and hybridisation sequences for antisense RNAs HBx:At11473 and 
HBx:At2165i. A) and C) The HBV ayw sequences targeted by HBx:Rz11473and 
HBx:Rz2i65i are indicated with the pairing ribozyme sequences of the helix I 
and helix III domains. HBx:Rz11473 is complementary to HBV ayw bases from 
co-ordinates 1465 to 1481 and HBx:Rz21651 is complementary to bases 1643 
to 1661. The 5' GUC 3' cleavage motifs are shaded and the arrows indicate 
the sites of cleavage. The ribozyme catalytic cores are located within the helix 
II domains. The underlined U residue of the HBx:Rz11473 cleavage motif is 
substituted for a C in HBV subtype adw. Circled G and A bases are 
substituted for A and C residues respectively in the sequences encoding 
catalytically inactive ribozymes HBx;Rz1*i473and HBx: Rz2*i65i- B)and D) The 
HBV ayw sequences targeted by antisense control molecules HBx:At11473 and 
HBx:At2165i. These sequences both lack ribozyme helix II domains and thus 
exert their inhibitory activity by hybridisation (antisense effects).
Plasmid pHBV adw HTD has been described previously (Blum et at., 
1991b), and is a HBV replication competent plasmid that comprises a head-to-tail 
dimer of the entire HBV genome (strain adw) cloned into pGEM 7F+ (Promega, 
Wl, USA). The plasmid p(3-actin (3-gal contains an expression cassette with the p- 
galactosidase reporter gene under control of the p-actin promoter (Wang and 
Stiles, 1994). The reporter plasmid pCI neo GFP expresses the gene for 
Enhanced Green Fluorescence Protein (EGFP) under constitutive control of the 
CMV promoter (Passman et ai, 2000; Weinberg et a i, 2000).
2.3.3 In vitro transcription and cleavage
The /-/Bx-encoding plasmid, pBS-X, ribozyme plasmids p/-/Bx:Rz1 1473 and 
pHBx:Rz2165i and their catalytically inactive counterparts pHBx:Rz1*u73 and 
p/-/Bx:Rz2*-i65i were linearised by digestion with Xba\. Linearised DNA templates 
were eluted from a 1% agarose gel, and extracted using phenol/chloroform as 
described in 2.3.1 and Appendix A4-1. DNA pellets were resuspended in H20  to 
a final concentration of 1 ju.g/ju.1. Radiolabelled target HBx RNA was transcribed 
from Xbal-linearised pBS-X. The reaction mixture contained 2 pg of template 
DNA, 10 mM dithiothreitol, 40 mM Tris-HCI (pH 8.0), 8 mM MgCI2, 2 mM 
spermidine, 20 U RNasin (Promega, Wl, USA), 0.5 mM ATP, 0.5 mM TTP, 0.5 
mM UTP, 12.5 pM GTP, 25 pCi of a-32P GTP (3000 Ci/mmol; NEN du Pont, 
USA), and 20 U of T3 RNA Polymerase (Promega, Wl, USA) in 20 pi. After 
incubating at 37°C for 1 hour, 20 U of DNase I (Promega, Wl, USA) were added 
to the reaction mixture for 20 minutes at 37°C. RNA fragments were purified 
using the Qiagen RNeasy (Qiagen, CA, USA) RNA purification kit according to 
the manufacturers instructions. In vitro transcription reactions for ribozymes and 
their catalytically inactive controls were performed at 37°C for 1 hour in a 20 pi 
reaction mixture containing 2 pg of template DNA, 10 mM dithiothreitol, 40 mM 
Tris-HCI (pH 8.0), 8 mM MgCI2, 2 mM spermidine, 20 U RNasin (Promega, Wl, 
USA), 0.5 mM NTPs (0.5 mM each ATP, TTP, UTP and GTP), 20 U of T7 RNA 
Polymerase (Roche, Germany). Similarly, 20 U of DNase I (Promega, Wl, USA) 
were added to the reaction mixture for 20 minutes followed by RNA purification
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Figure 2.2 The target sequences for hammerhead ribozymes HBx.Rz11473 and 
/-/Bx:Rz2165i. Both antisense RNAs HBx:At1473 and HBx:At2165i (not 
shown above) target the same sequence region for hybridisation as 
their respective ribozymes: /-/Bx:Rz11473 and HBx:Ftz21651 A) The pCI 
neo HBx vector is shown with ribozyme targets of the ayw HBx 
transcript. The cytomegalovirus immediate early promoter/enhancer 
(CMV), intron and polyadenylation signal (pA) of the expression 
cassette are also indicated. B) The pHBV adw HTD vector is 
represented by the head-to-tail dimer of the HBV adw genome. The 
HBV transcripts (horizontal arrows) and HBx:Rz2165i target are 
indicated.
as above. The cleavage reaction was carried out in a 40 pi reaction mixture 
containing a five-fold molar ratio of ribozyme to radiolabelled target RNA in the 
presence of 20 mM MgCI2, 50 mM Tris-CI (pH 8.0) and incubated at 37°C. 
Aliquots (10 pi) were removed after incubation for 5 and 60 minutes and then 
added to 3 pi of RNA loading buffer (see Appendix B2-3). Samples were resolved 
on a 6% polyacrylamide, 7 M urea denaturing gel at 60 W (until the bromophenol 
blue dye front reached the end of the gel) and autoradiographed.
2.3.4 Cell Culture
PLC/PRF/5, Chang and Huh7 cell lines were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% foetal calf serum (FCS), 
penicillin (50 lU/ml) and streptomycin (50 pg/ml) (Gibco BRL, UK). Primary 
cultures of malignant hepatocytes were prepared from a resected tumour of a 
HBV chronic carrier patient with hepatocellular carcinoma. The patient’s serum 
was positive for HBsAg but negative for HBeAg on testing with Ausria and Axsym 
kits (Abbott Laboratories, IL, USA). After resection, the tissue was rinsed in 
HEPES buffered saline containing collagenase (0.025% collagenase, Sigma 
grade I; 0.075% CaCI2.2H20; 161 mM NaCI; 3.15 mM KCI; 0.7 mM Na2HP04; 33 
mM HEPES, pH 7.65). To dissociate the cells and remove fibrous material, the 
tissue was teased and passed through a fine stainless steel mesh. The cells 
collected after this treatment were washed and cultured in Ham’s F12 medium 
(and plated at 90% confluency) supplemented with 10% foetal calf serum (FCS), 
penicillin (50 lU/ml) and streptomycin (50 pg/ml).
2.3.5 Transfection and detection of HBx mRNA in cultured cells
On the day prior to transfection, Huh7 cells were seeded at one fifth of their 
confluent density. Transfections were performed according to the calcium 
phosphate method (Graham and van der Eb, 1973) (Appendix A7-1). Cells in 100 
mm diameter culture dishes were co-transfected with a combination of 20 pg of 
pCI neo HBx and 10 pg of either p/-/Bx:Rz11473, p/-/Bx:Rz1*-|473 pHBx:Rz2165i, 
pHBx:Rz2*165i or pCI neo. Similar quantities (10 pg) of the reporter plasmid pCI 
neo GFP were also included in each transfection. Prior to RNA extraction,
equivalent transfection efficiencies were verified by fluorescence microscopy that 
detected similar numbers of EGFP expressing cells in each culture dish 
(Appendix C2). Seventy-two hours after transfection, total cellular RNA was 
isolated from the cells using the Guanidinium Thiocyanate method (see Appendix 
A3) (Schaller and Fischer, 1991a).
To detect HBx mRNA using reverse transcriptase (RT) and PCR, first 
strand cDNA synthesis was performed at 42°C for 1 hour in a 20 pi reaction 
mixture containing 1 pg of total cellular RNA, 0.8 pg oligo (dT)i5 (Promega, Wl, 
USA), 1 mM each of dATP, dCTP, dTTP and dGTP, 2.5 mM MgCI2, 10 mM Tris- 
HCI (pH 8.3), 50 mM KCI, 5 U RNase inhibitor (Roche, Germany) and 4 U AMV 
Reverse Transcriptase (Promega, Wl, USA). Aliquots (4 pi) of the cDNA reaction 
mixture were used to amplify HBx and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) sequences separately. The PCR reaction mixtures 
included 2.5 pCi of a-32P dATP (3000 Ci/mmol; ICN, CA, USA), 50 mM KCI, 10 
mM Tris-HCI (pH 9 at 25°C), 0.1% Triton X-100, 1.5 mM MgCI2, 0.2 mM each of 
dATP, dCTP, dTTP and dGTP, 10 pmol each of forward and reverse primers, 
and 2.5 U of REDTaq™ DNA polymerase (Sigma, MO, USA). Sequences of 
forward and reverse GAPDH and HBx primers are given in Table 2.3.
Table 2.3 Forward and Reverse primers for G A P D H  and H Bx.
G APDH  F 5' CCCTTCATTGACCTCAACTACATG 3'
G APDH  R 5' CATGCCAGTGAGCTTCCCGTTCAG 3'
H B x  F 5' CCCTT CATT G ACCT CAACTACAT G 3'
H B x  R 5’ CATGCCAGTGAGCTTCCCGTTCAG 3'
After an initial denaturing step at 92°C for 3 minutes, thermal cycling reactions 
were conducted at 92°C for 30 seconds, 57°C for 30 seconds and 72°C for 1 
minute. Aliquots were removed from the PCR reaction mixtures during the
exponential phase of amplification after 15 and 25 cycles. Samples were resolved 
using 8% polyacrylamide gel electrophoresis for ± 1.5 hours at 100 V and then 
subjected to autoradiography overnight.
2.3.6 Transfection and detection of p-galactosidase activity
On the day prior to transfection of PLC/PRF/5 and Chang liver cells, 
approximately 2x105 cells were seeded at one tenth of their confluent density. 
Primary cultures of malignant hepatocytes were plated at 90% confluence. All 
cells were seeded in 35 mm diameter culture dishes. Transfections, as described 
in section 2.3.5, were carried out with a combination of 2 pg reporter plasmid (p 
p-actin p-gal), 8 pg of a target plasmid (pCI neo HBx or pHBV adw HTD) and
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Figure 2.3 Principle o f the HBx tra n s -activation assay. HBx activates the p-actin prom oter 
inducing an increased expression o f the dow nstream  p-galactosidase gene. 
Thus, the presence o f HBx can be m easured by assaying fo r p-galactosidase 
activ ity using histochem ical staining techn iques (X-gal is the chrom ogenic 
substra te fo r p-galactosidase).
8 jug of ribozyme (p/-/Bx:Rz11473 and/or pHSx:Rz2165i) or control plasmid (pCI 
neo). Seventy two hours after transfection, the cells were fixed and stained with 
X-gal solution (Sanes et al., 1986) (see Appendix B1-9).
Cells that had a dominant blue colouration on microscopic examination 
were assessed as positive. The number of positive cells was counted from an 
entire dish and verified by an independent observer. Duplicate transfections were 
performed on the primary cultures. The means and standard errors of the means 
(SEM) were calculated from the data of six independent transfections of 
PLC/PRF/5 and Chang cells. The analysis of variance was calculated using 
Dunnett’s multiple comparisons test with the number of p-galactosidase-positive 
cells detected in the transfections with pp-actin p-gal and pCI neo HBx without 
ribozyme as the control for comparison. This value was normalised to 100%.
2.4 Results
2.4.1 The selection of conserved regions of the HBx ORF for 
hammerhead ribozyme and antisense RNA hybridisation
Of the possible twelve 5' GUC 3' hammerhead ribozyme cleavage triplets in the 
HBx ORF of HBV strain ayw (Figure 2.4B), two sites were selected as candidate 
target regions for complementary hammerhead ribozymes and antisense RNAs. 
These include regions 1465-1481 and 1643-1661 for hammerhead ribozyme 
HBx:RZI1473 and HBx:Rz2i65i (or antisense RNA HBx:At1u 73 and HBx:At2165i) 
respectively. The hammerhead ribozyme cleavage triplet sites 1473 and 1651 
correspond to the position 3' of the 5' GUC 3' cleavage triplet on the HBx ORF of 
HBV ayw. The RNA folding program, Mfold® (Genetics Computer Group, Wl, 
USA) was used to predict the putative secondary structure of the HBx ORF to 
ascertain accessible regions for the annealing of complementary ribozyme and 
antisense sequences. The HBx sequence appears to conform to a highly 
structured secondary structure and the sites indicated in Figure 2.4A were only 
modestly accessible for nucleic acid hybridisation in the secondary structure 
predictions of the HBx ORF RNA sequence. As a result, the target cleavage sites 
were primarily selected on the basis of their relative position in conserved regions
within the HBx coding sequence (Appendix C3). Hammerhead ribozyme 
HBx:Rz1 1473 cleaves within a region shared by both HBx and P ORFs, while 
HBx:Rz2i65i cleaves within the BCP/Enh II sequence on the HBV genome.
2.4.2 Design of hammerhead ribozyme, antisense RNA and target 
vectors
Two eukaryotic expression vectors, p/-/Bx:Rz11473 and pHBx:Rz2i65i, encoding 
ribozyme sequences that hybridise to targets surrounding 5' GUC 3' cleavage 
motifs within HBx, were constructed (Figure 2.1). The ribozymes included 8 
(p/-/Bx:Rz1 1473) or 10 (pHBx:Rz2i65i) complementary bases in helix I, while in 
both ribozymes there were 8 complementary bases in the helix III domain. 
Sequence changes in the helix II domain were introduced to propagate the 
enzymatically inactive control vectors. To inhibit HBx expression, the eukaryotic 
expression vectors were generated to express hammerhead ribozyme RNA 
sequences under control of the constitutively active CMV immediate early 
promoter/enhancer (Figure 2.1 A and C). Moreover, these sequences were cloned 
between T3 and T7 RNA promoters for preparation of ribozyme RNA in vitro. 
Equivalent vectors encoding catalytically inactive ribozymes (Figure 2.1 A and C) 
and antisense RNAs (Figure 2.1B and D) were also generated. Plasmids 
expressing the target HBx sequences are depicted in Figures 2.2A and 2.2B. 
Plasmid pCI neo HBx contains the HBx sequence from HBV strain ayw cloned 
downstream of the CMV immediate early promoter/enhancer. pHBV adw HTD is 
a replication competent HBV plasmid that contains two head-to-tail copies of the 
entire HBV genome (adw strain). In this plasmid, HBx gene expression is similar 
to that of replicating HBV. The triplet cleavage motif of HBx:Rz1 1473 is substituted 
with a 5' GCC 3' sequence in pHBV adw HTD.
2.4.3 Ribozyme-mediated cleavage of HBx RNA in vitro
To test the endonucleolytic cleavage activities of the two designed hammerhead 
ribozymes in vitro, ribozyme and target RNAs were transcribed from linearised 
templates using T7 and T3 RNA polymerase respectively. A 584 nt substrate
HBx ORF (HBV ayw) - RNA secondary structure 
Mfold' (Genetics Computer Group, Madison, Wl)
Figure 2.4 The accessibility of HBx RNA sequences for hammerhead ribozyme and antisense RNA hybridisation. A) The most energetically 
favourable (8G) secondary structure of the HBx RNA ORF sequence (HBV ayw, GenBank® accession number: J02203) obtained using 
Mfold®. The 12 twelve 5' GUC 3' cleavage triplets are shown (bold). Cleavage sites (arrows) and hybridisation regions are annotated. 
B) HBx ORF RNA sequence showing all twelve 5' GUC 3' cleavage triplets. Underlined are the hybridisation sites for both hammerhead 
ribozyme and antisense RNA sequences.
RNA encoding the HBx ORF was subjected to cleavage by both hammerhead 
ribozymes HBx:Rz1 1473 and HBx\Rz2i65i under single turnover conditions (a five­
fold molar excess of ribozyme over substrate RNA). Ribozyme and target RNA 
were incubated for up to 60 minutes under standard physiological conditions. 
Both ribozymes cleaved their target substrate at the predicted cleavage sites 
(Figure 2.5A and 2.5B). These results indicate that both ribozyme target sites are 
accessible for cleavage in vitro and that the designed ribozymes are able to 
display their wild-type phenotypic behaviour.
Hammerhead ribozyme HBx:Rz1 i473 cleaved the 584 nt target RNA 
yielding products of 168 and 416 nt in length. Similarly, HBx:Rz2i65i generated 
cleavage products of 350 and 234 nt in length (Figure 2.5A). No cleavage was 
observed for the catalytically inactive ribozyme counterparts for both 
hammerhead ribozymes HBx:Rz1 1473 and HBx:Rz2165i. Helix II bases G5 and Ai4 
(nomenclature according to Hertel et al., 1992) are substituted for A and C residues 
respectively in the sequences encoding catalytically inactive ribozymes 
HBx:Rz1*i473 and HBx:Rz2*-i65i. The mutant ribozymes theoretically retain the 
ability to hybridise by the complementary base-pairing of helices I and III, while 
being catalytically inactive. Both ribozymes cleaved their respective target 
sequences while the catalytically inactive ribozyme variants were ineffective in 
vitro. Hammerhead ribozyme HBx:Rz2-i65i appears to be less effective than 
ribozyme HBx:Rz1 i473, which may be more accessible for ribozyme cleavage due 
to a favourable secondary structure conformation of the substrate RNA in vitro.
For all ribozyme reactions, 5'-end cleavage products were present in 
greater abundance than 3'-end products. This is likely the result of an inefficient 
transcription reaction in vitro, which can produce truncated transcripts containing 
variable 3' ends. Incomplete transcription of the substrate RNA may also be due 
to a lack of unradiolabelled GTP during the T3 RNA polymerase reaction. 
Moreover, there did appear to be some degradation of the RNA throughout the 
incubation. This was particularly evident for reactions involving the defective 
ribozyme species.
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Figure 2.5 Hammerhead ribozyme-mediated cleavage of an in vitro transcribed HBx RNA 
substrate (HBV strain ayw). A) In vitro cleavage of HBx RNA by ribozymes 
and their catalytically inactive counterparts. The cleavage reaction was 
carried-out as a 5:1 molar ratio of ribozyme to target. The lengths in bases of 
the substrate and cleavage products are annotated to the right of the 
autoradiograph. B) Schematic representation of T3 RNA polymerase 
generated run-off transcripts encoding HBx. The expected cleavage products 
for hammerhead ribozymes /-/Bx:Rz11473 and HBx:Rz2165i are shown on a 
cleavage map.
2.4.4 Inhibition of HBx trans-activation by hammerhead ribozymes and 
antisense RNAs in cell culture
Transcriptional activation of the p-actin promoter and increased expression of p- 
galactosidase mediated by HBx were used to mark cells expressing the viral 
protein. The cells shown in Figure 2.6 were co-transfected with a combination of 
either pCI neo and pp-actin p-gal or pCI neo HBx and pp-actin p-gal (Figure 2.3). 
When co-transfected with pCI neo HBx, the number of cells that was 
histochemically positive for p-galactosidase expression was consistently 8 and 20 
fold higher in Chang and PLC/PRF/5 liver cells respectively (Figure 2.6). Thus, 
under the assay conditions, not all cells transfected with pCI neo and pp-actin p- 
gal were positive for p-galactosidase activity, and the number of positive cells 
increased significantly as a result of trans-activation by HBx. Histochemically 
detectable p-galactosidase-positive cells in the transfections with pCI neo in the 
absence of HBx may reflect an increase in the intracellular copy number of pp- 
actin p-gal in these cells. Uptake of vector molecules by individual cells during 
calcium phosphate transfection is variable. In cells where the intracellular copy 
number of the marker plasmid is high, p-galactosidase expression would be 
sufficient to produce histochemically positive cells without p-actin promoter trans- 
activation by HBx. To enable comparison of the ribozyme effects on PLC/PRF/5 
and Chang liver cell lines, the mean number of positive cells in the series 
transfected with pCI neo HBx (positive control) has been normalised to 100%. 
This corresponds to an average of 255 p-galactosidase-positive PLC/PRF/5 cells 
and 184 p-galactosidase-positive Chang cells per dish of transfected cells. This 
indirect histochemical method of detecting cells expressing p-galactosidase and 
HBx appears to be more specific and sensitive than immunohistochemical 
detection of HBx. The effects of transfecting the ribozyme vectors on the number 
of Chang and PLC/PRF/5 cells that are histochemically positive for p- 
galactosidase activity are depicted graphically in Figure 2.7 and 2.8. After co­
transfection of Chang cells with either p/-/Bx:Rz1 1473 or pHBx:Rz2165i, the number 
of positive cells diminished significantly when compared with the cells expressing 
HBx without ribozyme (P<0.01) (Figure 2.7A). The inhibitory effect of 
p/-/Bx:Rz1 1473 was more marked than that of p/-/Bx:Rz2165i.
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Figure 2.6 Representative low power microscopic field of p-galactosidase positive PLC/PRF/5 (A and B) and Chang (C and D) cells transfected with 
pP-actin p-gal and pCI neo (A and C) or pp-actin p-gal and pCI neo HBx (B and D).
Transfection of Chang cells with p/-/Bx:Rz1-i473 and p/-/Bx:Rz2165i in combination 
had a similar effect to that of pHBx:Rz1 1473 alone. Furthermore, there was no 
significant difference (P>0.01) between the number of p-galactosidase-positive 
cells detected in the negative control (pCI neo with pp-actin p-gal) and in the co­
transfections with pHBx:Rz11473 alone or together with p/-/Bx:Rz2165i- In 
PLC/PRF/5 cells (Figure 2.7B), pHBx:Rz2165i alone or in combination with 
pHBx:Rz1-i473 diminished the number of p-galactosidase positive cells 
significantly (P<0.01) and p/-/Bx:Rz2165i was more effective than p/-/Bx:Rz1 1473. 
The number of positive cells detected after co-transfection with pHBx:Rz2165i or 
the two ribozyme plasmids together was not significantly different to the number 
detected in the negative control (reporter plasmid with pCI neo) (Figures 2.8A 
and B). Co-transfection of the pCI neo backbone vector with pCI neo HBx and the 
reporter did not change the number of positive cells (not shown). These data 
indicate that both ribozyme expressing plasmids inhibit FIBx trans-activation in 
transfected PLC/PRF/5 and Chang cells.
The inhibitory effects of both antisense encoding plasmids, 
p/-/Bx:At1 1473 and p/-/Bx:At2165i were compared in similar co-transfection 
experiments in PLC/PRF/5 cells (Figure 2.8A and B). Unlike the ribozyme- 
encoding plasmid p/-/Bx:Rz1 1473, p/-/Bx:At1 1473 did not reduce the number of p- 
galactosidase-positive cells. However, the addition of pHBx:At2165i reduced the 
number of positive cells to the levels detected for the negative control (Figure 
2.8A). This observation suggests that an antisense effect generated by 
pWBx:At2-i65i is equally as effective as the ribozyme-encoding sequence 
counterpart, p/-/Bx:Rz21651. Without being able to determine cleavage conditions 
in vivo, it cannot be ruled out that the ribozyme-encoding sequences are 
generating their inhibitory effects through an antisense mechanism alone. 
However, there is a clear difference between the effects of pHBx:Rz1 1473 and 
p/-/Bx:At1 1473, which may indicate that ribozyme cleavage is directly responsible 
for the greater inhibitory power of p/-/Bx:Rz1 1473.
To determine the effects of pHBx:Rz2165i and p/-/Bx:At2i65i on HBx 
expressed in the context of normal HBV sequences, PLC/PRF/5 cells were co­
transfected with the HBV replication competent plasmid, pHBV adw HTD (Figure 
2.2B). Relative to the baseline expression of reporter in the negative control
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Figure 2.7 Effect of ribozyme co-transfection on the number of p-galactosidase positive 
Chang cells (A) and PLC/PRF/5 cells (B). The data in each column are given 
relative to the mean number of p-galactosidase positive cells transfected with 
pP-actin p-gal and pCI neo HBx (positive control of 100%). The plasmids co­
transfected with pp-actin p-gal are indicated below each column. The means 
and standard errors from six independent experiments are given in A and B.
pCI neo + - - pCI neo - + - -
pCI neo H B x + + + pHBV adw HTD + - + +
pHSx:At1i473 ! + + p/-/Bx:Rz2i65i - - + -
pHBx:At2i65i f - + pHBx:At2i65i - - - +
Figure 2.8 Effect of ribozyme and antisense co-transfection on the number of p- 
galactosidase positive PLC/PRF/5 cells (A and B) and hepatocytes derived 
from primary cultures of resected malignant liver tissue (C). The data in each 
column are given relative to the mean number of p-galactosidase positive cells 
transfected with pp-actin p-gal and pCI neo HBx (positive control of 100%). 
The plasmids co-transfected with pp-actin p-gal are indicated below each 
column. The means and standard errors from six independent experiments 
are given in A and B. The data in C represent the means from two 
independent transfections (the positive control consists of a mean value of 263 
histochemically positive cells per plate).
vector, pCI neo, the number of positive cells resulting from transfections with the 
vector pHBV adw HTD was approximately 60% that of pCI neo HBx (data not 
shown). Relative to the number of positive cells generated by the vector pHBV 
adw HTD (reflected as a positive control of 100% in Figure 2.8B), baseline cell 
numbers that were histochemically positive for p-galactosidase activity were in 
the order of 40%. This difference is expected since the CMV promoter is likely to 
be more powerful than the endogenous HBx promoter (Schaller and Fischer, 
1991a). Co-transfection of pHBV adw HTD with the vectors expressing 
p/-/Bx:Rz2i65i and pHBx:At2-i65i diminished the number of positive cells to a level 
similar to that of the negative control (pCI neo). Additionally, this result suggested 
that for p/-/Bx:Rz2165i and pHBx:At2165i, ribozyme and antisense-mediated effects 
are largely indistinguishable.
Co-transfection experiments were performed on a primary culture of 
malignant hepatocytes derived from a tumour resected from a patient who was a 
non-replicative chronic carrier of HBV (HBsAg positive, HBeAg negative, HBeAb 
positive). In these cultures, the number of histochemically positive cells 
transfected with pCI neo and the reporter plasmid was similar to the number from 
transfection with pCI neo HBx and pp-actin p-gal (Figure 2.8C). These data 
suggest that there is endogenous expression of HBx and are in keeping with the 
frequent finding of HBx and HBx RNA in HBV related HCC (Paterlini et al., 1995; 
Su et al., 1998). PCR analysis confirmed that HBx is integrated into the genome 
of these malignant cells (not shown, see acknowledgements). p/-/Bx:Rz1u73 and 
p HBx: Rz2 1651 each diminished the number of transfected cells expressing p -  
galactosidase to 35% and 45% of the transfections with pCI neo and/or pCI neo 
HBx. The two ribozyme plasmids in combination further decreased the number of 
cells that were positive for p-galactosidase activity.
2.4.5 Ribozyme-expressing vectors decrease HBx mRNA in transfected
cells
Total cellular RNA was extracted from transfected Huh7 liver cells to determine 
the effects of the two anti-HBx ribozymes on HBx mRNA expressed from 
transiently transfected pCI neo HBx. A sensitive method employing reverse
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Figure 2.9 Detection of HBx mRNA fom Huh7 cells transfected with ribozyme and HBx- 
encoding sequences. Reverse transcriptase (RT) and PCR amplification of 
HBx and GAPDH mRNA isolated 72 hours after transfection of Huh7 cells. 
Autoradiography of 8% polyacrylamide gels demonstrating representative 
amplified HBx and GAPDH fragments. Fragments produced during the 
exponential phase of amplification were analysed. Lane 1, RT-PCR using 
water as the amplification substrate. Lane 2, PCR amplification of RNA 
extracted from cells transfected with pCI neo HBx without RT treatment. RT- 
PCR of RNA isolated from cells transfected with pCI neo (lane 3), pCI neo 
HBx (lane 4), pCI neo HBx and pHBx:Rz1i473 (lane 5), pCI neo HBx and 
pHBx:Rz21651 (lane 6), and pCI neo HBx, pHBx:Rz11473 and pHBx:Rz2i65i 
(lane 7). Again equivalent transfection efficiencies were confirmed in each 
plate by detecting similar numbers of cells labelled with green fluorescent 
protein.
transcription and PCR was used to determine the effect of the ribozymes on the 
concentration of HBx mRNA. Radiolabelled HBx and standard GAPDH DNA 
fragments produced during the exponential phase of PCR amplification were 
compared and a representative example of the detected bands is given in Figure 
2.9. The amount of amplified HBx DNA relative to the GAPDH standards 
indicates that pHBx:Rz1 i473 and pHBx:Rz2i65i effectively decrease the HBx 
mRNA concentration in transfected cells (Figure 2.9, lanes 5 and 6). There is a 
further decrease in the amount of amplified HBx DNA when both ribozymes were 
transfected (Figure 2.9, lane 7). Although this result is only semi-quantitative, the 
data support previous observations, confirming the inhibitory effects of 
pHBx:Rz1 1473 and p/-/Bx:Rz2i65i on HBx fra/is-activation and indicating that the 
inhibitory effects are a result of post-transcriptional degradation of target HBx- 
encoding RNA.
2.5 Discussion and conclusions
The true accessibility of target RNA for hybridisation by small oligonucleotides is 
not easily determined in vivo since many factors play a role in the folding of RNA 
(see 5.2.1). As a result, the intracellular mechanism of action involving substrate 
cleavage by the ribozyme encoding vectors is often difficult to predict. The usual 
approach is to evaluate the target RNA sequences by computer-aided secondary 
structure predictions and in vitro cleavage assays (Bramlage et al., 1998; 
Thomson et al., 1997). Of the twelve 5' GUC 3' consensus sequences on the 
HBx ORF, the two sites selected for targeting were only moderately accessible 
for ribozyme cleavage using the computer program Mfold®, a program which is 
widely used to predict the putative secondary structure of RNA (see Figure 2.4A) 
(Matzura and Wennborg, 1996; Zuker and Jacobson, 1998). Although the 
hybridisation regions surrounding both cleavage triplets (Figures 2.1A and C, and 
2.4) represent conserved sequences that are unique to hepadnaviruses, the 
decision to target these specific two sites was largely guided by trial and error. 
The most important measure of ribozyme efficacy is achieved by inhibiting the 
function of the translation product of the target sequence, which in this case is the 
trans-activation function of HBx. The in vitro cleavage data serves more to 
confirm the functional properties of the designed hammerhead ribozymes.
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However, for evaluating the accessibility of target RNA for hammerhead 
ribozyme-mediated cleavage, data obtained through in vitro cleavage is usually 
more reliable than data generated by computer program predictions. To this 
effect, both hammerhead ribozymes generated in vitro were able to cleave their 
target sequences efficiently and specifically under standard physiological 
conditions in a cell-free environment (section 2.4.3 and Figure 2.5). Interestingly, 
computer predictions of the site cleaved by hammerhead ribozyme HBx:Rz2i65i 
(or the region hybridised by antisense RNA HBx:At2-|65i) indicate that it is 
localised within single-stranded or loop regions, thus making it theoretically more 
accessible for Watson-Crick hybridisation. However, the in vitro cleavage result 
suggests the opposite, since HBx:Rz1 1473 appears to cleave more efficiently. This 
discrepancy between in vitro cleavage data and computer-generated secondary 
structure predictions has been observed by others (Dropulic and Jeang, 1994) 
and points to limitations in the use of computer programs as a predictive method 
in designing target sites for hybridisation.
Ribozymes are thought to be more effective than antisense 
oligonucleotides at specifically inactivating target RNA since ribozymes possess 
catalytic activity. Yet the exact mechanism of ribozyme-mediated inactivation of 
target RNA is difficult to predict in the complex intracellular environment. 
Information regarding the activity of newly designed ribozymes is largely obtained 
from in vitro cleavage experiments. Since ribozyme activity in vitro is assessed in 
a synthetic environment, these experiments may not necessarily be applicable in 
vivo. Defining the activity of hammerhead ribozyme trans-cleavage in vivo has 
proved to be difficult. This is largely owing to the inefficiency of RNA-mediated 
catalysis in cells and the rapid degradation of reaction products by cellular 
nucleases (Sullenger and Cech, 1993). Northern blot and nuclease protection 
assays have been used to detect ribozyme cleavage products. These techniques 
are laborious and products are often observed close to the detection threshold 
(approximately 1 pg of RNA) (Bertrand et al., 1994; Sambrook et al., 1989). PCR- 
based methods are more sensitive and are often used to detect cleavage 
products (Cantor et al., 1993; Ramezani et al., 1997). However, PCR-based 
techniques are indirect and ribozyme-mediated cleavage efficiency has been 
difficult to quantify. Albuquerque-Silva et al. (1998) used a modified competitive 
RT-PCR technique, rapid amplification of cDNA ends (RACE), that results in the
amplification of unknown cDNA 3'-end sequences. In this technique, cDNAs 
representing 3' ribozyme cleavage products are tailed with a 5' homopolymeric 
sequence with terminal deoxynucleotidyl transferase prior to PCR amplification. 
Competitive RACE was used to detect approximately 10 fg (less than 1% of 
cleaved products) produced by endogenously expressed ribozymes directed to 
the mumps virus nucleocapsid mRNA in transfected cells (Albuquerque-Silva et 
al., 1998; Albuquerque-Silva etal., 1999).
A different method for determining the kinetic properties of intracellular 
hammerhead ribozyme catalysis was developed by Samarsky et al. (1999). In 
this system, a hammerhead ribozyme was localised to the yeast nucleolus by 
using the U3 small nucleolar RNA (snRNA) as a carrier. The snRNA:ribozyme 
hybrid (or "snorbozyme") generated cleavage products which, unlike most 
intracellular ribozyme products, are stable snRNA sequences that can be 
conveniently measured. This snorbozyme cleaved a target RNA sequence with 
nearly 100% efficiency in vivo in yeast (Samarsky et al., 1999). The methodology 
employed for this system, which uses a yeast model and snRNA sequences as 
products of ribozyme cleavage, is unlikely to be generally applicable.
Since the instability of most intracellular ribozyme cleavage products 
has hampered their direct detection in vivo, further alternative approaches have 
been adopted to distinguish between hammerhead ribozyme cleavage and 
antisense effects. Indirect measurements using catalytically inactive ribozyme 
sequences or antisense RNA sequences are used in most cases. Catalytically 
defective hammerhead ribozymes have sequence changes within the helix II 
region, which negatively affects catalytic activity. Helical arms I and III remain 
unchanged allowing complementary hybridisation to the substrate sequence. 
However, catalytically defective ribozymes/antisense RNAs are still capable of 
inducing the post-transcriptional inhibition of target RNA, although these effects 
are usually less pronounced than ribozyme-mediated effects (Dorai et al., 1994; 
Kintner and Hosick, 1998; Steinecke et al., 1992). In the present study, 
catalytically inactive ribozymes possessed no cleavage activity in vitro, yet 
antisense RNA expressed from p/-/8x:At21651, which targets the same region as 
pH8x:Rz2165i of the HBx ORF, induced significant inhibitory effects in transfected 
PLC/PRF/5 cells (Figure 2.8A and B). In contrast, antisense RNA generated by 
p/-/Bx:At11473 was an ineffective inhibitor of HBx frans-activation. It is not clear
why the antisense effects generated by p/-/Bx:At2-i65i (in combination with 
p/-/Bx:At1 1473) were better than p/-/Bx:At11473 alone in inhibiting HBx trans- 
activation function. It is known that maximal antisense effects usually require 
longer contiguous complementary sequences than the 17 nt present on both 
antisense molecules (Lieber et al., 1995). The differences may be explained by 
taking into account that the intracellular secondary and tertiary structure of HBx 
RNA may preferentially favour the binding of pHBx:At2165i and pHBx:Rz2i65i. 
Since p/-/Bx:Rz1u 73 has cleavage activity, this may account for its better 
inhibitory effect in vivo than the antisense counterpart p/-/Bx:AtlH73. Although 
inactivation of HBx mRNA is likely to be at the post-transcriptional level (Figure 
2.9), antisense effects are likely to play an important role in the observed 
inhibition of HBx frans-activation by both hammerhead ribozymes, especially for 
the ribozyme expressed by p/-/Bx:Rz2165i. Noticeably, there were slight variations 
in the efficiency of the two ribozyme-encoding vectors p/-/Bx:Rz1i473 and 
p/-/Bx:Rz2-i65i at inhibiting HBx trans-activation in Chang and PLC/PRF/5 cells. 
This can be explained by the fact that hammerhead ribozyme transcripts, which 
are expressed from a mammalian expression vector, include 5' and 3' vector- 
derived sequences. These additional sequences may affect the hybridisation of 
the ribozyme to target RNA, resulting in differing inhibitory effects within the 
intracellular environment of Chang and PLC/PRF/5.
In conclusion, hammerhead ribozymes, which were functionally active 
in vitro, successfully inactivated HBx mRNA and inhibited HBx trans-activation 
function in transfected liver-derived cells. By inhibiting the expression of HBx 
mRNA post-transcriptionally, hammerhead ribozymes possess the ability to block 
translation and decrease the intracellular concentration of HBx, thus 
concomitantly preventing HBx function in vivo. The precise mechanism, however, 
of ribozyme-derived inhibitory action in vivo remains unknown. Antisense 
hybridisation or antisense effects can elicit the specific degradation of target 
RNA. This mechanism may be largely responsible for the observed ribozyme- 
induced inhibitory effects in transfected cells. By inhibiting the function of HBx, 
which is required for natural viral infection, hammerhead ribozymes or antisense 
RNAs may interfere with the natural life cycle of the virus. It remains to be 
determined whether the targeted knockdown of HBx RNA, which must include 
other viral RNA species, will result in the inhibition of viral gene expression. Since
the HBx sequence is present within viral pregenomic RNA, viral replication and 
propagation may be directly inhibited with the degradation of this viral replicative 
intermediate.
3.0 HAMMERHEAD RIBOZYME-MEDIATED 
INHIBITION OF HBV GENE EXPRESSION IN Huh7 
HEPATOMA CELLS
3.1 Summary
The inhibitory activity of the two endogenously expressed hammerhead 
ribozymes and their catalytically inactive ribozyme controls on HBV gene 
expression and replication was assessed in Huh7 hepatoma cells. Ribozyme- 
encoding vectors were co-transfected with the replication-competent HBV vector, 
pHBV adw HTD. Northern blots performed on total cellular RNA extracted from 
co-transfected cells indicate that the two ribozymes were capable of inhibiting the 
expression of 2.1 kb preS1/S HBV mRNA species. By contrast, the relative 
inhibitory activities of the two catalytically inactive variants were significant. 
Moreover, ribozyme-induced reduction of the 2.1 kb preS2/S mRNA corroborated 
the measurements of HBsAg and HBeAg secretion from cell culture 
supernatants, which were obtained from the same plates used to detect viral 
RNA. This suggests that the two ribozymes p/-/Bx:Rz1-i473 and p/-/Bx:Rz2-t65i 
possess only a modest antireplicative ability and their inhibitory effects in vivo are 
likely to be generated largely by antisense hybridisation and not necessarily by 
ribozyme cleavage. When transfected together, the two ribozymes decreased the 
concentration of 2.1 kb viral RNA to undetectable levels and inhibit the secretion 
of viral antigens by up to 80%. Similar co-transfections were performed using the 
vector pCH-EGFP, in which the preS2/S ORF of the modified replication- 
competent HBV plasmid pCH-9/3091 was replaced by the EGFP ORF. Using this 
vector, both hammerhead ribozymes were able to reduce significantly the number 
of EGFP fluorescent cells when compared to inactive ribozyme controls. This 
novel system allowed for the rapid determination in situ of anti-HBx ribozyme- 
mediated inhibition of HBV replication in transfected Huh7 cells. These results 
were correlated by a reduction in HBsAg when using the replication-competent 
vector pCH-9/3091.
3.2 Introduction
Hammerhead ribozymes that are targeted to the HBx ORF of HBV should, in 
theory, be able to inactivate gene expression of all transcribed sequences, 
including viral pgRNA. On this account, ribozyme-mediated targeting of the HBx 
ORF may be applied therapeutically to abrogate viral replication and propogation 
in chronically infected individuals. In Chapter 2, the HBx sequence was 
successfully targeted by hammerhead ribozymes in vitro and by
ribozyme/antisense RNAs in a number of different transfected human hepatoma 
cell cultures (sections 2.4.3 and 2.4.4). The accessibility of two sites within the 
HBx RNA sequence was confirmed as targets for nucleic acid-based 
hybridisation. These results are in accord with studies using antisense 
ODNs/RNAs (Moriya et al., 1996; zu Putlitz et a i, 1999), hairpin ribozymes 
(Welch et al., 1997; zu Putlitz et al., 1998) and hammerhead ribozymes (Kim et 
al., 1999; Yim et al., 2000) (see section 5.1.1), which indicate the accessibility of 
the HBx sequence as a target for nucleic-acid hybridisation both in vitro and in 
cultured cells. However, the inhibitory effect of hammerhead ribozymes on HBV 
gene expression and replication has yet to be confirmed in an intracellular 
context.
Since little is known of the exact mechanism of ribozyme-induced 
inhibition in mammalian cells, most studies make use of antisense RNAs and 
catalytically inactive ribozyme variants as additional controls. These controls do 
not always reveal the exact kinetic mechanism of intracellular inhibition observed 
by the endogenously expressed ribozymes. It has been technically challenging to 
measure the actions of ribozymes in vivo since target instability after ribozyme 
cleavage makes detecting the products of ribozyme action difficult. In this 
chapter, the anti-HBV inhibitory activity of hammerhead ribozyme and inactive 
ribozyme variants was determined using cell culture models of HBV infection. 
Ribozyme-mediated effects were determined by measuring a decrease in viral 
gene expression and the secretion of viral products, HBsAg and HBeAg, into the 
culture medium. Although ribozyme cleavage activity was not determined in vivo, 
a method was developed for measuring the action of ribozymes targeted to the 
HBx ORF in situ in transfected cells. The coding region of EGFP was used to 
substitute part of the preS2/S ORF in an HBV-encoding vector that expresses all
HBV-derived transcripts. This study demonstrated that the number of transfected 
cells that express EGFP correlates with the secretion of HBsAg and is an index of 
the inhibitory effects of the vectors expressing ribozyme sequences. The results 
presented in this chapter pave the way for the development of improved 
therapeutic ribozymes that are targeted to the HBx ORF of FIBV.
3.3 Materials and Methods
3.3.1 Target vectors
The target vector pFIBV adw HTD and the ribozyme vectors have been described 
previously in sections 2.3.1 and 2.3.2. pCFI-9/3091 has been described 
previously (Nassal et al., 1990) and contains a greater-than-genome-length 
sequence of HBV subtype ayw. In this plasmid, the transcript derived from the 
CMV promoter generates a 3500 nt pregenomic transcript (Figure 3.1A). To 
generate pCH-EGFP, the preS2/S ORF of pCFI-9/3091 was replaced with a 
sequence encoding EGFP (Passman et a i, 2000) (Figure 3.1 B). The EGFP 
sequence was excised from pCI neo GFP (described in section 2.3.1) with Xho\ 
and Xba\ and inserted into the Xho\ and Spel sites of pCH-9/3091 to generate 
pCH-EGFP.
3.3.2 Northern blot
Fluh7 cells were transfected with pFIBV adw HTD together with control or 
ribozyme plasmids using a procedure similar to that described in section 2.3.3. In 
summary, cells in 100 mm diameter culture dishes were transfected with a 
combination of 20 pg of pHBV adw HTD and 10 pg of either p/-/Bx:Rz11473, 
p/-/Bx:Rz1*1473 pHBx:Rz2i65i, pHBx:Rz2* i65i or pCI neo. Similar quantities (10 
pg) of the reporter plasmid pCI neo GFP were also included in each transfection 
to control for equivalent transfection efficiencies. Seventy-two hours after 
transfection, total cellular RNA was isolated from the cells using the guanidinium 
thiocyanate method of extraction (see Appendix A3) (Schaller and Fischer, 
1991a). For northern blot analysis, 20 pg samples of total cellular RNA were 
separated by electrophoresis in 1.4% formaldehyde-agarose gels. A duplicate gel
was stained with ethidium bromide to ensure for similar amounts of RNA in each 
lane. Unstained gels were blotted overnight onto Hybond C-extra membranes 
(Amersham, United Kingdom) and RNA fixed to the membranes by baking for 2 
hours at 80°C. Hybridisation was performed in Quickhyb solution (Stratagene, 
Wl, USA) to a multiprime (Amersham, United Kingdom) labelled probe that 
encompassed the entire HBV genome. See section 3.3.2.1.
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3.3.2.1 Preparation of HB V-specific probe.
pHBV adw HTD was digested with EcoRI resulting in two fragments. The 3183 bp 
fragment encompassing the entire HBV genome was eluted from a 1% agarose 
gel and purified as described in Appendices A4-1 and A4-2. A multiprime random 
labelling kit (Megaprime DNA Labelling System; Amersham Pharamcia Biotech, 
England) was used to label the probe to a specific activity of 2.38 x 106 cpm/pg.
3.3.3 HBsAg and HBeAg secretion from transfected cells
Huh7 cells were transfected with pHBV adw HTD (described in section 2.3.2) 
together with control or ribozyme plasmids (section 3.3.1) in 100 mm diameter 
culture dishes. HBsAg and HBeAg secretion into the culture supernatants was 
measured daily for three days using Axsym (ELISA) immunoassay kits (Abbot 
Laboratories, IL, USA). The means of HBsAg and HBeAg immunoassay 
measurements were calculated from two independent transfections.
3.3.4 In situ detection of hammerhead ribozyme activity
Huh7 cells were grown, seeded and transfected as described in section 2.3.4 and 
2.3.5. Transfections were performed in 60 mm diameter culture dishes. Cells 
were co-transfected with a combination of 3 pg of pCH-EGFP and 6 pg of a 
ribozyme-encoding plasmid: pHBx:Rz1 1473, pHBx:Rz1*1473, pHBx:Rz2165i,
p/-/Bx:Rz2*i65i or pCI neo (ribozyme-negative control). Similarly, cells in 100 mm 
diameter culture dishes were co-transfected with a combination of 7 pg of pCH- 
9/3091 and 14 pg of a ribozyme encoding plasmid: p/-/Bx:Rz1i473, pHBx:Rz1*1473, 
pHBx:Rz2165i, pHBx:Rz2*-i65i or pCI neo. For the transfections using pCH- 
9/3091, equivalent transfection efficiencies were confirmed by co-transfection 
with 10 pg of pCI neo GFP followed by fluorescence microscopy (Appendix C2).
Cells labelled with EGFP were detected by fluorescence microscopy 
three days after transfection. The mean number of fluorescent cells as well as the 
standard error of the mean (SEM) was calculated from experiments performed in 
triplicate. HBsAg secretion into the culture supernatants for cells transfected with 
pCH-9/3091 was measured on three successive days post-transfection similarly
to 3.3.3. The means and SEMs of HBsAg immunoassay measurements were 
calculated from triplicate transfection experiments. Analysis of variance was 
calculated using Dunnett’s multiple comparisons test.
3.4 Results
3.4.1 Vectors expressing target sequences
The replication-competent HBV vector, pHBV adw HTD, was used to reconstitute 
HBV infection in transfected Huh7 cells, thus generating all viral mRNA species, 
including viral pgRNA. This vector was used to determine hammerhead ribozyme 
inhibitory effects on viral mRNAs, and the secretion of HBsAg and HBeAg into 
culture supernatants. A sequence encoding EGFP was used to substitute the 
preS2/S ORF and to generate pCH-EGFP. Transfection of cultured cells with 
pCH-EGFP allowed fluorescence microscopy to be used to detect marker gene 
expression in situ in living cells. The HBx region of HBV is common to naturally- 
occuring HBV transcripts as well as the mRNA species that are expressed in the 
target vectors used here. Ribozyme-mediated endonucleolytic cleavage thus 
includes target sequences on transcripts required for translation of EGFP and 
HBsAg in pCH-EGFP and pCH-9/3091 respectively.
3.4.2 The effects of ribozyme-expressing vectors on HBV RNA 
expression in transfected cells
HBV RNA was extracted from transfected Huh7 liver cells to determine the 
effects of the two HBx ribozymes on HBV gene expression. pHBV adw HTD in 
combination with pHBx:Rz1-i473 and pHBx:Rz2165i or their catalytically inactive 
counterparts were used to transfect the established liver cell line. RNA extracted 
from these cells was measured using northern blot hybridisation (Figure 3.2). The 
size of the detected RNA (approximately 2.1 kb) indicates that the dominant 
bands were from the group of transcripts derived from preS1 and preS promoters 
(Figure 1.2). This observation is consistent with results that suggest these
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Figure 3.2 Detection o f HBV RNA fom  Huh7 cells co-transfected with ribozym e vectors 
and an HBV replication com petent vector. Tw enty m icrogram s o f total 
ce llu lar RNA was isolated from  Huh7 cells, resolved e lectrophoretica lly and 
subjected to northern blotting w ith hybrid isation to a HBV genom ic probe. 
Cells had been untransfected (lane 1) and transfected w ith pCI neo GFP, 
pHBV a d w  HTD and e ither pCI neo (lane 2), pH Bx:R z11473 (lane 3), 
pH Bx:R z21651 (lane 4), pB B x:R z11473 and p/-/Bx:Rz2 165 i (lane 5), 
p/-/Bx:Rz1*1473 (lane 6) o r p/-/Bx:Rz2*165i (lane 7). A  duplicate gel was 
stained w ith e th id ium  brom ide to verify the presence o f sim ilar am ounts o f 
total ce llu lar RNA on each lane. Equivalent transfection  effic iencies were 
confirm ed by detecting sim ilar num bers o f transfected cells labelled with 
green fluorescent protein in each culture plate.
c/s-elements are the most active HBV transcriptional regulatory sequences 
(Schaller and Fischer, 1991a). Compared with p/-/Bx:Rz2-i65i, pHBx:Rz11473 is 
less effective at decreasing the concentration of HBV RNA (Figure 3.2, lanes 3 
and 4). This finding is consistent with a diminished effectiveness of p/-/Bx:Rz11473 
as a result of the altered base that is found at the target cleavage triplet of 
p/-/Bx:Rz1 1473 in transcripts from pHBV adw HTD. Together, p/-/Bx:Rz1 1473 and 
p/-/Bx:Rz2i65i decrease the detectable 2.1 kb mRNA to a concentration similar to 
that of the negative control (Figure 3.2, lane 5). Surprisingly, the catalytically 
inactive ribozymes were also found to decrease the concentration of HBV RNA in 
the transfected cells. However, this pronounced inhibitory effect was not a 
consistent observation and was not corroborated by the measurement of HBsAg 
and HBeAg secretion from transfected cells (see below). The inhibitory effects of 
p/-/Bx:Rz1*i473 and p/-/Bx:Rz2* i65i are likely to result from an antisense 
mechanism that destabilises HBV mRNA.
3.4.3 Measurements of HBsAg and HBeAg secretion in co-transfected 
Huh7 cells
Since HBx is common to all HBV transcripts, p/-/Bx:Rz1-i473 and pHBx:Rz2165i 
should therefore encode ribozymes that act on preC/pregenome, surface as well 
as HBx mRNAs (Figures 1.1,2.2 and 3.1). As with cellular mRNA, the first ORF is 
translated most efficiently from HBV transcripts (Schaller and Fischer, 1991a). 
Translation initiated from the preC initiation codon of the preC/pregenome 
transcript generates a precursor protein that is modified by proteolysis and is 
secreted as the HBeAg. The HBsAg is translated from the surface ORF of the 
preS2/S transcripts. As well as being indicators of translation from 
preC/pregenome and preS2/S transcripts, HBeAg and HBsAg production are 
markers of HBV replication in HBV-infected individuals. Therefore the effects of 
p/-/Bx:Rz1-i473 and p/-/Bx:Rz2i65i, as well as their catalytically inactive 
counterparts, pHBx:Rz1*1473 and pHBx:Rz2*1651, on the secretion of HBeAg and 
HBsAg from transfected Huh7 cells were investigated (Figure 3.3). During a 
period of three days after transfection, p/-/Bx:Rz1-i473 and p/-/Bx:Rz2165i 
decreased the secretion of HBeAg and HBsAg into the culture supernatant.
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Figure 3.3 Secretion of HBsAg and HBeAg into the culture supernatant after 
transfection of Huh7 cells. HBsAg (A) and HBeAg (B) concentrations in the 
culture supernatants were measured using the Axsym immunoassay 
protocols each day and for three days. The mean (n = 3) values of HBsAg 
and HBeAg were calculated as the sample to noise ratio (HBsAg) or sample 
to cutoff ratio (HBeAg) according to the supplier’s instructions (SEM not 
shown). Huh7 cells were untransfected (- control) or transfected with pHBV 
adw HTD and pCI neo (+ control), pHBx:Rz11473, p/-/Bx:Rz2165i, 
p/-/Bx:Rz1i473 and pHBx:Rz2165i, p/-/Bx:Rz1*1473 or pHBx:Rz2*1651. 
Equivalent transfection efficiencies were confirmed in each culture plate by 
detecting similar numbers of cells labelled with green fluorescent protein.
pHBx:Rz1-i473 was slightly more effective than p/-/Bx:Rz2165i despite the altered 5' 
GUC 3' cleavage motif in the pHBV adw HTD vector which renders p/-/Bx:Rz11473 
catalytically inactive (Figure 2.1). This observation confirms the results obtained 
using antisense RNAs and suggests that an antisense effect of these ribozyme 
sequences, without substrate cleavage, may be an important mechanism of their 
action (see section 2.4.4). In combination, the two ribozyme-encoding vectors 
further inhibited HBsAg and HBeAg secretion to a level that is only slightly higher 
than that of the negative control. Plasmids p/-/Bx:Rz1*i473 and p/-/Bx:Rz2* i65i 
exerted modest inhibitory effects on HBsAg and HBeAg secretion. Interestingly, 
pHBx:Rz1i473 should not be capable of cleaving transcripts derived from pHBV 
adw HTD, yet its effects are diminished by the helix II mutations of 
p/-/Bx:Rz1*i473- The reason for this may be a significantly altered secondary 
structure of pHBx:Rz1*1473. Helix II is a conserved sequence in hammerhead 
ribozymes, and mutations in this region are likely to compromise the availability of 
helix I and helix III sequences for binding to their complementary target bases. 
This would diminish antisense effects of the anti-HBx ribozymes that have helix II 
mutations. Taken together with section 3.4.2, the data suggest that the ribozyme 
sequences inhibit HBV gene expression. However, a dominant antisense effect 
that results from compromised helix II mutations cannot be excluded.
3.4.4 In situ detection of ribozyme activity in transfected Huh7 cells
3.4.4.1 Ribozyme modulation of EGFP marker gene expression
The effect of ribozyme sequences on expression from pCH-EGFP was measured 
in situ by quantitation of fluorescent transfected cells expressing EGFP (Figures
3.4 and 3.5). The cells shown in Figure 3.4 are representative fluorescence
microscope fields of co-transfections with combinations of pCH-EGFP and pCI 
neo, p/-/Bx:Rz1 1473 or p/-/Bx:Rz1*H73. The mean and SEM of the number of cells 
expressing EGFP were calculated at day three from triplicate experiments. The 
mean of the positive control (cells co-transfected with pCH-EGFP and pCI neo) 
was normalised to 100% and represents a figure of 972 fluorescent cells per 
culture dish (Figure 3.5B). The mean percentage of fluorescent cells was 
significantly decreased when p/-/Bx:Rz11473 (25.5 ± 5.3%, p<0.01) or
pHBx:Rz2i65i (13.3 ± 3.4%, p<0.01) was co-transfected with pCH-EGFP.
Substitution of the catalytically inactive counterparts, p/-/Sx:Rz1*i473 or 
pHBx:Rz2*i65i, resulted in a diminished inhibitory effect on expression of EGFP in 
transfected cells. Once again, the inhibition by the catalytically inactive vectors 
may be due to an antisense mechanism that involves hybridisation of helix I and 
helix III domains to complementary HBx sequences. The more marked effects of 
p/-/Bx:Rz1 i473 and p/-/Bx:Rz2i65i suggest that the ribozymes encoded by these 
vectors operate by intracellular cleavage of the HBx-containing substrates. The 
effect of pHBx:Rz1 i473 was more marked than that of p/-/Bx:Rz2i65i and indicates 
a more favourable interaction between ribozyme and target sequence.
pCH-EGFP + pCI neo pCH-EGFP + pHBx:Rz1*i473
pCH-EGFP + p HBx: Rz1 M73 Untransfected
Figure 3.4 Combined phase contrast and fluorescent microscopic field of Huh7 cells 
transfected with pCH-EGFP and either pCI neo (A), p/-/Bx:Rz1*1473 (B), 
pBBx:Rz1 1473 (C) as well as untransfected cells (D).
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Figure 3.5 Effect of ribozyme co-transfection on HBsAg production (A) and on the 
number of EGFP positive Huh7 cells (B). HBsAg measurements are given 
as a mean percentage of the positive control with SEM indicated. The 
plasmids used in the transfection are indicated below each column. The 
data are given as the mean sample to noise ratio from experiments 
performed in triplicate.
Ribozyme effects detected in situ and HBsAg secretion measurements in co­
transfected Huh7 cells
HBsAg concentration in the culture supernatants was measured from cells 
transfected with pCH-9/3091 together with ribozyme (pHBx:Rz11473 and 
pHBx:Rz2i65i) or control vectors (pCI neo, pHBx:Rz1* i473 and p/-/Bx:Rz2*165i)- A 
vector constitutively expressing EGFP (pCI neo GFP), which is not susceptible to 
anti HBx ribozyme cleavage, was included to confirm equal transfection 
efficiencies in each of the culture plates. The mean and SEM were calculated 
from triplicate experiments and the results are depicted in Figures 3.5A and 3.6. 
In Figure 3.5B, the mean of the positive control has been normalised to 100% to 
enable comparison to the effects of p/-/Bx:Rz1-i473 and p/-/Bx:Rz2i65i on HBsAg 
secretion. At day 3, HBsAg secretion is significantly lower in the culture plates 
transfected with p/-/Bx:Rz1-i473 (84 ± 2.1%, p<0.01) and pHBx:Rz2i65i (78.3 ± 
2.8%, p<0.01) when compared to the positive control transfected with pCI neo
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Figure 3.6 Effect of ribozyme co-transfection on HBsAg production from plasmid 
pCH-9/3091. Three day time course of HBsAg secretion from transfected 
Huh7 cells. The data are given as the mean (n = 3) sample to noise ratio 
from experiments performed in triplicate (SEM not shown).
and pCH-9/3091. Daily measurements of HBsAg secretion (Figure 3.6) confirm 
that the effects of the ribozyme and control vectors follow a similar trend with 
time. The inhibitory effect is lower in the catalytically inactive vectors and, as with 
the effect on EGFP expression, p/-/Bx:Rz2165i inhibits FIBsAg secretion more 
effectively than does p/-/Bx:Rz1-i473.
The inhibitory effect of the ribozymes on HBsAg secretion is less 
marked than on EGFP expression detected in situ. However, ribozyme-induced 
inhibition of HBsAg secretion is less pronounced than earlier results in section 
3.4.3. The differences in HBsAg secretion may be a result of using the CMV 
promoter rather than endogenous HBV promoters to drive the expression of viral 
mRNA in the vector pCH-9/3091. The correlation between the effects of each of 
the ribozyme-encoding sequences on HBsAg secretion and EGFP expression 
demonstrate that in situ detection of EGFP expression using the vectors 
described is an index of HBV gene expression.
3.5 Discussion and conclusions
Ribozyme and antisense therapies, which are based on nucleic acid 
hybridisation, are potentially effective therapeutic agents for the treatment of 
chronic HBV infection. The selection of therapeutic and target HBV sequences can 
be determined by measuring efficiently the intracellular action of ribozymes. 
However, the development and discovery of novel treatment regimens for HBV, 
including the use of therapeutic hammerhead ribozymes, has been hindered by 
the lack of cell culture models of viral infection. Most hepatoma cells are not 
readily receptive to HBV infection. Although primary hepatocytes do respond well 
to being infected, these cells must remain in the differentiated state (Galle et al., 
1989). Since it has been technically difficult to culture primary hepatocytes that 
are receptive to HBV, alternative in vitro systems for the study of HBV replication, 
utilising continuous cell lines, have been developed. Human HCC cells are 
transfected with vectors encoding tandem repeats of the viral genome. 
Expression cassettes that generate greater-than-genome-length HBV RNA 
sequences result in transient or persistent HBV expression (Sells et al., 1987; 
Tsurimoto et al., 1987). In HBV-infected hepatocytes, cleavage of pgRNA would 
prevent the amplification of viral cccDNA. Nevertheless, HBV-encoding vectors,
which continuously produce viral pgRNA via foreign promoters or from a 
replicating plasmid template, represent artificial models of infection. Establishing 
a cell line capable of being infected by HBV remains important for the 
development of new therapeutic agents. Existing transfection-based cell culture 
models of viral infection do, however, offer valuable information regarding the 
principle and efficacy of new antiviral strategies.
The inhibition of HBV gene expression that was demonstrated in cell 
culture models of HBV infection is an indicator of promising efficacy of 
endogenously expressed hammerhead ribozymes in vivo. The approach used in 
this study has been to develop an assay for measuring the inhibitory effects of 
ribozymes targeted to the HBx ORF in situ in transfected cells. A modified HBV- 
derived plasmid, where the preS2/S region is replaced by DNA encoding EGFP, 
allowed for the in situ measurement of hammerhead ribozyme-mediated effects 
in transfected cells. Since the HBx ORF is present downstream of the EGFP 
coding region on three of the four major viral transcripts, the hammerhead 
ribozymes presented in this thesis probably inhibited all EGFP-expressing 
transcripts. Moreover, ribozyme-modulation of EGFP marker gene activity in situ 
was corroborated by measurements of viral HBsAg and HBeAg secretion 
generated by transfection with a replication-competent HBV vector. This in situ 
assay may thus be a useful marker of the antireplicative effects of ribozymes 
targeted to the HBx ORF. It should be noted that the results presented here 
reflect an indirect assessment of the inhibition of viral replication in cell culture by 
hammerhead ribozymes. Ideally, the antireplicative effects of these hammerhead 
ribozymes should be determined in cell culture systems that permit a complete 
HBV replication cycle such as, inter alia, primary tuapaia hepatocyte cultures and 
human HepaRG cells.
In conclusion, results presented in this study indicated that 
hammerhead ribozymes targeted to the HBx ORF of HBV were capable of 
significantly inhibiting viral gene expression and markers of viral replication in an 
intracellular environment. Once again catalytically inactive ribozymes were shown 
to be modestly effective in inhibiting viral gene expression and replication in 
cultured cells. Catalytically-defective ribozyme controls were designed specifically 
to negate the effects of ribozyme catalytic activity as a means of inactivation. 
However, since hammerhead ribozymes appear to function under single-turnover
conditions in vivo, these ribozyme-inactive variants may merely behave like 
competitive inhibitors and their effects may be largely indistinguishable from their 
catalytically active counterparts. In fact, the nucleases responsible for antisense 
effects in vivo may be as efficient as ribozyme-mediated endonuclease activity.
Taken on their own, the two ribozyme-expressing vectors do not 
sufficiently inhibit viral gene expression to the extent necessary for their 
therapeutic application. Before applying these ribozymes clinically, improvements 
are needed to increase their intracellular efficacy and specificity. Of particular 
interest is the fact that ribozyme vectors transfected together do have an additive 
effect. This suggests that the appropriate therapeutic approach is to target 
simultaneously more than one sequence using different ribozymes. This may 
have the dual effect of 1) increasing the intracellular ribozyme concentration, thus 
improving their efficacy; and 2) preventing the emergence of ribozyme-resistant 
viral mutants. There are numerous practical constraints that need to be 
addressed in order to successfully apply different ribozyme-encoding genes 
simultaneously. These are dealt with in the next chapter.
4.0 MULTIMERIC C IS- AND TR A N S -ACTING 
HAMMERHEAD RIBOZYMES THAT TARGET THE 
HBV H B x  OPEN READING FRAME
4.1 Summary
Vectors were generated to encode multiple hammerhead ribozyme units that 
simultaneously target three different sites on the HBx ORF. The rationale of this 
study was to improve the inhibitory effects of hammerhead ribozyme in vivo by 
increasing their intracellular concentration; and to prevent the emergence of 
ribozyme-resistant escape mutants. Each multimeric unit comprises a 
hammerhead ribozyme sequence flanked by an adjacent upstream 
complementary ribozyme target sequence and was designed to cleave 
intramolecularly (in c/s) and produce 5'- and 3'-processed hammerhead 
ribozymes that are free to function in trans.
Transcripts containing 4-mer, 8-mer and 24-mer c/s- and frans-cleaving 
ribozyme units efficiently cleaved in c/s to produce individual processed 
hammerhead ribozyme monomers in vitro that were able to cleave efficiently 
target HBx RNA in trans in a site-specific manner. Expression vectors encoding 
multimeric hammerhead ribozymes were tested for their antireplicative potential 
in transfected cell culture models of HBV infection. The inhibition of HBsAg and 
HBeAg secretion was measured along with the inhibition of EGFP fluorescence in 
situ. Vectors expressing 8-mer multimeric c/s- and frans-cleaving hammerhead 
ribozymes were more effective than their single-unit counterparts at reducing viral 
HBsAg and HBeAg levels. The 24-mer multimeric ribozyme expression vector, 
pCI-/W24/-/Bx:Rz1,2&3, containing 8-mer units of each of the three anti-HBx 
ribozymes, reduced EGFP fluorescence by ± 92% and viral antigen secretion by 
± 60%. This suggests an additive inhibitory effect when each of the three different 
ribozymes is targeted simultaneously. Since the multimeric ribozymes are more 
effective than previously described ribozymes at inhibiting markers of viral 
replication in transfected cells, these therapeutic agents have a greater potential 
to be used for the treatment of chronic HBV infection.
4.2 Introduction
The data in previous chapters demonstrate that the HBx region of HBV is 
accessible to hammerhead ribozyme hybridisation. These hammerhead 
ribozymes were successfully applied to inhibit HBx function and suppress HBV 
gene expression and replication in cultured cells. To date, a number of nucleic 
acid hybridisation strategies targeting different regions of the virus have been 
applied in vitro and in cell culture investigations with varying success (Beck and 
Nassal, 1995; Feng et ai, 2001a; von Weizsacker et al., 1992; zu Putlitz et al.,
1999). However, within the scope of cell culture models of viral infection, 
limitations regarding the efficacy of hammerhead ribozymes have emerged that 
make these agents, as they presently stand, unsuitable for clinical application. 
Since hammerhead ribozymes behave similarly to antisense RNA in vivo (Birikh 
et al., 1997b), approaches that are aimed at improving the intracellular inhibitory 
activity of hammerhead ribozymes remain an important medical objective. Since 
the hybridisation of ribozymes to their complementary target sequence is rate- 
limiting in vivo, hammerhead ribozyme-mediated inhibitory effects may be 
improved by generating a greater molar excess of ribozyme over target RNA. 
Moreover, as is evidenced by the data in Chapter 3, a combination of different 
ribozymes expressed simultaneously may improve their inhibitory efficacy in vivo.
Applying many ribozymes simultaneously may be advantageous in 
other ways. Mutations within the target RNA, especially within the hammerhead 
ribozyme cleavage triplet sequence, may prevent ribozyme-mediated cleavage, 
or less severely, affect the accurate hybridisation of ribozyme annealing arms 
with its target complementary sequence. There have been reports of ribozyme 
escape mutants generated for HIV-1 infections in cultured cells (Bertrand and 
Rossi, 1996; Dropulic et al., 1992). Although HBV is far less mutable than HIV, it 
replicates using the error-prone reverse transcriptase (RT), which lacks a proof­
reading function (Preston et al., 1988). Thus, by targeting a single site for 
ribozyme-mediated cleavage, there exists the real possibility of generating HBV 
replication variants capable of evading the therapeutic action of ribozymes.
To overcome the problem posed by the mutability of HBV, several 
ribozymes can be applied to target simultaneously different sites on the HBV 
sequence. One approach is to use multiple hammerhead ribozyme units that are
joined together and expressed on the same transcript (Bai et al., 2001; Chen et 
al., 1992; Ramezani et al., 1997). But, this method lends itself to steric hindrance 
between connected ribozymes (Ohkawa et al., 1993a). Various groups have 
developed systems in which connected ribozymes on the same transcript are 
liberated through intramolecular ribozyme cleavage (c/'s-cleaving ribozymes) in 
order to generare trans-acting ribozymes (Ohkawa et al., 1993a; Price et al., 
1995; Ruiz et al., 1997). This is achieved by using separate c/'s-cleaving 
‘processing ribozymes’, which flank the trans-acting ribozyme (Altschuler et al., 
1992; Ohkawa et al., 1993a); or by introducing a ribozyme recognition sequence 
between connected ribozymes such that each ribozyme first cleaves in c/'s before 
cleaving in trans (Ruiz et al., 1997). Since the same ribozyme can be copied 
many times, and multiple ribozymes can be connected together and expressed 
from a single transcript, these approaches have the advantage of increasing the 
intracellular ribozyme concentration.
This chapter describes the construction and application of eukaryotic 
expression cassettes that encode multiple c/'s- and trans-cleaving hammerhead 
ribozyme sequences. Transcripts expressed from a multimeric hammerhead 
ribozyme cassette were designed to consist of many ribozyme units bound head- 
to-tail. Each unit contains a ribozyme target recognition sequence and an 
upstream complementary ribozyme sequence. From within an expressed 
transcript, hammerhead ribozymes are theoretically capable of cleaving in c/'s 
(Figure 4.1 A) to generate therapeutic trans-acting ribozymes with processed 5' 
and 3' ends (Figure 4.1 B). The aim was to modify the two previously described 
ribozymes and to introduce a third hammerhead ribozyme targeted to a different 
site within the HBx ORF. Vectors were generated to include multiple copies of the 
three selected hammerhead ribozyme-encoding sequences (Figure 4.1C). These 
were tested to inhibit viral gene expression and markers of viral replication in cell 
culture models of HBV infection.
4.3 Materials and Methods
4.3.1 Plasmid vectors encoding multimeric ribozyme sequences
4.3.1.1 Plasmids containing single cis- and trans-cleaving ribozyme units
The M1HBx:Rz1 1 4 7 3, M1HBx:R z2 i 6 5 i and M1HBx:R z 3 -i6o7  single-unit cis- and 
trans-cleaving hammerhead ribozyme sequences respectively encode the 
catalytic and annealing sequences of ribozymes HBx:R z l- 1 4 7 3 , HBx:Rz2i65i and 
HBx:Rz3i607 as well as a downstream target sequence recognised by each 
ribozyme for cis-cleavage. For hammerhead ribozyme M1HBx:Rzl-1473, 5' and 3' 
flanking arms represent hammerhead ribozyme helices I and III respectively and 
span regions 1466 to 1479 for internal cis-cleavage and regions 1461 to 1484 for 
trans-cleavage. Hammerhead ribozyme M1HBx:Rz2i65i is complementary to 
HBV ayw co-ordinates 1644 to 1658 for cis-cleavage and co-ordinates 1639 to 
1663 for trans-cleavage. Similarly, 5' and 3' flanking arms of M1 HBx:Rz3i6o7 span 
regions 1600 to 1613 for cis-cleavage and regions 1595 to 1618 for trans- 
cleavage (HBV ayw sequences: GenBank® accession number J02203) (see 
Figures 4.1 and 4.2).
With the exception of pBS-M7/-/Bx;Rz2-i65i, the construction of each 
single-unit cis- and trans-cleaving multimeric ribozyme-encoding plasmid 
proceeded in two separate cloning operations, since mutant clones were often 
observed when annealing chemically synthesized fragments larger than 60 nt.
Plasmid pBS-M7/-/Bx:Rz2ir<si
Two complementary 70-nucleotide oligodeoxynucleotides encoding sense and 
antisense sequences were synthesized by standard phosphoramadite chemistry 
using a DNA synthesizer (Ranson Hill, USA). The annealed, dsDNA fragment 
contains Xba\ and Spel cohesive ends and encodes a single unit cis- and trans- 
cleaving hammerhead ribozyme along with its respective downstream cis- 
cleavage recognition sequence and 5' GUC 3' cleavage site. Sense (S) and 
antisense (A) oligonucleotide sequences for the single cis- and trans-cleaving
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Figure 4.1 The principle of multimeric hammerhead ribozyme cis- and trans-cleavage action. A) C/s-cleavage reaction showing both the cis- 
acting ribozyme sequence (blue) and its c/s-recognition sequence (red) with a 5' NUH 3' cleavage triplet (shaded). B) Ribozyme 
trans-cleavage of HBx-encoding RNA (red). The lengths of helices I and III are longer for the frarrs-cleavage reaction. C) A 
precursor transcript comprising several cis- and trans-cleaving hammerhead ribozyme units. Single-unit ribozymes are released 
through internal cis-cleavage and retain their frans-cleaving function to cleave three sites within an HBx-encoded RNA sequence.
Single-unit cis- and trans-cleaving hammerhead ribozyme- 
encoding oligonucleotide sequences
M1HBx\ Rz1 1473
Trans-ribozyme Cis-cleavage 
recognition sequence
C/'s-ribozyme
h- H h- H
Spe l/Xbal
X£,a\ Helix I Helix II Helix III fusion
5' CTAGAACCAGTCCCAAGCTGATGAGTCCGTGAGGACGAAACCCCGAGAAGGACTAGATCGGGGTCGCTTGGA 3’
3' TTCTCAGGGTTCGGACTACTCAGGCACTCCTGCTTTGGGGCTCTTCCTGATCTAGCCCCAGCGAACCTGATC 5'
Spel
72 bp
M1 H8x:Rz21650 Trans- ribozyme C/s-cleavage
i__________________________________________________________ i recognition sequence
C/s-Ribozyme 1
Xfra\ Helix I Helix II Helix III
5' CTAGACCTCTTATGTAACTGATGAGTCCGTGAGGACGAAACCTTGGGCAATGGTTCCAAGGTCTTTACATA 3’
3’ TGGAGAATACATTGACTACTCAGGCACTCCTGCTTTGGAACCCGTTACCAAGGTTCCAGAAATGTATGATC 5'
Spel
• 70 bp
M1 HBx:Rz3w07
Trans- ribozyme
i----------------------------------------------------------- 1
C/'s-ribozyme
i----------------------------------------------- 1
Cis-cleavage 
recognition sequence
4
Spel/Xbal
Xba| Helix I Helix II Helix III fusion
5 ’ CTAGAAGGTCTCCATGCCTGATGAGTCCGTGAGGACGAAACGTGCAGAGGTACTAGATGCACGTCGCATGGA 3'
3' TTCCAGAGGTACGGACTACTCAGGCACTCCTGCTTTGCACGTCTCCATGATCTACGTGCAGCGTACCTGATC 5’
Spel
72 bp
Figure 4.2 Plus- and minus-strand sequences of a full-length cis- and frans-cleaving 
multimeric unit of ribozymes: HBx: Rz11473 and HBx.Rz21651 and 
A7Bx :R z 3 1607. The restriction sites used for cloning into a pBluescript™ II 
KS(+) vector are depicted at both 5' and 3' ends. Trans- and cis- 
hybridisation arms (for helices I and III) are annotated and bases shown in 
blue. The sequence length for each c/s-cleaving hammerhead ribozyme unit 
is shown. The construction of full-length single-units of cis- and trans- 
cleaving ribozymes HBx:Rz11473 and HBx:Rz31607 proceeded in a two step 
cloning operation. The cis- and trans-cleaving hammerhead ribozyme- 
encoding sequences were cloned separately from the ribozyme recognition 
sequence.
multimeric hammerhead ribozyme unit M1HBx:Rz2-i65i are represented in Table 
4.1.
Complementary oligonucleotides M1HBx:Rz2165i S and M1HBx:Rz2165i 
A were annealed by heating an equimolar mixture (1.3 nmol of each 
oligonucleotide in 10Ojal H20) to 95°C for 5 minutes followed by gradual cooling to 
room temperature. Once cooled, samples were quantified spectrophotometrically 
at A26o (Appendix A4-3) and brought to a final concentration of 30 pmol/pl.
Table 4.1 Complementary oligonucleotides for single-unit c/'s-cleaving hammerhead ribozyme 
cassette M1HBx.-Rz21651
M 1HBx: Rz21651 S
5' CTAGACCTCTTATGTAACTGATGAGTCCGTGAGGACGAAAC 
CTTGGGCAATGGTTCCAAGGTCTTACATA 3'
M 1HBx: Rz21651 A 5' CTAGTATGTAAGACCTTGGAACCATTGCCCAAGGTTTCGTCCT 
CACGGACTCATCAGTTACATAAGAGGT 3'
XbaI and SpeI cohesive ends, which flank the 5' and 3' ends of the annealed 
fragments, were used to introduce the single-unit ribozyme cassette into the Xba\ 
site of cloning vector pBSIIKS(+) to generate plasmid pBS-M'/HBx:Rz2165i. Both 
Xba\ and Spel share compatible cohesive ends resulting in bi-directional insertion 
into an Xbal-linearised vector.
Plasmid pBSIIKS(+) was initially digested with Xba\ and the linearised 
fragment was excised from a 1% agarose gel and eluted (Appendix A4). A 
ligation reaction containing a 150:1 fragment to vector molar ratio (30 pmol 
M1HBx: Rz2 1651 fragment insert to 0.158 pmol vector backbone) was conducted at 
room temperature for 1 hour in a 20 jul total volume that comprised 20 U T4 DNA 
ligase (New England Biolabs, MA, USA). A 10 pi volume was used to transform 
100 pi of competent E.coli DH5a, which was plated on ampicillin positive, X-gal, 
IPTG positive, LB agar plates for a-complementation (Appendix B3-3). Clones 
were selected and screened by restriction enzyme digestion with Xho\ and Xba\ 
and compared to a 100 bp molecular weight ladder (Promega, Wl, USA). Positive 
orientation candidate clones were then manually sequenced to determine their 
sequence fidelity (Appendix A5-2).
Plasmids pBS-M7/-/Bx:Rz1i473 and pBS-M1 /-/8x:Rz3i607
Plasmids pBS-M1 HBx.Rzl-|473 and pBS-/Wf/-/Bx;Rz3i607, each were derived from 
vectors that contained ‘short’ and ‘long’ segments of the complete cis- and trans- 
cleaving unit. The pBSIIKS(+)-derived plasmids, pBS-M1 /HBx/Rzl 1473 and pBS- 
M1lHBx:Rz3i607> encoded the ‘long’ HBx:Rz1 1473 and HBx:Rz3-|607 cis- and trans- 
cleaving hammerhead ribozyme sequence inserts respectively. Similarly, 
plasmids pBS-/W'/s/"/Bx;Rz11473 and pBS-/WfsHBx:Rz3i607 encoded the ‘short’ 
complementary cis- target recognition sequence of HBx:Rz1-i473 and HBx:Rz3 i6o7 
respectively (fora schematic illustration of the cloning, see Appendix C1-1).
Two sets of complementary 28-nt oligonucleotides encoding a ‘short’ 
ribozyme target sequence for HBx:Rz1 1473 and HBx:Rz3i6o7 were synthesized. 
The complementary oligonucleotide sets are designated: M1sHBx:Rz1 1473 S and 
M1 sHBx;Rz1 1473 A; and M1sHBx:Rz3-i607 S and M1sHBx:Rz3i607 A (see Table 
4.2). Similarly, two sets of complementary 52-nt oligonucleotides encoding the 
‘long’ hammerhead ribozyme region for HBx:Rz1 1473 and HBx:Rz3i6o7 were 
synthesized. The complementary oligonucleotide pairs are designated: 
M1lHBx:Rz1i473 S and M1LHBx:Rz1U73 A; and M fLHBx:Rz3i6o7 S and 
M1 L/-/Bx:Rz3i607 A (see Table 4.2). Sequences for both M1L and M1S 
complementary oligonucleotide pairs are represented in Table 4.2.
Xba\ and Spel restriction sites flank each end of both annealed 
oligonucleotides sets allowing for their introduction into the cloning vector 
pBSIIKS(+). Annealed dsDNA fragments M1sHBx:Rz1 i473 and M1 sHBx:Rz3:qo7 
were cloned into the Spel site of pBSIIKS(+), whilst fragments M1LHBx:Rz1 i473 
and M1lHBx:Rz3 16o7 were cloned into Xbal site of pBSIIKS(+). The construction 
of vectors pBS-/W’//_/-/Bx:Rz1 1473, pBS-/W7lHBx;Rz3i607 and pBS-A4fsHBx:Rz1i473, 
pBS-Mfs/-/Bx;Rz3i607 follows the same method as the construction of pBS- 
M1HBx:Rz2i65i> as mentioned above. Clones were screened for the correct insert 
by digestion with Xho\ and Xbal and resolved along with 37 pmol of annealed 
fragments M1sHBx:Rz1 1473 and M1LHBx:Rz1 1473 on a 8% non-denaturing 
polyacrylamide electrophoretic gel for approximately 1 hour at 100 V. Candidate 
positive orientation clones were, as mentioned previously, sequenced manually 
to determine the sequence fidelity (Appendix A5-2).
Table 4.2 Complementary oligonucleotide sequences for ‘long’ and ‘short’ multimeric 
hammerhead ribozyme units of both /-/Bx;Rz1 1473and HBx:Rz3 1607
M 1 sH B x : Rz11473 S 5' CTAGATCGGGGTCGCTTGGACTAGTCCA 3'
/I47sWBx ;Rz11473 A 5' CTAGTGGACTAGTCCAAGCGACCCCGAT 3'
M 1 lH B x :Rz11473 S 5' CTAGAAGAGTCCCAAGCCTGATGAGTCCGTGAGGACGAAA 
CCCCGAGAAGGA 3'
M 1 lH B x :R z '\ 1473 A 5' CTAGTCCTTCTCGGGGTTTCGTCCTCACGGACTCATCAGGC 
TTGGGACTCTT 3'
M 1 sH B x :R z 3 igQ7 S 5' CTAGATGCACGTCGCATGGACTAGTCCA 3'
M 1 sH B x : Rz31607 A 5' CTAGTGGACTAGTCCATGCGACGTGCAT 3'
M 1 lH B x :R z 3 A6Q7 S 5' CTAGATGGTCTCCATGCCTGATGAGTCCGTGAGGACGAAA 
CGTGCAGAGGTA3'
M 1 lH B x :Rz31607 A 5' CTAGTACCTCTGCACGTTTCGTCCTCACGGACTCATCAGG 
CAT GG AG ACCTT 3'
An additional Spel digestion site was present in both M1S annealed 
fragments due to an oversight in the original design of the annealed 
oligonucleotides. To remove the 8 bp sequence from pBS-M1 sH8x:Rz1 1473 and 
pBS-M7s/-/Bx:Rz3-i607, plasmids were digested with Spel, heat inactivated at 65°C 
for 30 minutes, and allowed to re-ligate for 20 minutes at room temperature. 
Transformed colonies were again screened and manually sequenced (Appendix 
A5-2). The resulting shortened (or truncated) plasmids were named pBS- 
M 1 StH B x :RZI1473 and pBS-M7srHBx:Rz3i607 respectively. Both these plasmids 
were constructed from a correct-orientation fusion of fragments containing the 
ribozyme catalytic domain (M1L) and its corresponding downstream target 
sequence. The construction of these vectors is illustrated in Appendix C1-1. To 
generate pBS-M7/-/Bx:Rz1 1473 and pBS-M 1 HBx.Rz31607 containing complete 
single unit self-cleaving hammerhead ribozyme cassettes, plasmids pBS-
/W?SrHBx:Rz1 i473 and pBS-/W'/srHBx:Rz3i607 were digested with Seal and Xba\ to 
produce two fragments* of 1863 and 1112 bp. The 1863 bp fragments contain the 
target-encoding sequence of both ribozyme M1 S7F/Bx;Rz1-i473 and
M 1 StH B x :Rz3i607- Each fragment was eluted from a 1% agarose gel and purified. 
Plasmids pBS-M7LP/Bx:Rz1i473 and pBS-M7i.HBx:Rz31607 were digested with 
Seal and Spel resulting in two fragments of sizes 1170 and 1843 bp. The 1170 
bp fragment containing the hammerhead ribozyme-encoding sequence for both 
ribozyme M1LHBx:Rz1 1473 and M1LHBx:Rz3i6o7 was similarly eluted and purified. 
M 1 st  and M 1 L fragments were ligated in a 20 pi reaction mixture containing an 
equimolar ratio of both fragments (2 pg of each fragment). Following ligation at 
room temperature for an hour, 10 pi of the ligation mixture was used to transform 
competent E.coli DH5a, which were plated on ampicillin positive LB agar plates. 
Clones were screened by Spel and Xba\ digestion followed by agarose gel 
electrophoresis.
4.3.1.2 Multimeric cis- and trans-cleaving hammerhead ribozymes
The construction of multimeric cis- and trans-cleaving hammerhead ribozymes is 
illustrated in Appendix C1-2. Plasmids pBS-M7/-/Bx:Rz1 1473, pBS-/W7/-/Bx;Rz21651 
and pBS-/V/f/-/Bx;Rz3i607 were each placed into two separate reaction mixtures. 
Xba\ and Seal restriction enzymes were used in the first reaction to yield two 
fragments of 1112 and 1921 bp for pBS-/W7/-/Bx:Rz1 i473 and pBS-/WfHBx:Rz3i607 
respectively (1112 and 1919 bp for pBS-/W7/-/Bx;Rz2165i) (See Table 4.3). Spel 
and Seal restriction enzymes were used in second reaction to yield fragments of 
1190 and 1843 bp for pBS-/W7HBx;Rz1i473 and pBS-A47/-/Bx:Rz3-i607 respectively 
(1188 and 1843 bp for pBS-A47HBx:Rz2i65i). Fragment 1190 bp (1186 bp) from 
the Spe\/Sca\ digest and fragment 1921 bp (1919 bp) from the Xba\/Sca\ digest 
were eluted from a 1% agarose gel. Each eluted fragment contains a single 
multimeric hammerhead ribozyme unit. Two micrograms of both eluted fragments 
(for pBS-/W7HBx:Rz1i473, pBS-M7HBx;Rz2i65i and pBS-/W7 /-/Bx:Rz3i6o7
* Initially, pBS-/W7srHBx:Rz1 1473 would not digest with X ba I due to unexpected methylation of the 
Xba\ site following the excision of a 8 bp Spel fragment. The plasmid was then transformed into a 
DNA adenine methylase negative (dam') E.coli strain that restored the integrity of the Xba\ site. 
Competent E.coli GM2929 were transformed with pBS-M7STHBx:Rz'\ 1473 resulting in successful 
cleavage byXbal following plasmid preparation.
respectively) were ligated in a 20 pi reaction volume. Following ligation at room 
temparature for an hour, 10 pi of the ligation mixture was used to transform 
competent E.coli DH5a, which was plated on ampicillin positive LB agar plates. 
Ten colonies from each plate were grown overnight followed by miniprep plasmid 
preparation (described in Appendix A2-1). Clones were screened by digestion 
with Spel and Xba\ and resolved on 2% agarose gels. Positive clones containing 
two multimeric cis- and trans-cleaving ribozyme units (dimer or 2-mer) were 
named pBS-/W2/-/Bx;Rz1 U73, pBS-/W2HBx;Rz2i65i and pBS-/W2/-/Bx:Rz3i607 
respectively. These dimer-containing vectors were again manually sequenced 
(Appendix A5-2). The same cloning strategy* was employed to construct 
plasmids bearing tetramer (4-mer) and octomer (8-mer) multimeric cis- and trans- 
cleaving hammerhead ribozyme units. The 4-mer constructs were named pBS- 
/W4HBx;Rz1 1473, pBS-M4/-/Bx:Rz2i65i and pBS-M4HBx:Rz3i607 while the 8-mer 
constructs were named pBS-M8/-/Bx:Rz1 1473, pBS-M8/-/Bx;Rz2i65i and pBS- 
M8HBx;Rz3i607- A 16-mer construct, pBS-/W76;Rz1 ,Rz2, containing 8-mer units 
of both hammerhead ribozymes HBx:RZI1473 and HBx:Rz2i6si was similarly 
constructed using the enzyme combinations Xba\/Xho\ and Spe\/Xho\ on 
plasmids pBS-M8/-/Bx;Rz1 i473 and pBS-/W8/-/Bx;Rz2i65i respectively. Employing 
the same strategy, pBS-/W24:Rz1,Rz2,Rz3, a 24-mer construct containing 8-mer 
units of hammerhead ribozymes HBx:Rz1i473, HBx:Rz2i65i and HBx:Rz3i6o7 was 
constructed by combining the 8-mer fragment of plasmid pBS-/V/8/-/Bx:Rz3i607 
with the 16-mer fragment of pBS-M76;Rz1,Rz2. (Table 4.3 and Appendix C1-2).
4.3.1.3 Eukaryotic expression vectors producing multi-unit cis- and trans- 
cleaving ribozymes
Expression vectors pCI-M8/-/Bx:Rz1 i473, pCI-M8/-/Bx:Rz2i65i and pCI- 
A48/-/Bx:Rz3i607 were constructed containing 8-mer cis- and trans-cleaving 
ribozyme units for hammerhead ribozymes HBx:Rz1h 73, HBx:Rz2i65i and
* T h is  c lo n in g  te c h n iq u e  e x p lo its  th e  fa c t th a t fra g m e n ts  p ro d u c e d  b y  d ig e s tio n  w ith  S p e l a n d  X b a I 
g e n e ra te  c o m p a tib le  c o h e s iv e  e n d s . H o w e v e r, a fte r  lig a tio n  o n ly  X b a \/X b a \ o r  S p e l/S p e l lig a tio n s , 
a n d  n o t X b a \/S p e \ o r  S p e \IX b a \ l ig a tio n s  a re  re -c le a v e d  b y  e ith e r  e n z y m e . T h is  fa c il ita te s  c lo n in g  
a n d  s c re e n in g  o f m u ltip le  fra g m e n ts  in s u c c e s s io n  s in c e  o n ly  h e a d -to -ta il ta n d e m s  g e n e ra te  
c o r re c t fra g m e n ts  u p o n  d o u b le -d ig e s tio n  w ith  X b a \ a n d  S p e l.
Table 4.3 pBSIIKS(+)-derived multimeric c is -  and trans-cleaving hammerhead ribozyme 
vectors
Starting plasmids Enzymes
Fragment 
sizes prod- 
uced(bp)a
Fragments 
eluted and 
ligated (bp)
Resulting plasmid 
constructs
pB S -M 1 stH B x iRz I  1473 X ba l, Seal 1112, 1863 1863
pBS-/W f H B x :R z1 1473
pB S -M 1LH B x :R z1 u73 Spel, Seal 1170, 1843 1170
pBS-/W fsrHSx:Rz3i607 X ba l, Seal 1112, 1863 1863
pBS-/W IHBx;Rz3i607
pBS*M f/.H8x.'Rz3i607 Spel, Seal 1170, 1843 1170
pB S -M 1 H B x:R z1 U73
X ba\, Seal 1 1 1 2 ,1921 1921
pB S -M 2H B x :R z11473
Spel, Seal 1190, 1843 1190
pB S -M fH B x :R z2 i6 5 i
X ba l, Seal 1 1 1 2 ,1919 1919
pBS-/W 2HBx;Rz2i65i
Spel, Seal 1188, 1843 1188
pB S -M 1 H B x :R z 3'\go7
X ba l, Seal 1 1 1 2 ,1921 1921
pBS-/W2HBx;Rz3i607
Spel, Seal 1190, 1843 1190
pB S -M 2H B x :R z1 i 473
X ba l, Seal 1 1 1 2 ,1999 1999
pBS-/W4H B x ;R z1 i 473
Spel, Seal 1268, 1843 1268
pB S -M 2H B x;R z2 i65 i
X ba l, Seal 1 1 1 2 ,1995 1995
pB S-/W 4H Bx:R z2 i65i
Spel, Seal 1263, 1843 1264
pBS-/H2HBx;Rz3i607
X ba l, Seal 1 1 1 2 ,1999 1999
pBS-M 4HBx:Rz3i607
Spel, Seal 1268, 1843 1268
pBS-/W4H B x ;R z1 i 473
X ba l, Seal 1112, 2155 2155
pB S -M 8 H B x:R z11473
Spel, Seal 1424, 1843 1424
pB S -M 4H B x :R z2165i
X ba l, Seal 1112, 2147 2147
pB S-M 8H Bx;R z2 i65 i
Spel, Seal 1416, 1843 1416
pBS-/W4HBx;Rz3i607
X ba l, Seal 1 1 1 2 ,2155 2155
pBS-M 8HBx;Rz3i607
Spel, Seal 1424, 1843 1424
pB S -M 8H 8x.'R z11473 Spel, X bo l 56, 3523 3523
p B S -M f6 ;R z1 ,R z2
pBS-/W 8HBx;Rz2i65i X ba l, Xbol 664, 2899 664
p B S -M 8H B x : R z31607 Spel, X bo l 56, 3523 3523
pB S -M 24:R z1,R z2,R z3
pBS-/W f6:R z1,R z2 X ba l, Xbol 1288, 2899 1288
fragm ents selected for cloning are shown in italics.
HBx:Rz3i607 respectively (Figure 4.3). A mammalian expression vector containing 
24-mer (8-mer of each ribozyme), c/'s- and frans-cleaving units for ribozymes 
HBx:Rz1 1473, HBx:Rz2i65i and HBx:Rz3i6o7 was also contructed. Plasmids pBS- 
M8HBx: Rz1 1473, pBS-M8HBx;Rz2i65i > pBS-A//8HBx:Rz3i607> arid pBS-
M24HBx:Rz‘\ ,Rz2,Rz3 were digested with Xho\ and Xba\. Fragment inserts were 
separated from vector backbone by elution from a 1% agarose gel (Appendix 
A4). pCI neo was digested with Nhe\ and Xho\ yielding a large vector backbone 
which was similarly eluted from a 1% agarose gel. A ligation reaction containing a 
50:1 annealed fragment to vector molar ratio (30 pmol annealed fragment insert 
to 0.6 pmol vector backbone) was conducted. Following tranformation, overnight 
growth and plasmid purification (Appendix A2-1), correct plasmid clones were 
identified by digestion with BglW and Spel.
4.3.2 In vitro transcription and and ribozyme cleavage
4.3.2.1 Preparation of transcription template
pBSIIKS(+)-derived c/'s- and trans-cleaving mutlimeric ribozyme plasmids 
carrying 1-mer, 2-mer, 4-mer and 8-mer units for ribozymes HBx:Rz11473, 
HBx:Rz2 1651 and HBx:Rz3i6o7 were linearised by digestion with Psfl. Single-unit 
vectors pBS-/\41lHBx:Rz1i473 and pBS-/W1/.HBx:Rz3i607, as well as multimeric 
c/'s- and trans-cleaving vectors pBB-MIdHBx'.Rz^ ,Rz2 and pBS-M24 
Rz1,Rz2,Rz3 were also linearised with Psfl. To generate control antisense 
transcripts, the above plasmids were also separately linearised by digestion with 
XbaI. Linearised DNA templates were then eluted from a 1% agarose gel and 
extracted using chloroform/phenol and precipitated with ethanol (Appendix A4-1, 
A4-2). Pellets were resuspended in H20  to a final concentration of 1 pg/pl.
4.3.2.2 Multimeric ribozyme cis-cleavage
Radiolabelled c/'s-cleaving RNA was transcribed at 37°C for 1 hour in a 20 pi 
reaction mixture containing 2 pg of template DNA, 10 mM dithiothreitol, 40 mM 
Tris-HCI (pH 8.0), 8 mM MgCI2, 2 mM spermidine, 20 U RNasin (Promega, Wl, 
USA), 8 mM ATP, 8 mM TTP, 8 mM UTP, 12.5 pM GTP (Roche, Germany) and
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Figure 4.3 A schematic illustration of the general structure of a multimeric cis- and trans- 
cleaving hammerhead ribozyme expression cassette. Transcript sequences 
encoding multiple ribozymes are under transcriptional control of the CMV 
promoter/enhancer. The expressed transcript cleaves in cis to release 5' and 
3'-trimmed monomeric trans- cleaving hammerhead ribozymes. The 
hammerhead ribozyme sequence is displayed. N refers to any base, which 
forms part of the annealing helices I and III, while X refers to non-annealing 
bases. The conserved bases of helix II are shown.
20 jaCi of a-32P GTP (3000 Ci/mmol; NEN du Pont, USA) and 20 U of T7 RNA 
Polymerase (Promega, Wl, USA). 20 U of DNase I (Promega, Wl, USA) were 
added to the reaction mixture for 10 minutes at 37°C. RNA fragments were 
purified using the Qiagen RNeasy (Qiagen, CA, USA) RNA purification kit 
according to the manufacturer’s instructions. The cleavage reaction was carried 
out in a 40 pi reaction mixture containing radiolabelled c/'s-cleaving multiribozyme 
transcript RNA. The mixture contained 20 mM MgCI2and 50 mM Tris-CI (pH 8.0), 
and was incubated at 37°C. Aliquots (10 pi) were removed after incubation for 0, 
5 and 60 minutes and added to 3 pi of RNA loading buffer (Appendix B2-3). 
Samples were resolved by 6% denaturing polyacrylamide electrophoresis until 
the bromophenol blue dye front reached the end of the gel. Gels were subjected 
to autoradiography for 1 to12 hours at -70°C.
4.3.2.3 Multimeric ribozyme trans-cleavage
Transcription of radiolabelled target RNA (Xbal-linearised pBS-X) was performed 
as described for the multimeric ribozymes above using T3 RNA polymerase. In 
vitro transcription reactions for the multiribozyme templates were performed 
similarly to that of the single-unit ribozymes. Antisense control pBS-X target RNA 
was transcribed using T7 RNA polymerase (Promega, Wl, USA) from an Xho\- 
linearised pBS-X template. The cleavage reaction was carried out in a 10 pi 
reaction mixture containing a molar ratio of ribozyme to radiolabelled target RNA 
of 5:1 in the presence of 20 mM MgCI2 and 50 mM Tris-CI (pH 8.0), and 
incubated at 37°C. The reaction was stopped after 1 hour with the addition of 3 pi 
of RNA loading buffer (Appendix B2-3). Samples were resolved as described in 
section 4.3.2.2.
4.3.3 In situ detection of multimeric hammerhead ribozyme activity
Huh7 cells were cultured, seeded and transfected as described in sections 2.3.4 
and 2.3.5. In a similar manner to that described in section 3.3.2, transfections 
were carried out in 100 mm culture dishes and contained a combination of 3 pg of
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Figure 4.4 Sequences targeted by three hammerhead ribozymes HBx:Rz1 1473, HBx:Rz216si, and HBx:Rz31607. A) Organisation of the hepatitis B 
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pCH-EGFP (Figure 4.4C) and 6 pg of plasmids p/-/Bx:Rz1 1473, pHBx:Rz1*-|473, 
p/-/Bx:Rz2165i, p/-/Bx:Rz2*165i, pCI-M8HBx:Rz11473, pCI-M8/-/Bx:Rz2i65i, pCI- 
/W8/-/Bx:Rz3i607, pCI-/\z/24/-/Bx:Rz1 ,Rz2,Rz3 or pCI neo. Cells labelled with EGFP 
were detected by fluorescence microscopy three days after transfection. The 
mean number of fluorescent cells as well as the standard error of the mean 
(SEM) was calculated from experiments performed in triplicate.
4.3.4 HBsAg and HBeAg assays
Similar to the method described in sections 2.3.2 and 3.3.5, Huh7 cells in 100
mm diameter culture dishes were transfected with a combination of 7 pg of pFIBV 
adw HTD (Figure 4.4B) and 14 pg of p/-/Bx:Rz1i473, p/-/Bx:Rz1*1473, 
p/-/Bx:Rz2165i, p/-/Bx:Rz2*165i, pHBx:At1 1473, p/-/Bx:At2165i, pCI-/W8/-/Bx:Rz1i473, 
p CI-M8HBx: Rz2 165i , pCI-M8HBx:Rz3i607, and pCI-M24HBx:Rz1 ,Rz2,Rz3.
Following transfection into Huh7 cells, HBsAg and HBeAg secretion into the 
culture supernatants was measured daily for three days using Axsym (ELISA) 
immunoassay kits (Abbot Laboratories, IL, USA). The means of HBsAg and 
HBeAg measurements were calculated from three independent transfections.
4.4 Results
4.4.1 Multimeric hammerhead ribozyme vectors
Cloning vectors, which contain the pBluescript II KS(+) backbone, were 
generated to encode single-unit and multiple-unit c/'s- and trans-cleaving 
hammerhead ribozyme-encoding sequences for hammerhead ribozymes 
HBx:Rz1 1473, HBx:Rz2165i, and HBx:Rz3 i607- The construction of head-to-tail 
multiples of each cis- and trans-cleaving hammerhead ribozyme sequence was 
facilitated by the presence of Spel and Xba\ cohesive ends for each cloned 
fragment insert. Figure 4.5 shows fragments resolved on agarose gels following 
digestion with Spel and Xba\ (Figure 4.5A) and Spel alone (Figure 4.5B). The 
digest results in different size fragment inserts for each of the multimeric
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Figure 4.5 Restriction endonuclease digestion of multimeric hammerhead ribozyme plasmid constructs with Spel and Xba\ (A) to release 
cloned multimeric hammerhead ribozyme fragment inserts; and with Spel (B) to linearise each multiple-unit plasmid. Digested 
fragments are observed on 1.5% (A) and 1% (B) agarose gels along with 1 kb and 100 bp markers (Promega, Wl, USA).
Figure 4.6 DNA sequences of dimer series pBSKSII(+)-derived c/'s- and trans-cleaving 
hammerhead ribozyme vectors: pBS-/W2HBx:Rz11473, pBS-M2HBx:Rz2165i 
and pBS-/W2/-/Bx:Rz31607. The 5' hammerhead ribozyme-encoding 
sequence (blue) is shown along with its respective cleavage recognition 
sequence (red) for each vector sequence. Annotated to the left of each 
sequence are the Xba\ and Spel restriction sites and all Xba\ISpe\ fusion 
knockout sites.
hammerhead ribozymes. The 5' ends produced by digestion with XbaI and Spel 
are complementary to each other. However, the re-ligation of Spel-generated 5' 
ends with Xba\-generated 5' ends resulted in sites that are not re-cleaved by 
either enzyme (Figures 4.5 and 4.6). This approach allowed for the use of both 
Xba\ and Spel restriction enzymes to generate vectors encoding up to 24 
multimeric ribozyme units bound sequentially head-to-tail (Figures 4.6, 4.7B and 
Appendix C1).
4.4.2 Proof of multimeric ribozyme efficacy
4.4.2.1 In vitro transcription and ribozyme cleavage
Each multimeric ribozyme transcript contains multiples of four (4-mer), eight (8- 
mer) and twenty-four (24-mer) c/s-cleaving hammerhead ribozyme units targeted 
to the three unique HBV sites HBx:Rz1 i473, HBx:Rz2165i, and HBx:Rz3-i6o7- To 
determine the c/s-cleaving activity of each c/s- and frans-cleaving hammerhead 
ribozyme unit, RNAs encoding multimeric ribozyme tandems were transcribed in 
vitro from linearised pBluescript II (KS+)-derived vector constructs. Free 
magnesium ions present in the transcription buffer stimulated ribozyme c/s- 
cleavage during transcription. For all transcripts generated from in vitro 
transcription, c/s-cleavage was very efficient, resulting in 100% monomeric 
cleavage products before a separate designated cleavage reaction step (Figure 
4.7A). To diminish ribozyme c/s-cleavage during transcription, the ribonucleotide 
concentration was increased to absorb free Mg2+ in the transcription buffer. 
Nevertheless, no full-length transcripts were detectable after transcription (Figure 
4.7A) and c/s-cleavage resulted in approximately 80% single-unit cleavage 
products. The c/s-cleavage reaction observed in Figure 4.8A appears to be more 
efficient than reactions reported by other c/s-cleaving hammerhead ribozyme 
constructs (Ohkawa et ai, 1993b; Ruiz et al., 1997). Dimer, trimer and tetramer 
cleavage products were the only remaining multimeric units following in vitro 
transcription (Figure 4.8A). These products underwent further c/s-cleavage 
following additional 60 minutes incubation during the cleavage reaction.
The addition of vector-derived sequences, present at the 5' terminus of 
each transcript, produced single monomer cleavage products of 107 nt in length
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Figure 4.7 In vitro cis-cleavage of multimeric c/s- and trans-cleaving hammerhead 
ribozymes HBx.Rzl i473 and /-/Bx:Rz316o7- A) C/s-cleavage showing 
monomeric cleavage products for 4-mer and 8-mer constructs of ribozyme 
species HBx.Rzl 1473 and HBx:Rz316o7- B) Schematic illustration of the 
cleavage products generated for the 8-mer transcript of all three 8-mer 
ribozymes. The cleavage products for HBx:Rz21651 are included as boxed 
inset, although the cleavage of fragments is not shown in A.
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Figure 4.8 Cis-cleavage in vitro of transcripts containing multimeric hammerhead 
ribozymes. A) Cis-cleavage showing intermediate cleavage products for 4- 
mer, 8-mer and 24-mer constructs of all three ribozyme species: HBx.Rz11473, 
/- /8 x :R z 2 1651 and /-/6x;Rz316o7- A single-unit cis- and trans-cleaving 
hammerhead ribozyme M1HBx:Rz11473, is used as a control to denote a 5' 
monomeric cleavage product of 107 nt. B) Schematic illustration of the 
cleavage products generated for the 24-mer transcript, M24HBx:Rz1,2&3, 
including the cleavage products generated at the junction of ribozymes 1/2 
and 2/3.
for c/s-cleaving ribozyme constructs containing 4-mer, 8-mer units of ribozymes 
HBx:R zl-1473 and HBx:Rz3-i6o7, and 98 nt in length for constructs containing 4-mer 
and 8-mer units of ribozyme HBx:Rz2165i (Figures 4.7B and 4.8B). The 107 nt in 
length monomeric cleavage product generated by the 24-mer multimeric 
ribozyme transcript, is similar to the sequence at the 5' terminus of the 8-mer 
multimeric construct of ribozyme HBx:Rz114/3. This unique 107 nt fragment, 
produced only once per transcription cycle, can serve as an internal control, 
enabling a quantitative comparison of products generated by different c/s- 
cleaving multimeric ribozyme templates. The most abundant cleavage products 
were monomer units of individual ribozymes with trimmed 5' and 3' termini. These 
were observed as a 78 nt band for ribozymes /-/Bx:Rz11473 and HBx:Rz3i6o7, and 
as a 76 nt band for ribozyme /-/Bx:Rz21651. Multimeric constructs containing eight 
cis-cleaving hammerhead ribozyme units (8-mer constructs) produced, as 
expected, a more intense 78 nt (or 76 nt for HBx:Rz21651) band of monomer units 
when compared to the 4-mer constructs. The autoradiograph in Figure 4.7A 
shows the difference in the concentration of monomeric units generated between 
8-mer and 4-mer multmeric ribozyme transcripts for hammerhead ribozymes 
HBx.Rzl -I473 and HBx:Rz3i607- This result is also shown for all three ribozymes in 
Figure 4.8A. The 24-mer transcript, which includes multiples of each of the three 
hammerhead ribozymes, produced, in addition to the 78 nt and 76 nt monomer 
units, single monomers of 69 and 85 nt in length. These single cleavage products 
represent respectively the junction between 8-mer units of ribozymes 
HBx.Rzl 1473 and HBx.’Rz2-i65i> and between ribozymes HBx:Rz2i65i and 
HBx:Rz3i607- Other cleavage products include an array of incomplete reaction 
intermediates. One such intermediate, visible as a 103 nt product, represents a 
78 nt self-cleaved monomer of ribozyme HBx:Rz3-i607 with 24 nt of attached, 
uncleaved 3' terminal vector sequence. These results suggest that cis-cleavage 
is highly efficient and specific for all ribozyme species and that independent 
liberated ribozymes can be generated to act in trans.
4.4.2.2 In vitro trans-cleavage activity of 5 - and 3-trimmed monomeric 
ribozymes generated by cis-cleavage
Cis-cleaved 5'- and 3'-trimmed monomeric hammerhead ribozyme units were 
prepared for a trans-cleavage reaction. The processed ribozymes were 
generated from transcripts containing 1, 2, 4 and 8-mer ribozyme units as 
described in sections 4.3.1.1 and 4.3.1.2. Sense and antisense target HBV RNA 
was produced by T7/T3 RNA polymerase using a linearised pBluescript-derived 
vector, pBS-X, as template. Plasmid pBS-X encodes the HBx ORF of HBV. To 
determine the trans-cleavage activity of monomeric ribozymes generated by cis- 
cleavage of a multimeric transcript, target transcript RNA was cleaved in trans by 
each individual processed ribozyme. All multimeric units of each of the three 
ribozymes were able to cleave target RNA in trans to generate two cleavage 
products: 173 and 411 nt for ribozyme HBx:Rzl-1473; 351 and 233 nt for ribozyme 
HBx:R z 2 1651; and, 306 and 278 nt for ribozyme HBx:Rz3-i607 (Figures 4.9A and 
4.9C). Antisense HBx template RNA (587 nt), produced by T7 RNA polymerase, 
was not cleaved by any single-unit or multimeric hammerhead ribozyme (Figure 
4.9B). Ribozyme /-/Bx:Rz3i607 proved to be significantly more efficient at cleaving 
target substrate than both ribozymes HBx:Rz1 1473 and HBx:Rz2i65i. This can be 
deduced from the intensity of the cleaved products and the lack of substrate 
RNA, represented by a 548 nt band. A 16-mer of HBx.:Rz1i473 and HBx:Rz2165i 
and a 24-mer containing each of the three ribozyme species also produced all the 
expected cleavage products (Figure 4.10A).
4.4.3 Multimeric ribozyme inhibitory effects on HBV gene expression in 
transfected liver-derived cells
In order to observe the effects of the cis- and trans-cleaving multimeric ribozymes 
in transfected Huh7 cells, all 8-mer and the 24-mer ribozyme constructs were 
cloned into the mammalian expression vector pCI neo under control of the 
immediate/early CMV promoter. This resulted in 8-mer vectors pCI- 
M8HBx:Rzl-1473, pCI-A48/-/Bx:Rz2165i and pCI-M8/-/Bx:Rz3-i607, as well as the 24- 
mer, pCI-M24HBx:Rz1,Rz2,Rz3.
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generated HBx RNA transcripts.
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Figure 4.10 The frans-cleaving action in vitro of transcripts encoding multimeric cis- and 
trans-cleaving units of different hammerhead ribozymes. A) Trans-cleavage 
fragments generated by multimeric ribozymes M16HBx.Rz1&2 and 
M24HBx:Rz'\ ,2&3. The single-unit hammerhead ribozymes HBx:Rz11473 and 
HBx:Rz 316o7 are used to compare cleavage fragments generated by the 
multimeric ribozymes. B) Schematic illustration of the expected size 
fragments for the trans-cleavage reaction.
4.4.3.1 The inhibitory effects of multimeric ribozymes in situ
The cells shown in Figure 4.11 are representative fluorescence microscope fields 
of co-transfections with combinations of pCH-EGFP and both single-unit and 
multimeric cis- and frans-cleaving hammerhead ribozyme expression vectors. 
The mean and SEM of the number of cells expressing EGFP were calculated at 
day three from triplicate experiments. The catalytically-inactive ribozyme control 
pHBx:Rz1 1473 (cells co-transfected with pCH-EGFP and p/~/Bx.Rz1 1473) 
produced a mean of 130 ± 15 fluorescent cells per culture field. Since plasmid 
p/-/Bx:Rz1*i473 was the least effective vector at reducing the number of 
fluorescent cells per field, it was regarded as the negative control. Relative to 
p/-/Bx:Rz1*1473 both single-unit ribozymes pHBx:Rz1u 73 and pHBx:Rz2i65i 
significantly inhibited fluorescence by 42% and 55% respectively. The 
catalytically inactive ribozyme p/-/Bx:Rz2* i65i modestly inhibited (35 ± 7.6%, 
p<0.01) the expression of EGFP in transfected cells. These results correlate with 
those observed in section 3.4.4 taking into account the possibility that plasmid 
pHBx:Rz1*i473 has contributed to some antisense effects. Multimeric ribozyme 
expression vectors, pCI-M8/-/Bx:Rz1 i473, pCI-/W8/-/Bx:Rz21651 and pCI-
M8HBx: Rz3 1607 express transcripts that cleave in cis to generate eight (8-mer) 
individual monomer trans-cleaving hammerhead ribozyme units. Apart from pCI- 
M8HBx\Rz2i65i, these multimeric vectors were more effective than their single­
unit counterparts in inhibiting the number of fluorescent cells per field (Figure 
4.12). Compared to the inhibitory effects of p/-/Bx:Rz1*H73, plasmid pCI- 
M8HBx: Rz3 1607 inhibited fluorescence by ± 60%. Plasmid pCI-
M24HBx\Rz1,Rz2,Rz3, which expresses 8-mer units of each of the three 
ribozyme species, proved to be the most effective vector and inhibited 
fluorescence by ± 92% (Figure 4.12). These results suggest that both cis and 
trans cleavage is taking place in cultured cells. Moreover, the data demonstrate 
that these multimeric cis- and trans-cleaving ribozymes are more effective than 
previous constructs in preventing HBV gene expression, and are thus likely to 
possess significant antireplicative activities.
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Figure 4.11 In situ ribozyme modulation of EGFP activity in co-transfected Huh7 cells. Combined phase contrast and fluorescence microscopy 
of Huh7 cells transfected with pCH-EGFP and either single-unit inactive ribozyme controls or various ribozyme-expressing 
constructs.
In situ modulation of GFP activity
Figure 4.12 An in situ quantitative comparison of the number of EGFP-positive Huh7 
cells modulated by the transfection of various ribozyme-encoding 
expression vectors. Cells were counted from fluorescence microscopy 
fields of Huh7 cells transfected with pCH-EGFP and either single-unit or 
multimeric ribozyme-expressing constructs. Single-unit ribozyme-inactive 
variants were used as negative controls. The data are the mean ± SEM of 
thee separate transfections.
4.4.3.2 Effects of multimeric ribozyme on HBV antigen secretion in cell culture
supernatants
To assess the effects of single-unit hammerhead ribozymes and multimeric self­
cleaving ribozymes on HBsAg and HBeAg secretion, Huh7 cells were co­
transfected with ribozyme-encoding vectors and a replication-competent HBV 
vector, pHBV adw HTD (this vector is described in section 2.3.2). Cell culture 
supernatants were analysed three days after transfection for the secretion of 
HBsAg and HBeAg (Figure 4.13). All transient co-transfections were performed in 
triplicate (mean and SEM are indicated) and were normalised to 100% of the 
positive control. Plate-to-plate variations in transfection efficiencies were
H BsAg and H BeAg m easurem ents
Figure 4.13 Measurement of HBsAg and HBeAg secretion from Huh7 cells co-transfected with single-unit and multimeric ribozyme vectors (as 
well as antisense RNA) and a replication-competent HBV vector, pHTD adw HBV (Figure 4.4). HBs/HBeAg measurements are 
given as a mean percentage of the positive control (pHTD adw HBV only) with standard error of the mean (SEM). The plasmids 
used in the transfection are indicated below each column. The data is given as the mean from experiments performed in triplicate 
and is compared to 100% for the control.
determined by assessing the relative expression of EGFP in each plate (see 
Appendix C2). As expected, single-unit ribozymes p/-/Bx:Rz1-i473 and 
pHBx:Rz2-i65i decreased the secretion of HBeAg and HBsAg into the culture 
supernatant (Figure 4.13). The catalytically inactive ribozyme control 
p/-/Bx:Rz1*i473 had only a modest inhibitory effect on HBsAg and HBeAg 
secretion whilst the inactive ribozyme control p/-/Bx:Rz2*i65i was completely 
ineffective. These results are similar to those obtained in section 3.4.3, 
suggesting that single-unit ribozymes are only moderately efficacious. Once 
again, p/-/Bx:Rz1 1473, which cannot cleave RNA sequences generated by the 
pHBV adw HTD vector (see section 3.4.3), was slightly more effective than 
pHBx:Rz2165i. To confirm the results observed in the previous chapters, that 
antisense-effects play a dominant role in inhibiting HBV replication, antisense 
plasmids p/-/Bx:At1-|473 and pHBx:At2i65i were included in this study. The results 
for both antisense plasmids are similar to each respective single-unit ribozyme. 
Comparisons between the inactive ribozymes and antisense RNAs suggest that 
the catalytically inactive ribozymes are not necessarily true antisense controls. 
The catalytically inactive ribozymes cause only a modest reduction in antigen 
levels and may only partially elicit the antisense effects seen when using full- 
length antisense RNA sequences.
Multimeric ribozyme plasmids expressing 8-mer self-cleaving ribozyme 
units of hammerhead ribozymes HBx:Rz1 1473, HBx:Rz2i65i and HBx:Rz2165i were 
largely more effective than their single-unit counterparts in decreasing HBeAg 
and HBsAg levels (Figure 4.13). pCI-A//8/-/Bx:Rz3-i607 reduced both HBsAg and 
HBeAg secretion levels by approximately 75 and 70% respectively. Moreover, 
pCI-M8/-/Bx:Rz3i607 proved to be more effective than either a combination of all 
three 8-mer plasmids or the 24-mer plasmid, pCI-A424/-/Bx:Rz1,Rz2,Rz3, which 
simultaneously expresses eight units of each of the three ribozymes. Unlike the 
results obtained in section 4.4.2, pCI-/W24HBx:Rz1 ,Rz2,Rz3 reduced the 
secretion of HBsAg/HBeAg levels by approximately 60%. In conclusion, these 
results indicate that multimeric ribozymes are more effective at inhibiting viral 
gene expression than single-unit ribozymes, and implies some degree of 
ribozyme-mediated cleavage. It is unlikely that multiple, tethered antisense 
sequences targeting the same site will be more effective than single-unit 
sequences as multiple antisense sequences are likely to be hindered by steric
effects and competition for the same trans target sites and/or c/'s-recognition 
sequences. However, it may be that cis-cleavage is active whilst trans-cleavage 
is ineffective. In vivo, hammerhead ribozyme cis-cleavage has been shown to be 
more efficient than trans-cleavage (Dropulic et ai., 1992; Xing et ai., 1995) as 
both ribozyme and target sequences are co-localised. A molar excess of 
independent antisense RNA monomers (a situation where c/'s-cleavage takes 
place but not trans-cleavage) could generate similar results to those observed for 
the multimeric cis-cleaving ribozymes. Nevertheless, the results for the multimeric 
ribozyme constructs in general are encouraging and represent an improvement 
on previously constructed hammerhead ribozymes. These constructs are capable 
of significantly inhibiting HBV gene expression and replication in cell culture and 
are viable agents for further testing in animal models of chronic HBV infection.
4.5 Discussion and conclusions
Most studies to date suggest that ribozyme cleavage activity is relatively 
inefficient in vivo (Castanotto et ai., 2000). At present ribozyme research is 
restricted by a limited understanding of the catalytic activity of hammerhead 
ribozymes in an intracellular or in vivo environment. Few models exist which 
allow for the design ex novo of ribozymes or antisense RNA sequences for use in 
a clinical setting, let alone for use in treating chronic HBV infection. A number of 
unresolved issues include the identification of the optimal sequences which need 
to be targeted, the effect of inhibiting viral and cellular factors, subcellular co­
localisation of therapeutic and target sequences, the appropriate length of the 
hybridising sequences and the efficient delivery of therapeutic sequences to the 
infected hepatocytes (explored in a detailed discussion, see Chapter 5). Anti-HBV 
ribozymes produced by others (Beck and Nassal, 1995; Feng et ai., 2001a; Feng 
et ai., 2001b; Kim et ai., 1999; Welch et ai., 1997) confirm the results presented 
in Chapters 2 and 3 that ribozymes appear less effective when expressed 
endogenously in transfected cells than in cleavage reactions in vitro. Since many 
factors govern the interactions between RNA molecules in the intracellular 
physiological environment, improving the efficacy of ribozymes in vivo is the 
primary focus of therapeutic ribozyme development.
Ribozymes are distinguished from antisense RNAs in their ability to 
undergo multiple reactions. They may be applying their therapeutic effects sub- 
optimally by acting mostly as antisense RNAs in vivo. The hammerhead ribozyme 
catalytic efficiency (kcat) is several orders of magnitude lower in vivo compared to 
in vitro (James and Gibson, 1998), and single-turnover conditions prevail. As a 
result, a greater concentration of hammerhead ribozymes is needed to improve 
their intracellular efficacy. This has been confirmed by previous studies which 
indicate that a molar excess of ribozymes over its target substrate RNA is 
necessary in order to exert an inhibitory biological effect in vivo (Cameron and 
Jennings, 1989; Cotten and Birnstiel, 1989). One of the aims of this study was to 
increase the number of ribozymes present in vivo for cleavage. Various elaborate 
hammerhead ribozyme constructs have been tested with the specific aim of 
increasing the number of ribozyme catalytic units per cell, and thereby increasing 
the intracellular ribozyme concentration. DNA sequences, encoding single 
transcripts harbouring different ribozymes bound head-to-tail on the same strand, 
have been constructed to target various sites on BCR/ABL mRNA (Leopold et at., 
1995), HIV (Bai et al., 2001; Chen et al., 1992; Ohkawa et a i, 1993a; Ramezani 
et al., 1997) and HBV (von Weizsacker et al., 1992). For these ribozymes, 
cleavage efficiency was shown to be directly proportional to the number of 
ribozyme units present on the transcript RNA. However, there is a limit to the 
number of bound ribozymes which can exert maximal cleavage activity in vitro. 
No increase in cleavage efficiency was observed by adding more than three 
ribozyme units to the same transcript (Ohkawa et al., 1993a). Ribozymes bound 
together within a single transcript are catalytically constrained. However, the 
kinetic mechanism of bound ribozyme units has not been verified in vivo.
Ribozymes bound within a single transcript can be released from the 
parental chain through the action of flanking c/'s-cleaving hammerhead ribozymes 
present on both the 5' and 3' ends of a frans-cleaving ribozyme (Yuyama et al., 
1992). Released individual ribozyme monomers are capable of cleaving target 
RNA in trans (Ohkawa et al., 1993a; Ohkawa et al., 1993b; Yuyama et al., 1992; 
Yuyama et al., 1994). Trans-cleaving ribozymes processed from a single 
transcript are more efficient catalytically than the frans-cleaving action of 
ribozymes bound together on the same transcript (Ohkawa et al., 1993a). Later 
studies have used several different ribozymes that release themselves from a
single transcript (Taira’s “shotgun” ribozymes) (Ohkawa et al., 1993b). In this 
system, 5' and 3' processed frans-cleaving multimeric ribozymes were capable of 
inhibiting target HIV RNA expression when expressed from retroviral vectors 
transduced into cultured cells (Xing et al., 1995), but were no more effective than 
single-unit ribozymes in cell culture.
Taira’s shotgun multimeric ribozyme method (Ohkawa et a!., 1993a) 
has been simplified to include multimeric units of both c/s- and trans-cleaving 
hammerhead ribozymes (Ruiz et al., 1997). In this system each hammerhead 
ribozyme unit present on the transcript RNA includes a cis-cleaving ribozyme 
recognition sequence. Cis-cleaved individual monomeric ribozyme units are then 
capable of retaining their function to cleave a target RNA in trans. The Ruiz 
model was applied successfully in the present study to target multiple cis- and 
trans-cleaving hammerhead ribozymes to different sites of the HBx ORF. 
Although, Ruiz et al. (1997) applied their multimeric construct to cleave HBV core 
RNA sequences in vitro, their study made use of a transcript that comprises 
multiple copies of one hammerhead ribozyme. Moreover, the efficacy of the 
multimeric ribozymes at inhibiting gene expression in transfected cells was not 
assessed. The cis-cleavage reaction of Ruiz’s pentameric hammerhead ribozyme 
transcript was inefficient and contrasted with the data in Figures 4.7 and 4.8 that 
show highly efficient cis-cleavage using 4-mer, 8-mer and 24-mer ribozyme 
transcripts. For the in vitro transcription/c/s-cleavage reaction described in 4.4.2.1 
(Figure 4.8), efficient cleavage was achieved despite the presence of an 
increased nucleotide concentration, which sequesters free Mg2+ ions during 
transcription. This implies either that the hammerhead ribozymes chosen in 
Chapter 2 show a high specificity for their target, or that the HBx ORF is more 
accessible to the hybridising effects of the ribozyme annealing helices I and III. 
Since neither ribozyme kinetic studies nor a systematic comparison between 
different cleavage sites on HBV were performed, any discussion on comparative 
ribozyme efficiencies must remain speculative.
In the present study, the flanking arms in helices I and III (hybridisation 
arms) for the cis-cleavage reaction span approximately 14 nt of the 
complementary target sequence. The optimal length of ribozyme-substrate 
complementary sequences varies between 7 and 20 (Thomson et a!., 1997). As, 
the affinity of the c/s-cieaving ribozyme for its downstream recognition sequence
is high, ribozyme specificity and catalytic efficiency is less likely to be dependent 
on hybridisation conditions. Consequently, c/'s-cleavage proceeds optimally under 
multiple turnover conditions. The trans-cleaving hammerhead ribozymes have 
hybridisation arms which span approximately 24 complementary nt instead of the 
16-18 nt used for the same single-unit ribozymes in Chapters 2 and 3. Longer 
flanking arms were specifically designed to improve intracellular ribozyme 
specificity. Since the annealing reaction in vivo is the rate-limiting step, longer 
annealing arms often improve the inhibitory effects of the ribozymes (Bertrand 
and Rossi, 1996). However the higher affinity decreases the catalytic rate constant 
(kcat) and impedes the cleavage of multiple substrates by a single ribozyme (Hertel 
et al., 1994). The data generated from cell culture transfections (4.4.3) were not 
sufficiently sensitive to measure any differences in ribozyme-mediated inhibition 
due to the length of the annealing arms (see sections 5.2.1 and 5.2.2 for a 
detailed discussion).
It has been suggested that an alternative reason for the inefficiency of 
hammerhead ribozymes in vivo is the presence of non-hybridising sequences, 
which are found 5' and 3' of the ribozyme catalytic core sequence (Bramlage et 
al., 1998; Ohkawa et al., 2000). These auxiliary sequences are usually vector- 
derived and may interfere with the correct ribozyme secondary structure 
conformation, resulting in a catalytically compromised ribozyme (He et al., 1993; 
Ventura et al., 1993). Alternatively, these additional sequences may decrease 
ribozyme specificity, preventing the annealing arms from hybridising to target 
complementary sequences. The multimeric cis- and trans-cleaving hammerhead 
ribozyme system described in this study has the advantage of generating trans- 
cleaving monomers with defined 5' and 3' ends, thus minimising the presence of 
additional sequences both upstream and downstream of the ribozyme catalytic 
core. One serious concern for this multimeric ribozyme system is the question of 
ribozyme stability post-cleavage. The presence of exposed 5' and 3' ends makes 
these cleaved ribozyme molecules susceptible to nuclease degradation. It 
appears, however, that processed ribozyme monomers survive long enough to 
ensure that they exert their therapeutic effects in an intracellular environment.
In conclusion, the multimeric cis- and trans-cleaving hammerhead 
ribozymes are more effective at inhibiting cell culture models of HBV replication 
than the hammerhead ribozymes described in the previous chapters. There are
several advantages associated with using cis-and trans-cleaving multimeric 
ribozymes for the future treatment of chronic HBV infection:
1) Multimeric cis- and trans-cleaving hammerhead ribozymes increase the 
intracellular concentration of hammerhead ribozymes.
2) Ribozyme cis-cleavage generates trimmed 5' and 3' flanking 
sequences, thereby removing non-hybridising sequences that may 
interfere with the stability and antisense action of ribozymes in vivo.
3) Any number of different individual ribozyme units may be expressed on 
a single transcript. Simultaneous targeting of different sites within the 
HBV genome has the advantage of preventing the development of 
escape mutants (Appendix C3). Viral quasi-species that evade action 
of single ribozymes are easily selected due to the sensitivity of 
ribozymes to single base changes within the cleavage recognition 
sequence.
4) Since some cleavage sites within the target RNA remain inaccessible 
to both ribozyme and antisense action, an approach whereby a number 
of different sites are targeted simultaneously may prove to be 
synergistic. The cleavage of an accessible site may make a previously 
inaccessible region available for targeting.
The results of this study provide a compelling argument for the therapeutic 
application of these ribozymes in animal models of HBV infection. However, 
many factors need to be overcome in order to apply ribozyme-encoding genes in 
a clinical setting. These and other design considerations are discussed in detail in 
Chapter 5.
5.0 GENERAL DISCUSSION AND CONCLUSION
The studies presented in this thesis add significantly to the growing body of 
research on ribozymes targeted to HBV. In most cases, ribozymes have been 
shown to be specific to their target RNA sequence and are efficient inhibitors of 
both viral gene expression and replication in cell culture models of HBV infection. 
The clinical application of hammerhead ribozymes and other therapeutic 
ribozymes as future therapeutic agents for the treatment of HBV hinges on 
overcoming two important obstacles. Firstly, since hammerhead ribozymes are 
expressed endogenously from DNA-encoding sequences, ribozyme expression 
cassettes need to be effectively delivered to the HBV-infected liver. Secondly, as 
antiviral agents, therapeutic hammerhead ribozymes must be clinically efficacious 
and non-toxic in vivo. Prospects for overcoming these hurdles are dealt with in 
the following sections. In addition, important principles for the design of 
therapeutic hammerhead ribozymes are included.
5.1 Hammerhead ribozymes and HBV
5.1.1 Hammerhead ribozymes targeted to the HBx ORF
Since the trans-activation function of HBx is regarded as a potential risk factor in 
the development of HBV-associated carcinogenesis, the inactivation of HBx is 
likely to be important for future approaches to therapy of chronic HBV infection. 
Hammerhead ribozymes presented in this thesis inhibited endogenous HBx 
trans-activation in primary hepatocellular carcinoma cells, indicating that they 
have imminent therapeutic potential as agents capable of preventing HBV- 
associated hepatocellular carcinoma.
Two studies conducted contemporaneously have corroborated the 
inhibitory effects of hammerhead ribozymes targeted to the HBx ORF of HBV 
described in Chapter 2. Yim et at. (2000) generated a yeast expression vector 
containing a hammerhead ribozyme in cis with an HBx-lacZ fusion construct 
under transcriptional control of the yeast copper-inducible chelatin promoter 
(Cl/P1p). The hammerhead ribozyme, when expressed in transient transfected 
yeast cells, was able intermolecularly to cleave the target sequence, thus
disrupting the HBx-LacZ fusion mRNA. This resulted in histochemically negative 
(white) colonies on agar plates stained with the chromogenic substrate X-gal. 
This system, in which both ribozyme and target sequences are present on the 
same RNA strand, cannot, however, be used to infer the efficacy of hammerhead 
ribozyme-mediated trans-cleavage in vivo. In addition, as described earlier for 
snorbozymes, the intracellular environment of the yeast may be substantially 
different to that of the hepatocyte. Nevertheless, an interesting feature of this 
study is the fact that various catalytically inactive ribozyme variants, including an 
antisense RNA, were able to inhibit lacZ expression effectively with results similar 
to those for the active hammerhead ribozyme (Yim et al., 2000). All these 
hammerhead ribozyme and antisense RNA variants correspond to the same 
region as the catalytically active ribozyme. The results in yeast independently 
suggest that an antisense mechanism without substrate cleavage may be 
responsible for inhibiting target RNA.
In a very similar experiment to that described in 2.4.3, two 
hammerhead ribozymes, which target different cleavage sites on the HBx ORF to 
those described here, successfully cleaved target HBx RNA in vitro (Kim et al., 
1999). However, a 100:1 molar ratio of ribozyme to substrate was needed in 
order to cleave 75% of the substrate in a one-hour reaction under standard in 
vitro cleavage conditions. In this same study, a reporter plasmid pSV2CAT was 
constructed expressing chloramphenicol acetyl-transferase (CAT) under control 
of the SV40 early promoter, which is susceptible to frans-activation by HBx (Twu 
and Robinson, 1989). The ribozymes constructed by Kim et al. (1999) were able 
to inhibit HBx frans-activation function (by reducing CAT activity) in transiently 
transfected HepG2 human hepatoma cells. This study did not, however, correlate 
a decrease in HBx trans-activation with variations attributed to differences in 
transfection efficiencies between culture plates. Nevertheless, these results are in 
agreement with the data presented in sections 2.4.3 and 2.4.4.
5.1.2 Hammerhead ribozymes as antiviral agents
Of the two early studies using hammerhead ribozymes targeted to HBV, only 
Beck and Nassal have tried, albeit unsuccessfully, to observe the in vivo effects 
of hammerhead ribozyme-mediated cleavage of HBV pgRNA (Beck and Nassal,
1995; von Weizsacker et al., 1992). Since in vitro experiments are usually devoid 
of cellular factors, there is little value in studies aimed at developing therapeutic 
ribozymes strategies without studying the effects of hammerhead ribozymes in an 
intracellular environment. Ribozyme activity has been shown to differ remarkably 
in vitro and in cultured cells, often yielding conflicting results (see section 5.2) 
(Beck and Nassal, 1995; Crisell et al., 1993; Homann et al., 1993; Tabler et al.,
1994).
Three studies, which were performed contemporaneously with those 
presented here, have tried to observe the antireplicative effects of hammerhead 
ribozymes targeted to HBV. Ribozymes have been targeted to the core region 
(Feng et al., 2001a), the polyadenylation signal sequence (Feng et al., 2001b) 
and different sites within the HBx ORF (Kim et al., 1999). A hammerhead 
ribozyme was successfully targeted to the RNA sequence encoding the carboxy- 
terminus of the core protein in HepG2 cells that were transiently co-transfected 
with a ribozyme vector, its catalytically inactive counterpart, and a vector 
containing a replication-competent head-to-tail dimer of HBV (subtype adr) (Feng 
et al., 2001b). Viral DNA extracted from lysed cells and from HBV particles in the 
culture medium was reduced by approximately 50% by the ribozyme-encoding 
vector. These results were reflected in similar inhibitions in HBsAg and HBeAg 
secretion. The inactive ribozyme control showed a 25% reduction in both viral 
DNA and antigen levels (Feng et al., 2001b). In another study, the same authors 
targeted the polyadenylation signal region of the viral pgRNA for cleavage using 
a similar approach to that described for the anti-core ribozyme (Feng et al., 
2001a). This hammerhead ribozyme inhibited the production of intracellular viral 
RNA and DNA levels by approximately 70% compared to a 50% inhibition by the 
catalytically inactive ribozyme control (Feng et al., 2001a).
The hammerhead ribozymes produced by Feng et al. (2001a) are 
similar in efficiency to those presented in Chapters 2 and 3 as well as by others 
using hairpin ribozymes, proving that other sites of the viral genome can be 
targeted successfully in cultured cells to inhibit viral replication. Generally, 
however, the specificity of hammerhead ribozymes targeted to HBV is low. The 
multimeric cis- and trans-cleaving ribozymes described in Chapter 4 represent a 
significant improvement on existing HBV ribozymes.
A serious concern for the development of any future antiviral strategy,
including the use of ribozymes, is the possibility of developing HBV mutant 
strains that are resistant to treatment. As was noted for lamivudine and other 
nucleoside analogues, the HBV genome is flexible enough to sustain substitution 
changes necessary for the development antiviral-resistant HBV strains. The 
effects of hammerhead ribozymes are no exception. The ease with which single 
base substitutions can confer resistance to ribozyme therapy must be a worrying 
factor for their clinical implementation. A single change withing the catalytic site 
(the 5' GUC 3' cleavage triplet, for instance) can render the ribozyme functionally 
impotent. Targeting several sites on the HBV genome simultaneously (as was 
done in Chapter 4) may be the solution since the selective pressure of generating 
HBV strains that are resistant to a multi-faceted attack is likely to be too great a 
burden on any replicating virus. Clearly the latter approach represents a suitable 
option for clinical evaluation of hammerhead ribozymes in vivo in animal models 
of HBV infection.
5.2 Designing therapeutic hammerhead ribozymes
5.2.1 The effects of ribozyme flanking sequences
Hammerhead ribozyme specificity is determined by the flanking sequences of 
helices I and III, which hybridise to substrate RNA prior to cleavage. 
Theoretically, the hammerhead ribozyme annealing arms should be long enough 
to provide structural stability, specificity, and an adequate association rate (Birikh 
et al., 1997b). Yet the annealing arms must be short enough to ensure 
reasonable catalytic turnover. Generally, for short unstructured substrate 
sequences, 7 to 8 nucleotides for each flanking arm provide the most favourable 
result (Lieber and Strauss, 1995). These ribozymes have been shown to function 
equally well both in vitro and in vivo (Bertrand and Rossi, 1994). The 
hammerhead ribozymes of this study were designed with the intention of 
ensuring maximal specificity and catalytic turnover.
Hammerhead ribozymes with short hybridising arms are less likely to 
anneal to sequences with single base changes and thus have a greater potential 
to discriminate target sequences. Long flanking sequences lack the 
discriminatory power to distinguish mismatches (Hertel et al., 1996). Should the
position of the mismatch be close to the cleavage triplet, ribozyme-target 
association could be completely obstructed (Werner and Uhlenbeck, 1995). This 
was observed for ribozymes with hybridising arms of six nucleotides each that 
target the tat gene of HIV-1 in two different strains of the virus. Hammerhead 
ribozymes targeted to the mutant strain containing an adenosine 3' of the 
cleavage triplet significantly inhibited viral replication. No such effect was 
observed for the HIV-1 strain with a guanosine at the same site (Sun et a!.,
1995).
The length of ribozyme helix III (the 3' arm) is more critical than helix I 
(5' arm). Asymmetrical hammerhead ribozymes have been constructed with only 
three nucleotides for helix I and over 100 for helix III. These ribozymes were 
shown to be effective at cleaving HIV-1 RNA (directed to the long terminal repeat- 
gag region) both in vitro and in transfected cells (Tabler et al., 1994).
Some groups have reported that hammerhead ribozymes containing 
annealing arms greater than 30 nucleotides show effective and rapid cleavage in 
vitro and strong inhibition of target RNA expression in cultured cells (Crisell et al., 
1993; Homann et al., 1993; Tabler et al., 1994). The trans-cleaving ribozymes of 
section 4.4.1.2, which have 5' and 3' annealing arms that span 24 nt, produced a 
greater inhibitory effect than the equivalent ribozymes with shorter arms (16-18 
nt). However, it is unclear to what extent the observed inhibition is due to an 
increased intracellular ribozyme concentration. These latest results appear to 
conflict with the results of Lieber and Strauss (1995). The rate-limiting step in vivo 
for ribozyme-catalysed reactions is known to be the annealing of the ribozyme 
arms to complementary sequences on the target RNA. Since single-turnover 
conditions govern ribozyme action in the intracellular environment, the greater 
inhibitory power of ribozymes over antisense RNAs lies in their ability to cleave 
their target once annealed. It appears that target RNA is largely inaccessible in 
an intracellular environment. Since RNAs in vivo are found in varying secondary 
and tertiary conformations, Bertrand and Rossi (1996) suggest that cellular 
proteins may facilitate the annealing of ribozymes with long hybridising arms 
(discussed in section 5.2.2.2). Hammerhead ribozymes which were designed to 
target the HBV encapsidation signal indicate that longer ribozyme arms facilitate 
binding by interacting with single-stranded regions that are near the ribozyme 
cleavage site and which are not accessible to binding with ribozymes comprising
shorter flanking arms (Beck and Nassal, 1995). This is supported by the 
observation that single-stranded cognate sequences are indispensable for 
successful recognition of ribozyme hybridising arms for the substrate mRNAs 
(Rittner et al., 1993). At present, there are no clear rules governing the length of 
annealing arms for intracellular ribozyme action, and each system needs to be 
determined empirically.
5.2.2 Finding suitable target sites for ribozyme cleavage
For long, structured target RNA molecules, which undergo secondary or tertiary 
folding, the kinetic rate-limiting step is often the association of ribozymes with 
their target RNA. The RNA secondary structure may hide accessible cleavage 
sites and prevent effective ribozyme binding, which possibly explains why 
ribozymes targeted to different sites on the same mRNA strand in vitro show 
varying cleavage activities (Hendrix et al., 1996).
There appears to be an additional disparity between the observed 
ribozyme effects in vitro, and ribozyme function in vivo (in cell culture or animal 
models). Irrespective of these discrepancies, most therapeutic approaches first 
test newly constructed ribozymes in a chemically isolated environment. 
Experiments that test ribozyme cleavage parameters in vitro still represent the 
gold standard for ribozyme selection. In vitro cleavage experiments may yield 
important information regarding the catalytic properties of the constructed 
ribozymes, but often they offer little insight into the intracellular effects of 
ribozymes on their target RNAs.
Generally, a trial and error approach, although laborious, is often the 
most effective method to determine which sites will be best suited for ribozyme 
cleavage (Usman and Stinchcomb, 1996). However, for long mRNA substrates or 
for target mRNAs suspected of concealing ribozyme-accessible sites, several 
combinatorial screening techniques have been devised to determine ribozyme- 
accessible regions and effective cleavage sites.
5.2.2.7 Probing RNA secondary structure using computer algorithms
RNA folding programs, such as Mfold® (Genetics Computer Group, Wl, USA) and 
RNAdraw™ (Matzura and Wennborg, 1996), are used to predict RNA secondary 
structures based on global free-energy calculations (Matzura and Wennborg, 
1996; Zuker and Jacobson, 1998; Christoffersen et al., 1994; Sczakiel and 
Tabler, 1997). However, these programs are still in their infancy and, although 
they predict certain structural properties of RNA, they are currently inept at 
accurately predicting the correct RNA secondary folding, let alone determining 
accessible ribozyme cleavage sites. In some cases, predictions generated by 
such programs contrast directly with experimentally verified sites reported to be 
susceptible to ribozyme cleavage (Dropulic and Jeang, 1994). Most importantly, 
these programs fail to predict the secondary and tertiary RNA structure generated 
by associations with proteins and other factors in vivo. Although Mfold was used 
to determine HBx RNA secondary structure (Chapter 2), the program was unable 
to predict accurately accessible regions for nucleic acid hybridisation. 
Hammerhead ribozyme HBx:Rz3i6o7 targeted one of the least accessible sites on 
the HBx ORF and yet proved to be the most effective ribozyme in vitro and in cell 
culture transfections.
5.2.2.2 The accessibility of target RNA for ribozyme cleavage in vivo
RNAs within the cell associate with an array of proteins. Within the nucleus, 
heterogeneous nuclear proteins (hnRNPs) and small nuclear proteins (snRNPs) 
are often complexed to mRNAs. Whilst in the cytoplasm, mRNAs readily combine 
with hnRNPs, rRNAs and proteins associated with the translation complex. These 
proteins may either facilitate or inhibit ribozyme binding (Casas-Finet et al., 1993; 
Khan and Giedroc, 1992; Portman and Dreyfuss, 1994). Proteins such as a 
peptide polymer derived from the consensus sequence of the carboxy-terminal 
domain of the hnRNP A1 protein (Herschlag et al., 1994) and HIV-1-encoded 
NCp7 (Tsuchihashi et al., 1993) were shown to bind non-specifically to RNA. The 
proteins possess unwinding activity allowing, in some cases, a 1000-fold increase 
in the hybridisation rate (Bertrand and Rossi, 1994; Herschlag et al., 1994). For 
the most part, however, proteins associated with mRNAs in vivo prevent the
annealing of ribozymes to target sequences and represent a hurdle for the 
development of effective inhibitory endogenous ribozymes. Recently, Kato et al. 
(2001) developed a ribozyme expression vector, which includes an RNA motif 
with RNA helicase binding ability linked to a 5' ribozyme-encoding sequence. The 
unwinding of secondary structures inherent in intracellular target RNA molecules 
was shown to improve the catalytic efficiency of the designed ribozyme (Kato et 
al. 2001).
5.2.2.3 Combinatorial screening techniques for finding ribozyme cleavage sites
Ribozyme activity can be selected from a large ribozyme library with randomised 
substrate binding sequences (helices I and III for hammerhead ribozymes). A 
random pool of ribozymes, or ribozyme library, is challenged in vitro to cleave 
target RNA in order to determine susceptible cleavage sites (Lieber and Strauss, 
1995). The sites are often selected within an entire transcript and no prior 
knowledge of the transcript sequence is needed. Cleavage products generated 
by a random ribozyme library can be tailed, amplified by RT-PCR, and cloned 
into vectors. Clones can be sequenced to identify the most efficient cleavage 
sites. Ribozymes discovered using this approach efficiently cleaved human- 
growth hormone mRNA in vitro and strongly inhibited target mRNA expression in 
transduced cell cultures (Lieber and Kay, 1996; Lieber and Strauss, 1995). An 
adaptation of this technique was used by zu Putlitz et al. (1999) to generate a 
random hairpin ribozyme library targeted to HBV pregenomic RNA (see section 
1.4.3).
Another screening technique utilised a random oligodeoxynucleotide 
(ODN)-library to probe RNA folded in its secondary structure conformation (Birikh 
et al., 1997a; Christoffersen et al., 1994). RNase H can be employed to degrade 
any RNA hybridised to specific ODN probes. The resulting fragments are 
resolved and identified on denaturing polyacrylamide gels. The fragments 
generate an RNase H digestion pattern, which is compared to appropriate 
markers. This technique is a lot simpler than that used by Lieber and Strauss 
(1995) but reveals only broad hybridisation regions and not necessarily sites 
specific to ribozyme action.
A similar screening technique was used to determine accessible 
ribozyme cleavage sites in cellular extracts from target RNAs produced 
endogenously (Castanotto et al., 2000; Scherr and Rossi, 1998). This allows for 
screening of RNAs in their ‘native’ state. These target RNAs are folded into 
secondary structure conformations along with associated cellular proteins. Briefly, 
antisense ODNs, designed to hybridise to potential ribozyme cleavage sites, can 
be added to cellular extracts containing exogenously expressed target mRNA. 
Both RNA-DNA hybrids and ODNs undergo nuclease degradation and the 
resulting RNA fragments are amplified and quantitated using primers specific for 
the target mRNA. A direct correlation exists between the degree of antisense 
ODN-induced target RNA degradation and the accessibility of the respective 
target site for hammerhead ribozyme cleavage (Scherr et al., 2001; Scherr et al.,
2000).
Screening techniques for accessible sites in vitro do not necessarily 
result in improved cleavage in vivo. Although Birikh et al. (1997) have shown that 
their method represents a 150-fold improvement on predictions using the Mfold 
program, target accessibility screening procedures need to incorporate factors 
that may influence RNA folding in vivo.
5.2.3 Factors governing in vivo ribozyme activity
In addition to the accessibility of the target mRNA for ribozyme cleavage, there 
are a number of other important factors that influence the ability of ribozymes to 
inhibit the expression of target RNAs in vivo. An important determinant for the 
optimal endogenous ribozyme production is the nature of the expression system 
or cassette, which should include elements for regulating intracellular ribozyme 
concentration and persistence (Yu et al., 1993). The cassette should ensure the 
correct ribozyme structure and stability in vivo (Rossi and Sarver, 1990). 
Elements within the cassette can also facilitate co-localisation of ribozyme and 
target RNA in the same cellular compartment (Bertrand and Rossi, 1996; 
Castanotto et al., 2000; Kawasaki et al., 2000). Since the intracellular 
concentration appears to be a vital factor for endogenous ribozyme efficacy, the 
choice of promoter used for RNA expression is a crucial component of the design 
of a ribozyme expression cassette.
Promoters that constitutively express ribozyme-encoding RNAs are 
obviously desirable since such elements generate an abundance of intracellular 
RNA. The RNA polymerase II (Pol II) system produces mRNAs necessary for 
translation into proteins, but has also been widely used for the expression of 
ribozymes. The cytomegalovirus (CMV) promoter has been used previously to 
express ribozymes (Weerasinghe et al., 1991) and was used in expression 
vectors described in this thesis to ensure an equal and persistent expression of 
ribozyme and target genes in transfected cells. Some Pol II promoters have the 
advantage of being tissue specific and can be induced or regulated. Other Pol II 
promoters used to express endogenous ribozymes include retroviral promoters 
(Leopold et al., 1995), the simian virus 40 (SV40) promoter (Weerasinghe et al., 
1991), the p-actin promoter (Ojwang et al., 1992) and the U1 snRNA promoter 
(Bertrand et al., 1997). Pol ll-derived transcripts have ancillary sequences at both 
5' and 3' ends, namely 5' and 3' untranslated regions, a 5' m7GpppG cap 
structure and a 3' poly(A) tail. These additional sequences ensure mRNA 
stability, significantly prolonging mRNA intracellular half-life. Moreover, these 
sequences may be necessary for cytoplasmic localisation, and for functional 
recognition by the translation machinery. The multimeric cis- and trans-cleaving 
ribozymes produce 5'- and 3'-trimmed RNA monomeric units from a CMV-derived 
transcript. These ribozymes survive long enough to inhibit target RNA more 
efficiently than single-unit ribozymes, which possess non-annealing flanking 
sequences. Thus the stabilising effects of Pol ll-derived transcripts appear not to 
be critical and may in fact hinder ribozyme action in vivo. Ancillary nucleotide 
sequences, which are often hundreds of nucleotides long, may obstruct ribozyme 
trans cleavage by masking hybridisation sequences necessary for the annealing 
of the ribozyme with its target RNA. Additionally, factors of the riboprotein 
complex may also bind to Pol ll-derived mRNAs, resulting in encumbered 
transcripts that are less likely to interact freely with target RNAs in vivo.
Polymerase III promoters naturally drive the expression of small RNAs 
such as tRNAs, 5S rRNA and most snRNAs. Transcript expression levels for Pol 
III promoters are significantly higher (Cotten and Birnstiel, 1989) than for Pol II 
promoters and only short ancillary sequences are added to each transcript. Pol 
III promoters have thus been suggested as the optimal promoter choice for the 
generation of endogenous ribozymes (Kawasaki et al., 2000). However,
questions remain concerning the intracellular stability and half-life of Pol Ill- 
derived transcripts.
Anti-HBV hairpin ribozymes generated by zu Putliz et at. (1999) made 
use of both Pol III- and Pol ll-derived promoters without any significant difference 
observed in ribozyme expression or efficacy in Huh7 cells. Similarly, 
hammerhead ribozymes generated by Beck and Nassal (1995) were derived from 
a Pol III promoter system and although expression was high, no clear 
improvement of ribozyme efficacy was observed. In the Beck and Nassal study, 
increased ribozyme expression was not seen as the reason for failed ribozyme 
efficacy in transfected cells.
Ribozyme inhibition of gene expression is greatly facilitated by 
localising both ribozymes and their target RNA to the same intracellular 
compartment (Arndt and Rank, 1997; Castanotto et at., 2000; Sullenger and 
Cech, 1993). Each ribozyme application is different, however, and the nature of 
the target mRNA needs to be carefully studied prior to establishing a co­
localisation strategy. Directing target mRNA and ribozymes to the same 
subcellular region is often achieved by utilising auxiliary sequences which are 
often promoter-derived. These sequences include: viral packaging signals (Pal et 
at., 1998; Sullenger and Cech, 1993), and either nuclear localisation signals 
(Michienzi et at., 2000; Michienzi et at., 1998) or signals which allow co­
localisation of ribozymes and their pre-mRNA targets (Lee et at., 1999).
Signals which direct the trafficking of target pre-mRNAs can be 
attached to ribozymes, enabling co-localisation in the same subcellular 
compartment. This is best illustrated by the introduction, within the U1 snRNA 
coding region, of ribozymes that have 3'-end attached sequences which are part 
of the 3' untranslated regions (UTR) of certain mRNAs. Such ribozyme-encoding 
transcripts were channelled to 5' splice sites of targeted HIV-1 rev pre-mRNAs 
(Michienzi eta!., 1996).
The promoter used to drive expression of ribozyme encoding 
transcripts can be exploited for its localisation potential (some examples were 
given in section 1.2.2.3). HIV-1 utilises a tRNALys3 as a specific primer for reverse 
transcription. Ribozymes incorporated within the tRNALys3 coding region were 
able to generate a chimeric ribozyme-tRNALys3 transcript which co-packages 
along with HIV-1 into proviral particles and cleaves HIV RNA simultaneously with
reverse transcriptase priming (Welch et ai, 1997). Similarly, tRNAVal (Yuyama et 
al., 1992) and Adenoviral VAI (Prislei et ai, 1997) Pol III promoters embed 
regulatory elements within their naturally transcribed regions. Ribozyme 
sequences can be inserted within stem-loop structures of either tRNAVal or 
Adenoviral VA1 promoter systems to achieve high-level expression, ribozyme 
structural stability, and either nuclear or cytoplasmic ribozyme localisation.
5.2.4 Summary
Presently, the engineering of hammerhead ribozymes as therapeutic molecules 
represents a challenge with many variables. There are several design constraints 
when developing therapeutically effective hammerhead ribozymes in vivo. 
Hammerhead ribozymes, which are specifically designed and developed to 
inactivate the expression of target viral or cellular RNA, must be selected by 
addressing the following fundamental properties:
1) Hammerhead ribozymes should be present in higher molarity than their 
target RNA within the cell and must possess a functional and stable 
conformation under intracellular physiological conditions.
2) Hammerhead ribozymes must be specific to accessible target sites on the 
substrate mRNA for efficient cleavage and, if possible, possess catalytic 
turnover.
3) Endogenous hammerhead ribozymes should be constitutively and 
persistently expressed and directed to the same cellular compartment as 
their target mRNAs.
4) Presynthesized ribozymes or ribozyme-encoding sequences must be 
efficiently delivered to a large percentage of the target cell population.
5.3 Delivery of ribozymes
One of the most important requirements for all nucleic acid-based therapeutic 
strategies remains that of an efficient delivery mechanism. In order to function as 
therapeutic agents, ribozymes must be efficiently delivered to the appropriate 
tissue and cell type. Once inside the cell, ribozyme-encoding genes or
presynthesized ribozyme sequences should downregulate their respective target 
RNA and have pharmacologically significant effects. With regard to hammerhead 
ribozymes, there are two general methods employed for delivery into target cells 
in vivo. Firstly, ribozymes can be chemically presynthesized as 
oligoribonucleotides and delivered directly as exogenous agents. Secondly, 
ribozymes can be encoded as a DNA sequence, incorporated into an expression 
cassette, and delivered to target cells for endogenous ribozyme gene expression.
Direct or exogenous delivery of presynthesized ribozymes is an 
attractive therapeutic option. Concerning their pharmacological properties, 
presynthesized ribozymes are chemotherapeutic agents and in relation to other 
antiviral agents are considered to possess low cytotoxicity and high target 
specificity. Nevertheless, these ribozymes need significant chemical 
modifications in order to function therapeutically. Generally, direct delivery of 
unmodified RNA is problematic owing to the instability of RNA in bodily fluids. For 
example, unmodified RNA exhibits a typical half-life of approximately 0.1 to 20 
minutes in serum (Beigelman et al., 1995). Presynthesized ribozymes, whether 
chemically modified or not, are either administered naked or as a conjugate 
within cationic lipid vesicles. In contrast, endogenous expression of ribozyme- 
encoding genes usually makes use of a viral vector. Various vector systems, both 
viral and non-viral, have been utilised to deliver ribozyme-encoding cassettes 
within cells. Endogenous strategies rely on a biological approach towards 
achieving effective therapeutic action. Genes are native to any cellular 
environment and exploit the molecular machinery of the host cell irrespective of 
their biological origin. Thus, ribozyme-encoding genes can be constructed, 
produced and tested through the application and malleability of recombinant 
technology. Additionally, unlike the expression of protein-encoding genes, 
ribozyme-encoding genes can be expressed from any of the three cellular RNA 
polymerases. This specifically fine-tunes their intracellular expression and 
localisation. Irrespective of the present risks associated with the delivery and 
expression of gene sequences, gene-based approaches offer greater potential as 
future therapeutic agents owing to their specificity and low toxicity.
At present, delivery strategies for endogenous gene expression are 
less established for clinical application than exogenous delivery approaches. 
Significant progress in presynthesized ribozyme research, which utilises a more
orthodox pharmacological approach to therapy, has streamlined these ribozymes 
for clinical development. Nevertheless, significant progress is being made in 
developing suitable delivery strategies for gene therapy applications. Most 
notable is the research conducted in generating cationic liposomes as carriers of 
expression vectors. Presynthesized ribozymes remain an important component of 
hammerhead ribozyme therapeutics and deserve further mention prior to a 
discussion of delivery strategies aimed at endogenous ribozymes.
5.3.1 Presynthesized hammerhead ribozymes
Presynthesized ribozymes, if chemically modified, can remain free from 
nucleolytic attack for several days in serum, and for several hours in nuclear 
extracts (Heidenreich et ai, 1994; Heidenreich et at., 1996). In order to retain 
ribozyme catalytic activity and improve stability, three types of modifications are 
necessary (Usman and Blatt, 2000; Usman and Stinchcomb, 1996). These 
include 2'-sugar modifications (Hendry et at., 1992; Perreault et a i, 1990), 
phosphate backbone modifications (Ruffnerand Uhlenbeck, 1990; Shimayama et 
al., 1993) and base change modifications (Grasby et a i, 1993; Usman and 
Stinchcomb, 1996). Terminal (3'-end) stem-loop structures, present on 
unmodified ribozyme transcripts, have been shown to limit exonuclease 
degradation in vivo (Sioud et a i, 1992; Sioud et a i, 1994). However, these latter 
modifications were tested in cell culture and not in serum. The aim in developing 
optimally designed synthetic hammerhead ribozymes is to generate these agents 
with the minimum number of chemical modifications to ensure their increased 
serum longevity and therapeutic efficacy.
There have been two reported clinical trials using nuclease-resistant 
synthetic hammerhead ribozymes (Usman and Blatt, 2000). A synthetic ribozyme 
has been developed to inhibit the mRNA of Flt-1 (VEGF-R1), a high-affinity 
receptor for Vascular Endothelial Growth Factor (VEGF) that is involved in 
tumour angiogensis (Pavco et ai, 2000). This ribozyme may be useful in 
preventing tumour progression and is thus applicable for the treatment of several 
different cancers. Synthetic ribozymes have also been targeted to the 5'-UTR of 
the RNA genome of hepatitis C virus (HCV) for treatment of chronic HCV 
infection (Macejak et a i, 2000). Although the trials conducted thus far showed
promising results, there are some concerns regarding the safety of these agents. 
Their general toxicity following prolonged treatment remains to be determined. 
Moreover, since synthetic ribozymes are much larger (macromolecules) than 
conventional pharmacological agents, they possess relatively poor 
pharmacokinetic properties in vivo. These additional drawbacks really need to be 
overcome for synthetic ribozymes to be used widely as novel therapeutic agents 
(Usman and Blatt, 2000).
5.3.2 Viral-mediated delivery of ribozyme expression cassettes
Efficient delivery of ribozyme-encoding sequences relies on advances made in 
the development of viral vectors for gene therapy applications. A number of viral 
vectors have been studied regarding their ability to introduce genes into target 
cells (Morgan and Anderson, 1993). Each system has both advantages and 
disadvantages in their therapeutic application. Discussed below are some of the 
viral models used thus far for delivery of endogenous ribozymes to target tissues 
and cells. Viral-mediated delivery of anti-HBV hammerhead ribozymes is included 
in the discussion.
5.3.2.1 Retroviral vectors
Retroviral vectors are by far the most widely studied viral delivery vehicle for 
endogenous ribozyme expression. Retroviruses transduce a plethora of different 
cell types with high efficiency, and can stably integrate into the host cell genome. 
Persistence of ribozyme expression can be ensured owing to the maintenance of 
any introduced genetic material in progenitor cells. Consequently retroviruses are 
ideally suited for a range of different therapeutic applications (Morgan and 
Anderson, 1993). The shortcomings of retroviral therapy, however, include the 
inability to infect non-dividing cells (with the exception of lentiviruses). There are 
additional concerns regarding the safety of retroviral-delivery strategies since 
random retroviral integrants may elicit oncogenesis. Retroviruses are known to 
activate the host immune system by eliciting complement pathways. These 
pathways may in turn inactivate any transduced retroviruses. Additionally, there 
exists the possibility of reconstituting an active virus through recombination
events within packaging cell lines. These cells are tailored to reconstitute 
replication-incompetent recombinant retroviruses.
A number of infectious or acquired diseases, such as HIV (Bai et ai,
2001) and Moloney murine leukaemia virus infection (Lowenstein and Symonds, 
1997; Sun et ai, 1994), as well as various cancers (Funato et ai, 2000; Halatsch 
et a i, 2000; Kobayashi et a i, 2001; Shore et ai, 1993) have been targeted using 
different ribozyme-encoding retroviral vectors. One of the most promising 
applications of retroviral-delivered ribozyme therapy is for HIV infection, where 
progenitor T cells are stably transduced with ribozyme-expressing sequences 
that target HIV RNA. These T cells are then tested for their resistance to HIV 
infection. Thus far, practical efficacy in a clinical setting has been achieved for the 
ex vivo transduction of ribozyme-encoding sequences into T cells or bone 
marrow stem cells. These transformed cells, when reintroduced into patients 
infected with HIV, significantly reduce levels of viraemia in those patients for up to 
a year post-transplantation (Bertrand and Rossi, 1996). Although these studies 
are encouraging, ex vivo retroviral delivery of ribozymes for chronic HBV infection 
is not an option. Moreover, since hepatocytes (including those infected with HBV) 
are largely quiescent, retroviral applications in general are unlikely to prove 
efficacious. Retroviruses are unsuitable vectors for the delivery of c/'s- and trans­
acting multimeric ribozyme cassettes since self-cleavage prior to virion packaging 
would render the construct unviable.
5.3.2.2 Adenoviral vectors
Adenoviruses represent a popular alternative to retroviral-mediated delivery of 
ribozymes. This viral vector system has the advantage of infecting a wide variety 
of dividing and non-dividing cells without integrating into the host cell genome. 
Importantly, adenoviral vectors have a propensity for uptake by the liver (Smith et 
ai, 1993). Adenoviruses are present extrachromosomally as epigenetic elements 
within transduced cells. However, a serious limiting factor for sustained 
adenoviral therapy remains the transient expression of virally-encoded genes. 
The intracellular adenoviral vector is diluted-out as a result of repeated cellular 
division. Repeated administration of adenoviruses fails due to the effects of an 
efficient immune system clearance of adenoviruses in serum. Both a humoral and
cell-mediated response are launched against viral proteins, severely restricting 
the efficacy of adenoviral gene therapy approaches (Chirmule et al., 1999). In 
addition, there are concerns regarding the toxicity of adenoviral-mediated delivery 
approaches.
A number of studies have shown the in vivo effects of ribozyme- 
encoding recombinant adenoviruses (Huang et al., 1997; Patricia et al., 2001; 
Usui et al., 2001). Ribozyme-expressing adenoviral vectors were infused by vein 
injection into mice that were transgenic for human growth hormone (hGH). 
Ribozymes directed against hGH mRNA were able to eliminate 96% of the 
expressed mRNAs in this model (Lieberand Kay, 1996).
A recent application of ribozyme-encoded adenoviral gene therapy 
involved the use of U1 snRNA-ribozyme chimaeras that targeted the inhibition of 
the multifunctional growth factor (scatter factor/hepatocyte growth factor 
[SF/HGF]) and its receptor c-met. These have been implicated in multiple human 
malignancies, including gliomas. Both adenoviral and liposome vectors carrying 
endogenous ribozymes were able to inhibit the growth of intracranial glioma 
xenografts in infected/transfected rats, thus prolonging survival (Abounader et al.,
2002).
5.3.2.3 Adeno-associated viruses (AA Vs) and other viral systems
In addition to the two vector systems described above, viral vectors such as the 
adeno-associated virus (AAVs) and hepatitis delta virus (HDV) (Hsieh and Taylor,
1992) have also been used to transduce ribozyme-encoded expression 
cassettes. Unlike adenoviruses, AAVs have the advantage of integrating into a 
specific site on chromosome 19, leading to stable transduction of infected cells. 
Furthermore, AAVs do not elicit inflammation or a cell-mediated immune 
response (Hernandez et al., 1999). AAVs are limited to a packaging insert of 
4500 nt, which makes them ideally suited for ribozyme gene therapy, since 
ribozymes occupy a relatively small amount of sequence space. Nevertheless, 
relative to other viral delivery models, ribozyme-encoding AAVs have only 
recently been applied. This may be a result of the technical difficulties reported to 
date in establishing stable packaging cell lines since AAVs usually require co­
infection with helper-like adenoviruses or herpes virus. Additionally, producing 
high titres of recombinant AAVs for further use is inherently difficult.
AAV-encoding ribozymes have been shown to represent a potentially 
effective therapeutic strategy for dominantly inherited diseases that arise from 
malfunctional or misfolded protein (Lewin and Hauswirth, 2001). Such is the case 
for autosomal dominant retinitis pigmentosa (ADRP), which is most commonly 
associated with mutations in the gene encoding rhodopsin. Seminal studies were 
conducted using AAVs encoding ribozymes directed to the P23H mutation of 
rhodopsin. Ribozymes cleaved mutant rhodopsin mRNA and prevented 
photoreceptor degeneration in transgenic rats (LaVail et al., 2000; Lewin et al.,
1998). Ribozyme treatment protected functional vision in these transgenic rats for 
periods of up to eight months following AAV-ribozyme injection (LaVail et al.,
2000).
Ribozymes expressed from AAVs have been tested in cultured cells 
targeting HIV (Horster et al., 1999) and HCV (Welch et al., 1998). AAVs have 
also been targeted, in ex vivo studies, to both E6 and E7 genes of human 
papilloma virus (HPV), whose continued expression represents an oncogenic risk 
factor in HPV-induced human cancers (Kunke et al., 2000).
Other DNA-based viral vectors currently under consideration for the 
delivery of ribozyme-encoding genes are the herpes simplex virus (HSV) and 
simian virus 40 (SV40). These vectors may be potentially useful for the delivery 
of antiviral hammerhead ribozymes to HBV-infected hepatocytes. Although HSV 
infects quiescent cells and can include a large insert, it has an erratic life cycle. 
HSV has the propensity to lyse the host cell or enter into a latent phase of 
infection (Krisky et al., 1998a; Krisky et al., 1998b). SV40 is a relatively new viral 
vector and has yet to be tested completely for safety and efficacy. Nevertheless, 
SV40 can transduce a broad range of cell types, including quiescent cells. 
Although SV40 can accommodate only a 5000 nt insert, this may suit future 
application involving the delivery of ribozyme-encoding genes (Goldstein et al., 
2002; Jayan et al., 2001; Strayer, 2000).
5.3.3 Cationic liposomes and non-viral delivery strategies
Most non-viral delivery strategies employ a transfection-based approach for 
delivery into mammalian cells. Both presynthesized ribozymes as well as 
ribozyme-expressing vectors require carrier molecules since naked nucleic acids 
are either easily degraded or inefficiently transfected. Various cationic liposome 
formulations have been extensively studied as exogenous and endogenous 
ribozyme delivery systems. These include cationic lipids for transfecting 
presynthesized ribozymes (Duzgunes and Feigner, 1993), antisense- and 
ribozyme-encoding DNA (Akhtar et a i, 2000; Castanotto et al., 1997), and 
antisense RNA (Malone et al., 1989) into mammalian cells. For presynthesized 
ribozymes, other non-viral delivery strategies can be used, such as the 
conjugation of oligonucleotides to cholesterol or poly-L-lysine (Leopold et al., 
1995).
Various methods have been employed to direct cationic liposomes to 
target cells by conjugating the liposomes to ligands that interact with receptors on 
the target cell (Remy et al., 1995). Flepatocyte-specific receptors such as the 
asialoglycoprotein receptor (Ashwell and Harford, 1982) and the remnant 
receptor of Apolipoprotein E (Mahley, 1988) may be targeted using appropriate 
ligand-liposome conjugates for the delivery of anti-HBV therapeutic nucleic acids. 
However, there have been a number of drawbacks in studies aimed at targeting 
the asialoglycoprotein receptor (Rensen et al., 1996). These include the 
preferential uptake of lactosylated particles by the galactose receptor on Kupffer 
cells, and the decreased density of asialoglycoprotein receptors on hepatocytes 
of chronically-infected HBV individuals (Sawamura etal., 1984).
Notably, there are additional complications arising from the use of 
cationic liposomes in general. Nucleic acid-liposome complexes (lipoplexes) are 
often sequestered into endosomes on entry into target cells, thus diminishing 
their therapeutic effect. To prevent this, pH-sensitive liposomes are used in 
addition to membrane-disrupting peptides (Duzgunes et al., 2001) and are 
incorporated into cationic liposomes in order to disrupt the endosomal membrane 
and release liposomal contents into the cytoplasm of the target cell. Questions 
still remain regarding the overall therapeutic efficacy of liposome-based 
exogenous delivery techniques. At present, cationic liposomes do not efficiently
target a particular tissue or cell type and inefficient target non-dividing cells 
(Duzgunes et al., 2001). This raises concerns regarding their application as 
delivery vehicles targeting the liver, which is largely composed of quiescent cells. 
In addition, lipid formulations may have undesirable toxic effects. Although, as 
yet, non-viral delivery systems lack the cellular specificity of viruses, viral delivery 
systems are unlikely to be widely used for therapeutic purposes in the near future 
owing to concerns regarding their safe implementation. Thus, non-viral delivery 
systems may well prove to be more effective delivery vehicles for anti-HBV 
hammerhead ribozyme expression vectors. Further refinements are clearly 
necessary, however, for liposomes to be used successfully in a clinical setting.
5.4 Conclusion
The discovery of the catalytic nature of RNA challenges the conception that 
nucleic acids are merely inert repositories of information. RNA enzymes, or 
ribozymes, profoundly affect fundamental biochemical processes within the cell. 
This has prompted the theory of an ancient role for RNA in the evolution of life. 
Most naturally-occurring RNA catalysts function alongside proteins and other 
cellular factors. However, a number of small ribozymes discovered in unique 
organisms can function as independent RNAs and usually only require metal ion 
cofactors for catalysis.
The group of small ribozymes, which include the hairpin and 
hammerhead variety, are readily designed to hybridise to a complementary RNA 
sequence for the site-specific endonucleolytic cleavage in trans of the substrate 
phosphodiester backbone. Cleaved RNAs are thus rendered inactive. Since 
engineered ribozymes are specific for a target RNA sequence and can inhibit the 
phenotypic expression and/or the propagation of downstream products of RNA, 
they are applicable as therapeutic molecules for gene “knockdown” applications. 
Viral diseases in particular, which replicate and/or express unique RNA 
sequences, represent ideal targets for the use of therapeutic ribozymes.
Treatment of chronic HBV infection is a global medical objective and 
since most chemotherapeutic approaches used to date have only a modest effect 
on clearing viral infection, there exists a need for novel antiviral therapeutic 
agents. At present, patients treated with existing agents continue to be at risk for
cirrhosis and HCC. Future developments of novel nucleoside or nucleotide 
analogues may prove to be beneficial (Zoulim and Trepo, 1999). However, the 
emergence of nucleoside analogue-resistant strains of HBV remains a concern 
should prolonged treatment be necessary for removal of viral infection (Delaney 
et a/., 2001).
In the present study, the HBx ORF of HBV was selected as a sequence 
for the targeting action of endogenously expressed hammerhead ribozymes 
owing to: 1) the role of HBx in HBV-associated HCC; 2) the presence of HBx- 
encoding sequences within all viral transcripts, including the viral pregenome; 
and 3) the multifunctionality of HBx-encoded sequences, which overlap with 
polymerase and a number of viral c/'s-elements. Hammerhead ribozymes that 
efficiently cleaved HBx RNA in vitro significantly inhibited the trans-activation 
function of HBx when produced from an expression cassette in transfected liver- 
derived cell cultures. This included the inhibition of endogenous HBx trans- 
activator function in primary HCC cells. Apart from preventing the expression of 
the viral oncogene, HBx, these ribozymes behaved as general antiviral agents 
and were able to inhibit viral gene expression and markers of viral replication in 
cell culture models of HBV infection. Use was made of a plasmid containing a 
modified HBV sequence in which the preS2/S region was replaced by DNA 
encoding EGFP, thus allowing for the sensitive in situ measurement of ribozyme 
action in transfected cells. Ribozyme-modulation of EGFP activity in situ was 
accurately corroborated by measurements of viral HBsAg and HBeAg secretion. 
However, the exact mechanism of the ribozyme-induced inhibitory effects 
remains unclear. Both ribozyme cleavage and antisense-mediated effects may be 
responsible for the action of hammerhead ribozymes in cultured cells. Different 
ribozymes when applied simultaneously have an additive effect on the inhibition 
of viral gene expression. This feature was exploited by a multimeric ribozyme 
design that produces independent hammerhead ribozyme molecules from a 
single expressed transcript. The increased inhibitory effect observed by the 
introduction of multimeric ribozymes in vivo was either a result of an increase in 
ribozyme concentration or due to the simultaneous targeting of different sites on 
the target RNA. Additionally, independent processed ribozymes possessed 
trimmed 5' and 3' termini, which may, if uncleaved, interfere with the action of 
ribozymes in vivo. The most elaborate multimeric hammerhead ribozyme
construct, which contained twenty-four cis- and trans-cleaving hammerhead 
ribozyme units (24-mer), was highly effective at reducing markers of viral 
replication in cell culture. The 24-mer, multimeric ribozyme system, represents a 
significant improvement on previously constructed single-unit ribozymes or 
antisense RNAs and can be considered for application in gene therapy clinical 
trials.
The knowledge obtained from using ribozymes as antiviral agents may 
add value to other gene-based therapeutic strategies such as the development of 
dominant-negative mutants and DNA vaccines. The therapeutic potential of 
hammerhead ribozymes has been clearly shown in vitro and in transfected cells. 
However, it remains important to determine the efficacy of these agents in 
experimental or established animal models of infection, such as in DHBV, WHV 
or in transgenic mice. Factors that can be evaluated in these animal models 
include: the specificity of ribozyme gene therapy for the targeted gene; the 
stability and potential toxicity of the therapeutic expression cassette and its 
delivery to, and expression in, infected and non-infected hepatocytes. Moreover, 
since viral cccDNA has a long intracellular half-life (Whalley et al., 2001), the 
duration of antiviral therapy required to eradicate viral infection remains unknown. 
These factors must be addressed when choosing a suitable delivery vehicle.
Throughout the last decade, hammerhead ribozymes have been 
extensively applied as therapeutic molecules for the inhibition of gene expression 
in cell culture (Agrawal and Zhao, 1998; Lewin and Hauswirth, 2001). For the 
treatment of HBV chronic infection, hammerhead ribozymes presented in this 
thesis may well slow the progression of liver disease and improve the quality of 
life of chronic carriers by blocking viral gene expression. Additionally, by 
decreasing the viral load and/or by eliminating the presence of viral proteins such 
as HBx in infected hepatocytes, the onset of cirrhosis and HCC may be 
prevented. The delivery of hammerhead ribozyme-encoding genes, however, 
remains a significant hurdle. The lack of an effective delivery strategy has 
hampered the application of hammerhead ribozymes in vivo in animal models of 
HBV infection. Nevertheless, many ribozyme applications have, using existing 
viral and non-viral delivery vehicles, reached clinical evaluation and novel 
delivery systems continue to be discovered. Once shown to be safe and 
efficacious in living animals, hammerhead ribozyme gene therapy of HBV
infection may act alone or complement existing or future therapeutic strategies, 
such as interferon alpha, nucleoside/tide analogues, dominant negative mutants 
and peptide or DNA vaccines. The results presented in this thesis are 
encouraging and auger well for the future development of therapeutic 
hammerhead ribozymes for the treatment of chronic HBV infection.
6.0 APPENDICES
A Standard Laboratory Methods
A 1 Bacterial transformation
A1-1 Preparing competent E.coli
200 ml LB medium (Appendix B3-1) was inoculated with glycerol stocks of E.coli 
strains: XL1-Blue, DH5a or GM2929, and allowed to grow until a 
spectrophotometric cell density of 0.4 at A6oo- Cells were placed on ice for 10 
minutes followed by centrifugation at 4000xg in 50 ml tubes (Nunc, Denmark). 
Pellets were resuspended in 5 ml sterile Transformation Buffer (Appendix B1-6), 
pooled into two tubes and placed on ice for 15 minutes. Samples were then 
centrifuged at 2000xg for 5 minutes. Pellets were resuspended in 0.5 ml 
Transformation Buffer each and pooled. 100 pi aliquots were stored at -70°C.
A 1-2 Transformation of competent E.coli
Competent E.coli were transformed as follows: 1 pi (0.5 pg) of plasmid DNA was 
added to 100 pi of competent bacteria (thawed on ice). Samples were incubated 
on ice for 20 minutes, followed by a 90 second heat shock at 42°C. Positive 
transformants were then selected by overnight growth (37°C) on ampicillin- 
positive LB agar plates (Appendix B3-2).
A2 Plasmid DNA preparation
A2-1 Plasmid DNA preparation: Alkali lysis and silica matrix adsorption
Glycerol stock solutions of plasmid-bearing E.coli strains, or single colonies from 
transformed plates, were used to inoculate flasks containing 250 ml ampicillin 
positive LB medium (flasks with 50 ml LB amp were inoculated for a mini plasmid 
preparation or “miniprep”). Cultures were grown by incubation and shaking for 24 
hours at 37°C. The culture medium was transferred into 250 ml polypropylene 
tubes (Beckman, CA, USA) and centrifuged at 2000xg for 20 minutes in a
Beckman J2-21 Centrifuge (Beckman, CA, USA). For the miniprep method, 50 ml 
culture samples were centrifuged at 3000xg for 10 minutes in a Heraeus Biofuge 
primo centrifuge (Heraeus instruments, NJ, USA). Cells were collected and 
resuspended in 5 ml Glucose Resuspension Solution (see Appendix B1-1). SDS- 
NaOH Denaturing Solution (10 ml) (Appendix B1-1) is then added and mixed 
thoroughly. Lastly, Potassium Acetate Renaturation Solution (7.5 ml) (Appendix 
B1-1) is added to form a precipitate. Each solution is added sequentially in a ratio 
of 1: 2: 0.75 respectively. The mixture was then centrifuged at 1500xg for 10 
minutes in a Biofuge primo centrifuge. The supernatant was filtered through 
cheesecloth (nylon cloth) and one volume of isopropanol was added and mixed 
before incubation at -20°C for 30 minutes. Samples were then centrifuged at 
4000xg for 10 minutes. Following recovery of the pellet, samples were 
resuspended in 400 pi H20  containing 0.1 pg/pl DNase-free RNase (Roche, 
Germany) in autoclaved 1.5 ml microfuge tubes (Eppendorf, Germany) and 
incubated for 60 minutes at 37°C. Following RNAse treatment, 2 volumes (800 pi) 
sodium iodide solution (Appendix B1-2) and 75 pi silica solution (Appendix B1-3) 
were added. The samples were left on ice for 10 minutes and then centrifuged 
briefly (2 to 3 seconds) at 10000xg. The pellet was washed twice with 1 ml 
Ethanol Washing Buffer (Appendix B1-4) prior the elution of plasmid DNA from 
the silica matrix by resuspending the pellet in 100 pi H20  (50 pi for the minprep) 
followed by 5 minutes incubation at 55°C. Samples were then centrifuged at 
10000xg for 30 seconds and the supernatant containing the plasmid DNA was 
retained. Further purification was sometimes necessary depending on the later 
application of the plasmid DNA (see Appendix A5 and C1).
A2-2 Plasmid preparation: Alkali lysis and PEG precipitation
This method was similar to Appendix A2-1 up to, and including, the incubation 
step with RNase A. Samples were then extracted with chloroform-phenol as in 
Appendix A4-1 prior to being incubated overnight in a 550 pi PEG solution 
(Appendix B1-11). After centrifugation for 10 minutes, the supernatent was 
decanted and 190 pi of H20  was added. The pellet was dissolved at 45°C for 
approximately 15 minutes followed by the addition of 200 pi of isopropanol.
Tubes were cebtrifuged for 15 minutes at 13000xg prior to removing the 
supernatant and air-drying the pellet. Samples were resuspended in 50 pi H20  
and quantified by UV spectrophotometry (Appendix A4-3).
A3 RNA extraction and purification
A3-1 RNA preparation: guanidinium thiocyanate method
Following the removal of the Huh7 cell culture medium, 1 ml Guanidinium 
Denaturing Solution (Appendix B1-5) was added to directly to each 100 mm dish. 
The lysate was passed through a syringe several times by continuous aspiration 
and was divided into two aliquots of 500 pi each into two 1.5 ml microfuge tubes. 
A 50 pi volume of sodium acetate (2 M, pH 4) was added and mixed followed by 
500 pi water-saturated phenol and 100 pi of 49:1 chloroform/isoamyl alcohol. The 
mixture was vortexed for 10 seconds and allowed to stand at 4°C for 15 minutes. 
Following centrifugation for two minutes at 10000xg at 4°C, the top aqueous 
phase was transferred to a new 1.5 ml microfuge tube. The RNA was precipitated 
by adding 500 pi (1 volume) of 100% isopropanol and incubated at -20°C for 30 
minutes. After centrifugation at 10000xg for 10 minutes, pellets from both tubes 
were pooled and resuspended in 300 pi Guanadinium Denaturing Solution. The 
RNA was precipitated again with 300 pi isopropanol (1 volume) and incubated for 
30 minutes at -20°C. Following centrifugation at 10000xg, the RNA pellet was 
resuspended in 100 pi 75% ethanol, vortexed, and allowed to incubate for 10 
minutes at room temperature. The samples were centrifuged at 10000xg for 5 
minutes and the pellets were air dried and dissolved in 150 pi distilled H20 
(RNase free) for immediate use. Samples were quantitated 
spectrophotometrically (Appendix A4-3).
A4 DNA/RNA purification
A4-1 Choroform/phenol extraction of DNA
The choloroform/phenol method of nucleic acid extraction was routinely used 
following the elution of fragment DNAs from agarose gels and for general 
purification purposes. Briefly, DNA solutions were brought to a volume of 500 pi
with distilled H20  in a 1.5 ml microfuge tube. A 500 pi volume of 1:1 
phenokchloroform, (1x volume), was added to the samples which were briefly 
vortexed for 10 seconds to form an emulsion. The mixture was then centrifuged 
for 15 seconds at 12000xg in a microfuge at room temperature. Approximately 
500 pi of the aqueous phase was transferred to a fresh tube followed by the 
addition of 1 volume of chloroform. The samples were mixed, briefly vortexed and 
centrifuged again for 15 seconds at 12000xg at room temperature. The aqueous 
phase was removed and subjected to further purification by precipitation with 
ethanol.
A4-2 Ethanol precipitation of DNA/RNA
Preparations of either DNA or RNA were precipitated using ethanol and further 
purified. Generally, 0.1 volume of 3 M sodium acetate pH 5.2 was added to the 
nucleic acid containing solution followed by the addition of 2.5 volumes of 100% 
ice-cold ethanol. Samples were incubated at -70°C for 30 minutes followed by 
centrifugation at 13000xg for 15 minutes at 4°C. The pellet was recovered and 
washed with 70% ethanol (80% for RNA). Samples were air-dried to remove 
residual ethanol and resuspended in sterile H20.
A4-3 DNA/RNA spectrophotometric quantitation
Plasmid DNA or RNA concentrations were determined by optical density 
measurements (Unicam 8625 UVA/IS Spectrometer) at a wavelength (A,) of 260 
nm (At A 26o ,1 absorbance unit *  50 pg/ml dsDNA and 40 pg/ml RNA). Protein 
contamination was determined at A = 280 nm. Generally, DNA (plasmid) or RNA 
quality was established by resolving samples on an agarose gel alongside 1 pg of 
commercially available molecular weight markers.
A5 Manual DNA sequencing
A5-1 Sanger sequencing -  standard method
Plasmids were prepared using the silica adsorption method described in 
Appendix A2-1. All components were supplied within the T7 Sequenase DNA 
polymerase Kit (Pharmacia Amersham, England). An amount of 0.5 pmol M13 
24-mer Forward primer: 5' CGCCACGGTTTTCCCAGTCACGAC 3' was added to 
a 10 pi final annealing reaction mixture. The reaction mixture included 1 pg 
pBSIIKS(+)-derived plasmid DNA (Stratagene, CA, USA) and 2 pi T7 Sequenase 
reaction buffer (5x concentrate). The annealing reaction took place for 2 minutes 
at 65°C followed by 30 minutes of slow cooling at room temperature. The 
labelling reaction was performed in a total volume of 15 pi by adding the following 
to the annealed template-primer: 1 pi 0.1 M dithiothreitol, 2 pi labelling mix, 0.5 pi 
(5 pCi) of a-35S dATP (NEN du Pont, MA, USA) and 3,25 U T7 Sequenase 
polymerase. The reaction continued for 3 minutes at room temperature. A volume 
of 3.5 pi of the labeling reaction was then transferred to tubes containing 2.5 pi of 
each dideoxy nucleotide termination mixture. Tubes were incubated for a further 
5 minutes at 37°C. The reaction was stopped by adding 4 pi of stop solution 
(provided by the manufacturer). After heating at 95°C for 5 minutes, 2 pi of each 
sample was loaded on to a 6% polyacrylamide denaturing gel containing 7 M 
urea and resolved at 60 W. Gels were fixed in a 10% methanol, 10% acetic acid 
solution and dried on a gel drier (Bio-rad, Hoefer Scientific Instruments, CA, 
USA). The dried gel was autoradiographed overnight at room temperature.
A5-2 Sanger sequencing -  cycle sequencing method
This technique made use of the SequiTherm EXCEL™ II DNA Sequencing Kit 
(Epicentre Technologies. Wl, USA). A “premix” reaction mixture was prepared 
initially and included: 7.2 pi of SequiTherm EXCEL II® Sequencing Buffer, 1.0 pi 
of SequiTherm EXCEL II™ Prelabeling Mix, 2 pmol of unlabelled primer (M13 24- 
mer Forward primer: 5' CGCCACGGTTTTCCCAGTCACGAC 3'), 0.5 pi (5 pCi) of 
a-35S dATP (NEN du Pont, MA, USA), 1 pg of pBS II KS(+)-derived plasmid DNA 
and 5 U of SequiTherm EXCEL II™ DNA Polymerase. The total reaction volume
was 17 jj-I. Primers were allwed to anneal to the template DNA by heating to 95°C 
for 5 minutes followed by cooling to room temperature for a further 5 minutes. 4 pi 
of the premix were then added to four 0.5 ml microfuge tubes containing 2 pi of 
each dideoxy nucleotide termination mixture. The annealed primers were 
extended by incubating the mixture for 5 minutes at 65°C. The thermal cycling 
reaction included 30 cycles of 30 seconds at 95°C and 1 minute at 70°C. A 3 pi 
volume of stop solution (prepared by the manufacturer) was added. Samples (2 
pi) were loaded onto denaturing polyacrylamide gels and resolved as described 
in Appendix A5-1.
A6 Histochemical assay using X-gal
A6-1 (3-galactosidase detection in transfected mammalian cell culture
Seventy two hours after transfection, PLC/PRF/5, Huh7, Chang as well as 
primary HCC cells were the fixed for 5 minutes with approximately 400 pi (per 35 
mm plate) of Fixer Reagent (Appendix B1-8). Cells were then rinsed twice with 
PBS (Appendix B1-7) prior to the addition of 1 ml X-gal solution (Appendix B1-9) 
to each plate. These were then incubated for 37°C overnight prior to fixing with a 
solution containing 1% formaldehyde, 0.5% glyceraldehyde in 200 ml PBS 
(Appendix B1-7). p-galactosidase positive cells (blue cells) were observed and 
counted at 10x magnification on a standard dissecting microscope.
A7 Transfections into mammalian cells
A7-1 The calcium phosphate method of transfection into mammalian cells
This method follows closely to that developed by Graham and van der Eb (1973). 
PLC/PRF/5, Huh7, Chang or primary FICC cultures were seeded at one-tenth 
their confluent density and allowed to grow overnight. Fresh medium was added 
to each culture dish approximately 1.5 hours prior to transfection. A transfection 
solution containing a volume of 1000 pi (or one-tenth the volume of medium in 
each plate) was prepared for each 100 mm dish. Briefly, appropriate volumes of 
each plasmid were added to 62.5 pi 2M CaCI2 and 500 pi 2X HEPES (Appendix 
B1-10) and made up to a final volume of 1 ml with distilled water. This was gently
dispensed onto the cells. The volumes were scaled-down by a factor of five when 
using six-well dishes. After 16 hours incubation with the DNA/Calcium phosphate 
precipitate, the spent medium was aspirated and replaced with fresh medium. 
Using fluorescence microscopy (Zeiss Axiovert 100M, fluorescent microscope, 
488 nm), equivalent transfection efficiencies were confirmed by the detection of 
comparable numbers of EGFP expressing cells in each culture dish (except when 
using the plasmid pCH-EGFP). Transfected cells were cultured for 24 hours 
before any medium was collected for further analyses. Cells were used for the 
extraction of RNA (Appendix A3-1) after three or four days post-transfection.
B Solutions, Reagents and Buffers
B1 Solutions
B1-1 Alkaline lysis buffers for plasmid preparations
Glucose Resuspension Solution: 50 mM glucose, 25 mM Tris-HCI (pH 
8.0) and 10 mM EDTA (pH 8.0).
Denaturing Solution: 0.2 N NaOH (from a 10 N stock) and 1% SDS 
(from a 10% stock). The solution remained stable at room temperature 
in a plastic bottle.
Renaturing Solution: 1 litre contains 600 ml of 5 M potassium acetate, 
115 ml glacial acetic acid and 285 ml distilled H20. The solution is 3 M 
with respect to potassium and 5 M with respect to acetate.
B1-2 Sodium Iodide Solution
Sodium Iodide Solution contains 180 mM sodium iodide (Nal) and 60 mM sodium 
sulphite (Na2S03). The saturated solution was filtered through filter paper to 
remove any un-dissolved constituents. A further 0.5 g Na2S03 was added. The 
solution was stored at 4°C in the dark.
B1-3 Silica Matrix Solution
Silica powder, 120 g, was resuspended in 400 ml H20  and stirred for 1 hour. The 
solution was allowed to settle for 30 minutes. The supernatant was centrifuged to 
recover the fine silica particles (800xg for 5 min). The pellet was resuspended in 
100 to 200 ml distilled H20, followed by the addition of 50% volume of nitric acid 
followed by heating (close to boiling) in a fume hood and washed 4 times with an 
excess of distilled water (800xg for 4 minutes). Lastly, the Silica Solution was 
stored as a 50% slurry in distilled H20  at 4°C.
B1-4 Ethanol Wash Buffer
Ethanol wash buffer consists of 10 mM Tris-CI (pH 7.5), 0.1 M NaCI, and 50% 
ethanol. The solution was stored at -20°C.
B1-5 Transformation Buffer
Transformation buffer consists of 100 mM CaCI2, 10 mM PIPES-CI (pH 7.0), and 
15% glycerol. The solution was stored at -20°C.
B1-6 Guanidinium Thiocyanate Denaturing Solution
A working solution contains 4 M guanidinium thiocyanate, 25 mM sodium citrate 
(pH 7), 0.1 M p-mercaptoethanol and 0.5% /V-laurylsarcosine (Sarkosyl). A stock 
solution was prepared without p-mercaptoethanol and was stored for up to 3 
months at room temperature. Working solutions were used immediately.
B1-7 Phosphate-buffered Saline (PBS) Solution
PBS contains: 8 g of NaCI, 0.2 g of KCI, 1.44 g of Na2HP04, and 0.24 g of 
KH2P04 in 1000 ml of distilled H20. The pH was adjusted to 7.4 with HCI. The 
solution was dispensed into 200 ml aliquots and autoclaved for 20 minutes at 15 
lb/in2 on the liquid cycle. Aliquots were stored at room temperature.
B1-8 Fixer reagent for staining cultured mammalian cells
The solution contains 1% formaldehyde and 0.5% gluteraldehyde in PBS 
(Appendix B1-7). 500 ml of fixer was prepared and stored at 4°C.
B1-9 X-gal Staining Solution for histochemical assays
X-gal Staining Solution contains 4 mM potassium ferrricyanide, 4 mM potassium 
ferrocyanide, 2 mM MgCI2 and 0.4 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-p-D- 
galactopyranoside, Sigma, MO, USA) in DMSO. Typically, 50 ml X-gal Solution 
was prepared and stored at 4°C.
B1-10 2x HEPES Buffer
2x HEPES Buffer contains: 280 mM NaCI, 50 mM HEPES and 1.5 mM Na2HP04. 
The buffer was brought to a pH of 7.1 with NaOH and sterilised through a 0.22 
mm filter.
B1-11 PEG Solution
A PEG Solution consists of 13% Polyethylene Glycol 8000 and 1.6 M NaCI. The 
solution was prepared by heating at 56°C until dissolved followed by storage at 
4°C.
B2 Electrophoresis Buffers (Stock solutions)
B2-1 50x Tris Acetate EDTA Buffer (TAE)
A 50x stock solution of TAE buffer contains: 400 mM Tris-acetate (pH 7.6), 50 
mM Na2.EDTA
B2-2 10x Tris Boric Acid EDTA Buffer (TBE)
A 10x stock solution of TBE buffer contains: 900 mM Tris-borate (pH 8.3), 20 mM 
Na2.EDTA
B2-3 RNA Loading Buffer
A 2x stock solution of RNA Loading Buffer contains: 98% deionized formamide, 1 
mM EDTA (pH 8.0), 0.25% bromophenol blue and 0.25% xylene cyanol FF.
B3 Culture Media
B3-1 Luria-Bertani medium
10 g of bacto-tryptone (Oxoid, England), 5 g of bacto-yeast extract (Oxoid, 
England), and 10 g of NaCI in 1 litre distilled H20. The medium was sterilised by 
autoclaving for 20 minutes at 121 °C and 15 lb/in2.
B3-2 Luria-Bertani agar plates with ampicillin
15 g of bacto-agar (Oxoid, England) was added to 1 litre of dissolved LB medium 
and sterilised. For ampicillin-agar plates, 1 ml of a 1000x stock solution ampicillin 
(100 mg/ml made in a 50% ethanol) was added to the agar prior to solidification 
such that the final ampicillin concentration is 100 pg/ml. Plates were stored at 4°C 
for up to a month.
B3-3 Luria-Bertani agar plates with X-gal
A 40 jul volume of X-gal (20 mg/ml stock in dimethyl formamide; Sigma, MO, 
USA) and 4 pi of IPTG (200 mg/ml aqueous solution; Roche, Germany) were 
spread on LB agar (ampicillin positive) plates. Plates were air-dried at 37°C for 20 
minutes and stored at 4°C for up to a month.
C Other Appendices
C1 Construction of multimeric cis- and trans-cleaving vectors
C1-1 Constructing pBS-M1 series plasmids
Constructing plasmids: pBS-M 1  /-/Bx:Rz1i743 
and pBS-/Wf/-/Bx:Rz3i607
Constructing plasmid 
pBS-Mf HBx:Rz2i65i
*
S pel/Sca l
d igestion
pBS-M1 tHSx:Rz3i607
Spel and Seal digest, 
1170 bp fragment
\
*
Bssh\
/ V
Bss/)ll
Figure 6.1 A schematic illustration of the construction of a single-unit {M1 series) cis- 
and frans-cleaving hammerhead ribozyme cloning vector for each of the 
three hammerhead ribozymes. The construction of plasmid pBS- 
M1HBx:Rz11473 (A), pBS-MfHBx:Rz31607 (B), and pBS-/W7HBx;Rz2165i (C).
C1-2 Constructing pBS-M2 series plasmids
C o n s tru c tin g  p lasm ids : pBS-/W 2/-/Bx:Rz1i743 
and  pBS-/W 2HBx:Rz3i607
pBS-/WfH8x;Rz1i473
B C o n s tru c tin g  p lasm id  pB S -A /f2H B x:R z2 i65 i
BssAill
Figure 6.2 A schematic illustration of the construction of a multiple-unit {M 2  series) c/'s- 
and frans-cleaving hammerhead ribozyme cloning vector for each of the three
hammerhead rihozymes.
C2 Determination o f equivalent transfection efficiencies
pHBV adw HTD pHBV adw HTD 
pHBx.Atl1473
pHBV adw HTD 
pHBx;At21651
pHBV adw HTD pHBV adw HTD
pCI-/W8HBx:Rz1 1473 pCI-/W8HBx:Rz2l651
pHBV adw HTD 
pCI-/W8/-/Bx:Rz31607
pHBV adw HTD pHBV adw HTD
pCI-M24HBx;Rz1 ,2&3 pHBx.Rzl1473
pHBV adw HTD 
PHBx.Rzl*
pHBV adw HTD 
p/-/Bx:Rz21651
pHBV adw HTD 
PHBx:Rz2*1651
pCI neo
Figure 6.3 An example of the number of EGFP-expressing Huh7 cells transfected with 
the plasmid pCI neo GFP for the determination of equivalent transfection 
efficiencies (transfection reported in 4.4.3.2).
C3 HBx sequence variation for hammerhead ribozyme hybridisation 
and cleavage
HBx.Rz11473
1460 ▼ 1485
Serotype ayw J 02203 CCUUCUCGGGGUCGCUUGGGACUCU 25
Genotype D L27106D CCUUCUCGGGGUCGCUUGGGACUCU 25
Genotype A V00866A CCCUCUCGGGGCCGCUUGGGACUCU 25
Genotype A M57663AP CCCUCGCGAGGCCGCUUGGGACUGU 25
Genotype B D00329B CCCUCCCGGGGCCGCUUGGGGCUCU 25
Genotype C X75656C CCGUCUCGGGGCCGUUUGGGGAUCU 25
Genotype E X75664E CCGUCUCGGGGUCGCUUGGGGAUCU 25
Genotype F X75663F CCCUCCCGGGGUCGCUUGGGGCUGU 25
Genotype G AF160501 G CCCUCCCGGGGCCGUUUGGGGCUCU 25
Serotype ayw J 02203
HBx: Rz21651
1638 ^  1663
AUUGCCCAAGGUCUUACAUAAGAGG 25
Genotype D L27106D CUUGCCCAAGGUCUUAUAUAAGAGG 25
Genotype A V00866A CCUGCCCAAGGUCUUACAUAAGAGG 25
Genotype A M57663AP CCUGCCCAAGGUCUUACAUAAGAGG 25
Genotype B D00329B CCUGCCCAAGGUCUUGCAUAAGAGG 25
Genotype C X75656C AUUGCCCAAGGUCUUGCAUAAGAGG 25
Genotype E X75664E CUUGCCCAAGGUCUUACAUAAGAGG 25
Genotype F X75663F UUUGCCAACAGUCUUACAUAAGAGG 25
Genotype G AF1 60 501G UCUGCCAAGGCAGUUAUAUAAG----- 22
HBx: Rz31607
1595 ^  1618
Serotype ayw J 0 2 2 0 3 ACCUCUGCACGUCGCAUGGAGACC 24
Genotype D L27106D ACCUCUGCACGUCGCAUGGAGACC 24
Genotype A V00866A ACCUCUGCACGUUGCAUGGCGACC 24
Genotype A M57663AP ACCUCUGCACGUUGCAUGGAGACC 24
Genotype B D00329B ACCUCUGCACGUCGCAUGGAGACC 24
Genotype C X75656C ACCUCUGCACGUCGCAUGGAGACC 24
Genotype E X75664E ACCUCUGCACGUCGCAUGGAGACC 24
Genotype F X75663F ACCUCUGCACGUCGCAUGGAGACC 24
Genotype G AF1 60 501G ACCUCUGCACGUUACAUGGAAACC 24
Figure 6.4 GeneDoc™ alignment of HBV variant RNA sense strand sequences 
(GenBank® accession numbers indicated) of genotypes A to G with HBV 
serotype ayw indicating hybridisation regions for ribozymes HBx.Rzl 1473, 
HBx:Rz21651 and HBx:Rz316o7. GUC cleavage triplet sequences are shaded in 
blue; GUU cleavage triplet sequences are shaded in green (cleavage position 
is indicated by an arrow). The sequences are numbered according to 1/3182 
for the EcoRI site of HBV serotype ayw (GenBank® accession no. J02203). 
The number of aligned nucleotides is indicated to the right of each sequence.
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